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Abstract 
Background  
Genomics research has introduced significant transformations in the way health research is 
traditionally structured. Firstly, genomics research often requires long-term storage of biological 
samples for future unspecified uses. Secondly, the stored samples may be shared with 
researchers across the globe for the purposes of research. Thirdly, genomics researchers are 
increasingly required to make their research data publicly available for use by other researchers 
and institutions from around the world. Whilst data and sample sharing offers significant benefits 
for global health research, in Africa, it is taking place amidst a background of: structural inequities 
in health and health research between Africa and High Income Countries (HICs). There are also 
concerns around the exploitation of African researchers and study populations, mainly hinged on 
historical experiences in global health research, what has been termed scientific imperialism or 
“extractive” research. It is therefore not surprising that the rise in genomics research and 
biobanking studies in Africa has been accompanied by strong calls to address the ethical legal 
and social issues (ELSIs) raised by genomics research and biobanking in Africa. Some of these 
ELSIs focus on individual-level issues (micro-justice), others go beyond that to include broader 
societal ELSIs (macro-level justice) such as: secondary access to samples and data, benefit 
sharing, exploitation of African researchers and populations, intellectual property and the 
ownership of samples and data. One way of addressing these macro-level justice-related ELSIs is 
through governance.  
Aim and Objectives 
The aim of this study is to develop a governance framework that could be used to address macro-
level-justice-ELSIs in genomics research and biobanking in Africa.  
To achieve this aim, I put forth the following specific objectives: 
1. To identify principles, values and norms that could promote justice and fairness in 
genomics research and biobanking in Africa; 
 
2. To develop a principles-based governance framework for genomics research and 
biobanking in Africa that links its policies to the promotion of justice; 
 
3. To investigate how the governance of current day genomics research and biobanking 
projects in Africa have considered concerns of justice and fairness; 
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4. To explore the views of key stakeholders on fair and just governance mechanisms for 
genomics research and biobanking in Africa. 
 
Methodology 
To develop the governance framework, I used the normative practice-oriented bioethics (NPOB) 
approach. This required adopting a number of methodologies, both conceptual and empirical. 
The conceptual work used the convergence approach and consisted of a theoretical analysis of 
two theories of global health justice, namely: shared health governance (by Jennifer Ruger) and 
global governance for health (by Larry Gostin); as well as the African philosophy of Ubuntu. 
Through the conceptual and normative analysis, I identified a number of principles that could 
inform the governance of genomics research and biobanking in Africa. These principles were used 
to propose a governance framework that could address macro-level justice ELSIs in genomics 
research and biobanking programs in Africa.  
Following the development of the governance framework, we used empirical bioethics research 
methods to probe whether and how the framework’s principles could be practically promoted in 
genomics research and biobanking consortia in Africa and to revise the framework where 
necessary. To do this, I used the reflective equilibrium approach. This included checking the 
proposed framework’s principles and recommendations against current governance practices of 
a genomics research consortia in Africa as well as well as prompting various stakeholders to think 
of how these principles could be applied in practice, or how the have been applied within 
genomics research consortia in Africa. Using the Human Heredity and Health in Africa (H3Africa) 
Consortium as a case study, as well as two qualitative research methods: content analysis of 
H3Africa governance documents and one-on-one in-depth interviews (n=15), I checked the 
framework’s principles against the empirical data and revised as, and when necessary (reflective 
equilibrium).  
Results 
The conceptual analysis led to the identification of the following nine principles: solidarity, 
reciprocity, furthering the ideals of health justice (FIHJ), shared sovereignty, shared resources, 
transparency, shared responsibility; mutual trust and mutual collective accountability. These 
principles were used to develop a principles-based governance framework for genomics research 
and biobanking. Because I wanted develop a governance framework that is practically 
implementable, I made recommendations on how each principle could be actualised genomics 
research in Africa.  
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Analysis of the empirical data showed that the majority of the framework’s principles and or 
recommendations were being promoted or prioritized by H3Africa ELSI governance. Equally, 
many H3Africa the principles and recommendations were considered by various H3Africa 
stakeholders to be critical in promoting justice and fairness in genomics research and biobanking 
projects in Africa. This suggests that our framework’s requirements are not just theoretical but 
could be implemented in practice and that there was some buy-in by stakeholders involved in 
genomics projects in Africa.  
A key area of deviation between the principles-based framework and the empirical data was the 
involvement of study populations in decision making (e.g. decision making on sample and data 
use; research priority setting etc.) The empirical data however showed that there was little 
involvement of study populations in decision-making within the H3Africa consortium, our case 
study. Whilst the different stakeholders acknowledged the importance of including study 
populations in governance processes, there were parallel concerns about its practicability. 
Despite these, the conceptual analysis and interview data confirms that there is need to first and 
foremost consider study populations as a key stakeholder group that should be involved in 
decision making, including decisions on secondary use of samples and data and in the 
development of biobank policies that will directly affect them.  
A new principle emerged from the empirical data. This was the principle of mutual respect. 
Following the reflective equilibrium approach, the framework was revised to include mutual 
respect as a core guiding principle.  
Conclusion 
Using the normative practice oriented bioethics approach, I have developed a novel, principles-
based governance framework for genomics research and biobanking in Africa. This framework, 
which was derived following a conceptual analysis of the governance theories, as well as the 
reflective equilibrium approach, seeks to address justice-related-(macro-level)- ELSIs in genomics 
research and biobanking in Africa. It and is grounded in theories of global health justice and the 
African moral theory of Ubuntu. Although the framework was developed to support the 
governance of genomics research and biobanking in Africa, its principles are likely to be 
applicable to other forms of global health research.  
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Chapter 1: Introduction, Study Overview and 
Objectives 
There is an upsurge in the number of genomics research and biobanking projects in Africa. This 
is motivated, in part, by concerns that the near absence of genomics studies on African 
populations could cause a genomics divide between Africa and other parts of the world, and that 
this could in turn widen global health inequities (Singer and Daar, 2001b, H3Africa Consortium, 
2014, Newport and Rotimi, 2009, WHO, 2002). Another reason that has been advanced for the 
importance of population genomics studies in Africa, is that Africa’s rich genetic diversity is an 
essential resource for investigating the role of genomic variation in human health and disease 
(Gomez et al., 2014, Campbell and Tishkoff, 2008, Ramsay, 2012). Genomics research on African 
populations therefore offers potential not only in addressing global health inequities, but for 
improving human health globally (Rotimi et al., 2017). For the above reasons, a number of 
genomics research and biobanking consortia have been set up in a number of African countries. 
The majority of these projects, arguably, are funded by institutions in high income countries 
(HICs), involves collaborations between HICs and African researchers, and are sometimes 
organised in the form of a research consortium or network. Examples include: : the Southern 
African Human Genome Project (Pepper, 2011); The Malaria Genomic Epidemiology Network 
(The Malaria Genomic Epidemiology Network, 2008); the African Genome Variation Project 
(Gurdasani et al., 2015); the Human Heredity and Health in Africa (H3Africa) consortium (H3Africa 
Consortium, 2014) and the Bridging biobanking and Biomedical research (B3Africa) consortium.  
Genomic research consortia in Africa, such as those listed above, are likely to encompass a 
number research projects, taking place across different countries both in and out of Africa. The 
advantage of this kind of research structure is that it facilitates the attainment of large samples 
sizes and datasets that are often required to get statistically significant results in population 
genomics studies. It is therefore common practice for genomics research consortia to set up as 
biobanks as a critical arm of the consortium. It is expected that the samples stored in the biobanks 
alongside the genetic data generated from the projects, will eventually be made available 
(publicly or otherwise) for to researchers and entities from around the world. This includes 
researchers who may not have been part of the primary studies that collected the samples or 
generated the data. In cases where the data is not openly available, researchers, policy makers 
and innovators or other interested parties may apply to an identified body (research ethics 
committee, data access committee etc.) for permission to access and use the data. Genomics has 
therefore introduced significant transformation in the way health research is typically structured, 
whereby a single research group focused on a specific project and samples and data were used 
for that specific project and not stored for future unspecified uses.  
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Considering that the majority of genomics research and biobanking consortia in Africa are funded 
by agencies in HICs, and involve researchers from both HICs and African countries, they could be 
categorized as international health research. Also, because a good number of these studies aim 
to address health issues of pertinence to African populations, and possibly prevent a genomics 
divide between HICs and LMICs that could widen global health inequities, they could be 
considered as global health research1. Global health research has often played a significant role 
in: advancing health research in Africa, supporting research in HICs; and in reducing global health 
inequities (Dye et al., 2013b, GFHR, 2004, GFHR, 2008, Dye et al., 2013a, Benatar, 2001). Despite 
these benefits, global health research in Africa has sometimes been linked to the exploitation of 
African researchers and study populations (Benatar, 2000, Bhutta, 2002, Hawkins and Emanuel, 
2008). 
The sharing of samples and data in global has been a major cause of contention in global health 
research programs in Africa-It raises ELSIs that border on scientific imperialism and the 
exploitation of African researchers and study populations (Barchi et al., 2015, Nienaber, 2011, 
Tindana et al., 2014, Upshur et al., 2007, Tangwa, 2017). The underlying causes of exploitation of 
African researchers and study populations in global health research are related to disparities in 
biotechnology and research resources between Africa and HIC partners; and as the high disease 
burden in Africa. These disparities tend to confer more benefit for HIC research partners and may 
lead to perceptions of exploitation and imperialism in global health research (Benatar, 1998, 
Crane, 2013). For example differences in research resources between HICs and African countries 
could see the HIC partner setting the research agenda and defining research processes and 
resource allocation in ways that could be considered paternalistic by the African collaborators. 
Al these are concerns of inequities that would require a justice lens (Pratt and Loff, 2011, Pratt 
and Loff, 2014, Benatar, 2001, de Vries et al., 2015b, Molyneux and Geissler, 2008).  
Discussions on justice and fairness in genomics research and biobanking in Africa has been 
dominated by discussions around the possible exploitation of African researchers and study 
populations (de Vries and Pepper, 2012, de Vries et al., 2015c, Munung et al., 2017). This is 
because the export of samples and the sharing of data is an integral part of contemporary 
population genomics studies in Africa. Yet, sample export has been at the center of controversies 
around international health research conducted in Africa. The concept of “parachute” or “fly in, 
fly out” research in LMICs (Okwaro and Geissler, 2015, Smith, 2018, Heymann et al., 2016) has 
no doubt left a strain on global health research collaborations that plan to export samples and 
                                                     
1For differences between global health research and international health research, see Ooms G (2014. From 
international health to global health: how to foster a better dialogue between empirical and normative disciplines. 
BMC International Health and Human Rights: 14(1):36. 
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data. Genomics research in Africa or other form of global health research in Africa that plans to 
export samples and/or share research data will have to invest a lot of efforts in addressing 
concerns of “parachute” or “extractive” international health research in Africa. This will require 
these genomics research consortia, to first and foremost unpack the justice-related ethical issues 
that underlie concerns of exploitation; then identify ways by which they could be addressed. This 
is important not just for successful implementation of genomics studies in Africa, but also for the 
long-term sustainability of these projects and subsequent ones. Also, whilst one of the motivating 
factors for the huge investments in population genomics studies in Africa is the fear that the 
absence of genomics studies on African populations may widen global health inequities. A 
pressing question therefore is, how can genomics research and biobanking consortia in Africa 
ensure that their activities address concerns of global health inequities. This thesis seeks to 
suggest ways in which justice-related ethical issues in genomics research and biobanking 
consortia in Africa could be addressed.  
1.1 Study Aim and Objectives 
Power and economic disparities between LMICs and HICs, and global health inequities are the 
main forces behind concerns of exploitation in global health research in Africa. Therefore, 
mechanisms that could minimise the impact of these disparities, prevent exploitation of Africa 
researchers and populations could be the way forward.  
It has been suggested that the negative impact of power disparities in global health research 
collaborations and its potential role in concerns of exploitation, could be minimised through 
appropriate governance mechanisms (Lee and Mills, 2000, Pratt and Hyder, 2016, Pratt and 
Hyder, 2017, Winickoff, 2008). In this thesis, I will explore issues of justice-related ethical issues 
in genomics research and biobanking consortia in Africa. I will unpack the structural inequalities 
that inform and shape genomics research in Africa, the impact that these inequalities have on 
genomics research in Africa, and how the inequities could be addressed through governance.  
The overall aim of this study is to propose a governance mechanism for genomics research and 
biobanking in Africa2. To achieve this, I put forth the following specific objectives: 
1. Identify principles, values and norms that can promote justice and fairness in 
genomics research and biobanking in Africa 
                                                     
2 Africa is used in this thesis in more generic form. But that is not to say that it is a homogenous society. The continent 
enjoys lots of diversity including genetic, cultural and religious diversity. A more appropriate phrasing will be “certain 
African societies” in order to give room for this diversity. 
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2. Propose a principles-based governance framework for genomics research and 
biobanking in Africa that links its policies to the promotion of justice; 
3. Investigate how the governance of genomics research and biobanking projects in 
Africa have considered concerns of justice and fairness; 
4. Explore the views of key stakeholders on fair and just governance mechanisms for 
genomics research and biobanking in Africa. 
Normative practice oriented bioethics approach was used to achieve the study objectives. This 
involved different methodological approaches, both conceptual and empirical. Since governance 
should ideally be informed by principles, values or social norms that are considered morally 
relevant for all persons involved in a shared activity (Hufty, 2011), I will start by identifying 
principles that could be considered relevant by all stakeholders in genomics research and 
biobanking projects in Africa. The principles will be identified through a conceptual or normative 
analysis of different global health justice and governance frameworks using the convergence 
approach. The framework’s principles will then be tested through empirical scientific methods, 
mainly following the reflective equilibrium approach. This was to ensure that the governance 
mechanism actually addresses actual governance challenges of genomics research consortia and 
that it is not too abstract. First, I will provide an overview of some genomics research consortia 
in Africa and the justice-related ethical issues raised by genomics research and biobanking in 
Africa. 
1.2 Genomics Research and Biobanking in Africa: An Overview 
Genomics is the study of the structure, function, evolution and mapping of the genetic material 
of living organisms. It is a science that enables health researchers to elucidate how genes interact 
with each other and with the environment (non-genetic factors) and how this may impact on the 
health of individuals or populations (Burgner et al., 2006, Segal and Hill, 2003, Weatherall et al., 
1997). Genomics research differs from most types of health research in that it is often 
interdisciplinary in nature, involves the use of high-throughput technology and requires large 
sample sizes to yield statistically relevant results. The need for large sample sizes, diverse 
scientific expertise and technology, has led many genomics researchers to organise themselves 
into a consortium or network. A genomics research consortium will often have a common goal 
but with each project, within the consortium, investigating an objective that is complimentary to 
the overall goal of the consortium. The need for large sample sizes has also compelled research 
consortia to establish biobanks and genetic databases that will store biological samples and data 
from the different projects. It is hoped that the stored samples and research data will be used for 
future research studies (Meldrum, 1995, Nyika, 2009, Collins et al., 2003). At the time of sample 
collection, it is difficult to tell, in detail, the different types of studies that the samples will be 
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used for. Therefore, sample donors have to consent to future, unspecified, uses of their samples 
and data. Genomics is therefore changing more traditional forms of health research which 
involved a research team working mostly by itself on a defined research project, to more 
collaborative ways of working which requires: the storing of samples for future unspecified uses 
and the sharing of samples and data between researchers with the aim of expediting the 
generation of robust results (Nyika, 2009, Wright et al., 2013). 
The human genome project (1990-2003) was the first large scale international genomics project 
(Collins et al., 1998). The aim of the human genome project (HGP) was to completely sequence 
and map the entire human genome. The HGP involved researchers from 20 institutions in six 
countries, namely: France, Germany, Japan, China, the United Kingdom and the United States of 
America. Three founding principles of the HGP are worth highlighting as they inform the 
discussions on the ethics of human genomics research and biobanking in Africa. Firstly, whilst the 
HGP was a US-based project, it was open to research collaborations with researchers from other 
part of the world. Secondly, all information on the human genome sequence generated from the 
HGP was to be made publicly available within 24 hours of its assembly. Thirdly, the data from the 
project was made freely accessible for use by researchers, from any part of the world, in both 
academia and industry. The goal was to have an all-inclusive project that will benefit from diverse 
expertise and approaches (Chial, 2008). Although the human genome project, did not realise its 
initial hope of accelerating the discovery of new treatments for genetic diseases, it was arguably 
the kick-starter of the genomics revolution (Chial, 2008, Collins et al., 2003).  
Following the completion of the HGP, a number of collaborative international genomics 
initiatives have emerged in, each with a mandate to study and catalogue genomic variants from 
population groups around the world. However, very few of these studies have primarily focussed 
on population groups in Africa or involved African researchers as key players (Need and 
Goldstein, 2009, Rosenberg et al., 2010, Popejoy and Fullerton, 2016).  
The international Haplotype Mapping (HapMap) project (The International HapMap Consortium, 
2003) was arguably the first international research consortium to extend the human genomic 
revolution to Africa. It, involved researchers from Nigeria and Kenya, and collected human 
biological samples in both countries. However, by 2010, only four of the thousands of genome 
wide association studies (GWAS), had focussed exclusively on African populations (H3Africa 
Consortium, 2014, Rotimi and Jorde, 2010). To fill this gap, a number of human genomics 
research consortia have been established in Africa such as the African Genome Variation Project 
(AGVP); the Human Heredity and Health in Africa (H3Africa) consortium; and the 
Neuropsychiatric genetics of African Populations (NeuroGAP) consortium. Below, I briefly 
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describe three genomics research consortia in Africa that epitomises the characteristics of 
genomics research consortia in Africa. 
1.2.1 African Genome Variation Project (AGVP) 
The African Genome Variation Project (AVGP) was one the early population genomics studies to 
focus exclusively on African populations. It aimed to investigate how the structure of the African 
genome differs from that of populations of European descent with the outcome of suggesting a 
framework for human genetic research in Africa (Gurdasani et al., 2015). It also assessed the 
feasibility of using commercially available genotyping chips for genomics studies on African 
populations (Friedrich, 2015). AGVP was a collaboration with the African Partnership for Chronic 
Disease Research (APCDR) and received funding from the Wellcome Trust, UK.  
Samples for the AGVP were collected from Kenya, Nigeria, Uganda, Ethiopia, Ghana, The Gambia, 
and South Africa (Gurdasani et al., 2015). Genotyping was mainly done at the Welcome Trust 
Sanger Institute, UK and the genetic data was submitted to the European Genotype Archive 
(EGA). Access to data from AGVP is restricted and requires approval by the data from the data 
access committee of the ACPDR.  
1.2.2 The Human Heredity and Health in Africa (H3Africa) Consortium 
A second genomics research consortium in Africa is the Human Heredity and Health in Africa 
consortium (H3Africa). H3Africa was established in 2010 with funding from the U.S. National 
Institutes of Health (NIH) and the Wellcome Trust (H3Africa Consortium, 2014). One of its core 
objectives is to enhance the ability of African researchers to apply genomics technology to 
improving health research in Africa (H3Africa Consortium, 2014). H3Africa projects cover a range 
of diseases and will involve the creation of regional biobanks and a bioinformatics network and 
an ELSI arm (H3Africa, 2013). It is anticipated that about 75,000 samples would be analyzed as 
part of H3Africa research activities(H3Africa Consortium, 2014). . All H3Africa projects are nested 
in African research institutions and led by Africa-based researchers. Like the AVGP, H3Africa has 
a major African partner- the African Society of Human Genetics (AfSHG). 
Aliquots of all the samples collected from H3Africa projects will be stored in one of three H3Africa 
regional biobanks. Genomic and phenotypic data from H3Africa will be deposited at the EGA and 
access will be restricted, as is the case with the AVGP. Persons or groups wishing to access and 
use data and samples from H3Africa will have request for access through the H3Africa data and 
biospecimen access committee (DBAC). However, before data is sent to the EGA, it will be 
temporary archived at H3ABioNet for nine months (H3Africa Consortium, 2014). 
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1.2.3 Neuropsychiatric genetics of African Populations (NeuroGAP) 
A third consortium of interest is NeuroGAP. The main goal of NeuroGAP is to “advance genetic 
studies on mental illness”3. NeuroGAP was formed in 2017 and has partners in four African 
countries (Ethiopia, Kenya, South Africa and Uganda). Its HIC partners include: The Broad 
Institute, Oxford University and the Harvard Chan School of Public Health (Stevenson et al., 2019). 
The consortium is funded by the Stanley Center for Psychiatric Research at the Broad Institute, 
USA.  
NeuroGAP is organised into four broad arms, two research arms, one capacity building and the 
other focussing on ELSIs in the genomics of neuropsychiatric disorders. The two research arms 
are: NeuroGAP-Psychosis which investigates the genetics of schizophrenia and bipolar disorder; 
and NeuroDev which focusses on the genetics of childhood neurodevelopmental disorders). 
NeuroGAP-Pyschosis will collect saliva and phenotypic data from approximately 35,000 
individuals with schizophrenia and bipolar disease, as well as from persons without a history of 
psychosis (control group), from sites in all four participating African countries (Stevenson et al., 
2019). The second research arm, NeuroDev, aims to investigate genetic and environmental risk 
factors for neurodevelopmental disorders in African populations and will recruit a cohort of 5600 
participants in Kenya and South Africa (de Menil et al., 2019). Aliquot of samples collected as part 
of NeuroGAP will be sent to the Broad Institute, USA, for genotyping, whilst the remaining DNA 
extract will be stored in a designated biobank in one the participating African countries 
(Stevenson et al., 2019). NeuroGAP also plans to deposit genomic and phenotypic data from its 
research project into a public database and/or the European Genome-Phenome Archive. Access 
to the data will be through a controlled mechanism.  
1.2.4 Other genomics research and biobanking consortia in Africa 
Besides the three genomics research and biobanking consortia presented above, other genomics 
research consortia have focussed on African populations but may not have the majority of the 
characteristics which we aim to highlight that is: funded by institutions in HICs; involves the 
establishment of biobanks; focuses on African countries only; and requires the export of samples 
and the sharing of data. For example, MalariaGEN is a multicounty international genomics 
network that involves a number of LMICs in both Africa and Asia (The Malaria Genomic 
Epidemiology Network, 2008). The Southern African human genome project, on the other hand, 
is funded by the South African government and made of South African based researchers only 
(Pepper, 2011). Bridging biobanking and biomedical research in Africa (B3Africa) consortium will 
                                                     
3https://www.broadinstitute.org/stanley-center-psychiatric-research/stanley-global/neuropsychiatric-genetics-
african-populations-neurogap Accessed 29March 2019  
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not be collecting samples but will rather focus on building capacity for the management of 
biobanks. Table 1, below, provides a brief description of some of these genomics consortia in 
Africa.
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Table 1: Brief description of other genomics research consortia in Africa 
Consortia Objectives Participating Countries Funding  
The Southern 
African Human 
Genome 
Project4 
 Build capacity for genomics research in southern Africa 
 
 Establish a regional biobank 
 
 Knowledge translation to improve human health 
 
South Africa Department of 
Science and 
Technology, South 
Africa 
The Malaria 
Genomic 
Epidemiology 
Network 
(MalariaGen)5 
 Investigate how human genetic variation affects the biology 
and epidemiology of malaria 
 
 Use knowledge generated to develop malaria control tools  
Burkina Faso, Cameroon, 
Gambia Ghana, Kenya, 
Malawi, Mali, Nigeria 
Senegal, Sudan, Tanzania.  
 
Papua New Guinea, Sri 
Lanka, Thailand, Vietnam 
 
United Kingdom 
Bill and Melinda 
Gates foundation 
 
Wellcome Trust, UK 
B3Africa 6  Develop a cooperation platform and technical informatics 
biobanking framework between Europe and Africa.  
 
 Build capacity for the management of biobanks. Through 
the development of software, toolkits and ELSI frameworks 
for data sharing between Africa and EU member states 
Nigeria, Kenya, South 
Africa, Uganda 
 
Austria, France, Sweden 
and a pan-European 
biobanking consortium 
European Union  
                                                     
4 Pepper, M. S. 2011. "Launch of the Southern African Human Genome Programme." S Afr Med J 101 (5):287-8. 
5 Malaria Genomic Epidemiology Network. 2008. "A global network for investigating the genomic epidemiology of malaria." Nature 456 (7223):732 
6 http://www.b3africa.org/?page_id=2 accessed 29th May 2017 
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1.3 Ethical Issues in Genomics Research and Biobanking in Africa 
A common theme in the three projects described above (HGP; AGVP, H3Africa and NeuroGAP) is 
the sharing of samples and data. Data and sample sharing is fast becoming common practice in 
genomics research and has many benefits including: reduced cost for research, ease of 
reproducibility of study findings; and ease of reaching large sample sizes required for statistically 
significant results in genomics (Kaye et al., 2009). A number of funding agencies now have a 
mandatory data sharing policy backed by the argument that it allows for maximum use of limited 
research resources. It is therefore not surprising that sample and data sharing practices are now 
becoming a norm in global health research projects. However, it is backbone behind the macro 
justice-ELSIs that global health research consortia in Africa will have to deal with (de Vries et al., 
2015c, Tangwa, 2017, Van Rinsum and Tangwa, 2004).  
Although the flagship HGP set the pace for open data sharing in genomics research (data was 
made freely available within 24 hours), there has recently been some inertia by African 
researchers to share data without any restrictions (Bezuidenhout and Chakauya, 2018, Jao et al., 
2015). For example, access to data from the AGVP, H3Africa, and NeuroGAP, will be restricted or 
controlled and in some cases, the data will only be available for controlled access months after it 
has been generated. . These four projects have more or less the same funders and similar goals, 
yet there are nuance differences in their data sharing requirements. A compelling question, 
therefore, is: why are there differences in data sharing requirements between projects with a 
shared goal and same funders? This could be due to different reasons, some related to a history 
of scientific imperialism in international health research collaborations in Africa, whereby 
researchers from HICs collected samples from African populations, shipped them out of the 
countries without any benefit to the local population or researchers (Okwaro and Geissler, 2015, 
Tangwa, 2017, Parker and Kwiatkowski, 2016). Sample and data sharing also raises issues of 
ownership of biological material, secondary uses of samples stored in biobanks and benefit 
sharing (Barchi et al., 2015, Lucas et al., 2013, Moodley et al., 2014). It is believed that these 
different ethical issues could be addressed through defining mechanisms for promoting justice 
and fairness in genomics research consortia in Africa (de Vries et al., 2015c, Musolino et al., 2015, 
Parker and Kingori, 2016, Chen and Pang, 2015).  
1.3.1 Justice in Global Health Research 
Justice is at the nucleus of numerous philosophical theories. Some prominent accounts of justice 
that are relevant for health research include: distributive justice (fairness of outcomes); 
procedural justice (fairness of method and processes); and retributive justice (retribution and 
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punishment of an offender). Whilst fairness is a common theme in all three accounts of justice, 
there are different constructs of what fairness entails. A dominant view is that proposed by 
political philosopher, John Rawls. In his account of Justice as Fairness (Rawls, 1985), Rawls 
discusses fairness in light of two principles: liberty and equality. The liberty principle states that 
every person has an equal right to basic liberties. The equality principle, on the other hand, forms 
the basis of distributive justice and states that all institutions and positions should be open to all 
persons irrespective of their social background, ethnicity or gender and when that is not the case, 
inequalities should be to the advantage of the worst-offs. Justice is also one of the four core 
principles of biomedical ethics (Beauchamp and Childress, 2001) and forms the centre of the 
ethics debates in global health research (London, 2005, Hunt and Godard, 2013, de Vries et al., 
2015b, Pratt and Loff, 2011, Pratt and Loff, 2014).  
Recently, there have been calls for global health research programs to promote the ideals of 
justice and several tools, such as the research fairness index and the research for health justice 
framework have been developed to guide global health programs seeking to promote global 
health justice (Benatar, 2001, Ijsselmuiden et al., 2010, Musolino et al., 2015, Pratt and Loff, 
2011). These calls are based on concerns of exploitation of African populations in health research. 
The principle of justice has however received little attention in global health research compared 
to other principles like autonomy. This is not surprising given the historical development of 
research ethics and the multiple, complex and sometimes contrasting philosophical and social 
constructs of what justice entails. When the principle of justice has been invoked in health 
research, the discussions tend to center around: reducing global health inequities; allocation of 
research resources, exploitation of vulnerable groups; research priority setting; selection of 
research participants; fair research processes; research ethics review; research design, access to 
proven interventions; obligations of the different stakeholders in research; and standards of care. 
These ethical issues can be grouped under two (but interrelated) broad constructs of justice: 
micro-level justice and macro-level justice. 
1.3.1a Micro-level justice in global health research 
Micro-level justice focuses on individual-based perceptions of fairness such as: equality, need 
and merit (Rawls, 1971). Emphasis is on the needs of the individual and the relationship between 
individuals. In health research, macro-level justice issues will for example be those related to  the 
researcher-participant relationship, such as: standards of care in research conducted in LMICs 
and access to proven intervention (Hawkins and Emanuel, 2008).  
1.3.1b Macro-level constructs of justice. 
Macro-constructs of justice focus on the needs of society, rather than individuals. It is therefore 
more about aggregate fairness to society as opposed to fairness to individuals (Brickman et al., 
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1981). Macro-justice is concerned with: the structure and development of the social order and 
in encouraging people to participate in the development of their society and to have a voice in a 
social process. The assumption being that if people find a procedure to be reasonable and feel 
respected and validated, they are likely to judge the process as fair. In health and health research, 
macro-level concepts of justice will for example look at questions of global health inequities and 
the allocation of research resources. 
1.3.2 Justice-related ELSIs in genomics research and biobanking in Africa 
Recently, genomics research and biobanking consortia in Africa have seen an increase in funding 
for ELSI research. This is motivated, in part, by the need to address concerns of “extractive” 
research, mainly the exploitation of African researchers and study populations. Testament to this 
is a growing literature on the ELSIs of genomics research and biobanking in Africa, including 
questions around: appropriate informed consent models; informed consent comprehension; 
community engagement, secondary uses of samples and data, ownership of samples and data, 
intellectual property, benefit sharing, feedback of study findings, and equitable research 
collaborations (de Vries et al., 2011, de Vries et al., 2012, de Vries et al., 2017, Lairumbi et al., 
2012, Lairumbi et al., 2011, Munung et al., 2016, Nyika, 2009, Ramsay et al., 2014, Tindana and 
de Vries, 2016, Wonkam et al., 2011). Some of these ethical issues are related to the principle of 
autonomy, others are issues of justice and fairness. Below, I highlight some of these ELSIs with a 
focus on those that are linked to the promotion of justice and fairness.  
1.3.2a Secondary uses of samples and data for the benefit of African populations. 
Population genomics research thrives on collaborative research networks and the sharing of 
samples and data. This is partly due to statistical requirements for large sample sizes and a need 
for diverse scientific expertise (Kaye et al., 2009, Green et al., 2015). Therefore, samples collected 
as part of research projects will likely be shared with researchers or institutions that may not 
have been involved in the primary research projects. For example, in some genomics research 
projects in Africa, such as H3Africa it is required that aliquots of samples will be sent for 
genotyping to institutions in HICs and some stored n biobanks for future, yet undefined research 
use. Also, genomics researchers are increasingly expected to deposit their research data into 
public databases, with the hope that this will allow for maximum use of research data.  
Data sharing is now increasingly considered a professional and moral obligation for researchers 
(Choudhury et al., 2014). It is also fast becoming a default funding requirement by most funders 
of genomics research (Zawati et al., 2014, Hood and Rowen, 2013) . Open sharing of samples and 
data has numerous benefits including: the potential to increase the social value of health 
research (Boulton, 2012); enhance the efficiency of the research enterprise; accelerate scientific 
discoveries and reduce research costs (Vines et al., 2014, Pisani et al., 2010). 
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Despite the above mentioned benefits, data and sample sharing raises a host of ELSIs in Global 
health research (Bull et al., 2015, Rappert and Bezuidenhout, 2017) and in genomics research in 
particular (de Vries et al., 2015a, Kaye et al., 2009, Parker et al., 2009). Firstly, population 
genomics studies in Africa often involves research collaborations, some of which go beyond 
national borders, therefore adding to the complexity of how samples will be accessed and used 
(Budin-Ljøsne et al., 2014, Lucas et al., 2013, Moodley and Singh, 2016). Secondly, the export of 
research samples from LMICs  to HICs, has been major point of contention in global health 
research programs and the leading reason for fears bio-exploitation under the guise of global 
health research (Nienaber, 2011). Thirdly, there is little genomics research capacity in Africa, 
therefore some African researchers have expressed concerns that they may not be able to make 
downstream uses of samples in biobanks and the data generated from genomics research in 
Africa (Munung, 2016, Bull et al., 2015, Mulder et al., 2017). This leads to the question of whether 
samples collected from ongoing genomics studies in Africa and stored in biobanks for future 
research uses will eventually be used to investigate the pressing health needs of African 
populations. The same applies for genetic data generated from these projects and stored in 
genetic databases, or if the biobanks and databases would serve as a global research resource 
only, without due consideration on how use of the samples and data would benefit African 
populations. In case of the latter, one may then arguably say that African populations stand the 
risk of being exploited for the benefits of people in other parts of the world. Some initiatives and 
funding agencies have devised different ways by which concerns around exploitation and data 
sharing could best be addressed. For example H3Africa has adopted an “embargo” period during 
which data generated from consortium projects could only be used by the primary researchers 
even when it has been deposited in the public database. The European Union in developing the 
FAIR principles (Findability, Accessibility, Interoperability and re-usability) also puts more control 
of the data with the primary control of the data with the primary data generators (Wilkinson et 
al., 2016), a model which may also appeal in scenarios where fears of exploitation exist.  
1.3.2b Ownership of samples and data 
Data and sample sharing raises important questions around control and ownership of samples 
and data (de Vries and Pepper, 2012, Pepper et al., 2018, Barchi et al., 2015, Moodley et al., 
2014). This has broader implications for access to samples and data and for the translation of 
research findings (e.g. intellectual property). Discussions on ownership of samples and data are 
complex and there is little guidance on who can make claims to ownership of genetic information 
or biological material. An example is the recent dispute over ownership of samples collected 
during the 2014 Ebola outbreak in Liberia, Sierra Leone and Guinea, where researchers from the 
three West African countries have registered complains that local researchers are not able to 
access samples that were shipped to the USA, United Kingdom and South Africa, following the 
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outbreak (Freudenthal, 2019). Neither do the local researchers have knowledge on how the 
samples and data are being used. However, the report by Freudenthal, 2019, shows that a 
laboratory in Europe is currently commercialising strains of Ebola virus extracted from the 
samples. The three West African countries have since written to the laboratories in Europe and 
the US to reassert their ownership of the samples and by extension, the right to information and 
decision making on use of the stored samples. Similar concerns of ownership have been raised in 
the USA (O'Brien, 2009) and Indonesia (Fidler, 2007). These examples demonstrate, first-hand, 
how claims of ownership may lead to a downstream desire to control how samples and data are 
used.  
Debates on ownership of samples and data have led to the terminology of “custodianship”. 
Custodianship is about assigning caretaking responsibilities of data and samples to an individual 
or institution. A custodian has the responsibility of providing oversight ensuring fair access and 
use by all stakeholders whilst and recognises the contributions of the sample providers (Yassin et 
al., 2010). Proponents of the custodianship model argue that it promotes transparency, fairness 
to human research participants and shared accountability among all stakeholders (Yassin et al., 
2010). Ownership, on the hand, is informed by legal or symbolic attributions (Bjorkman, 2007). 
Therefore, ownership of samples and data may be ascribed to either: the sample providers; the 
researchers who generated the data; the institutions hosting biobanks; or the governments of 
the countries where the samples were collected. However, irrespective of who claims propriety 
rights over samples and/or data, the concern is that any stakeholder that retains ownership rights 
may hitherto have profound influence in decisions regarding sample and data use, in ways that 
prioritize their own interests sometimes at the expense of scientific advancement that may 
benefit the global population. In the custodianship model, stakeholders will have to decide on 
who has caretaking responsibilities for samples and data and how the entity would: promote 
fairness; ensure that there is maximum use of samples and data; uphold transparency and 
accountability (Winickoff and Winickoff, 2003, Fullerton et al., 2010, Yassin et al., 2010).  
There are suggestions that global health research programs that plan to share samples and data 
should identify an independent body/individual that could serve as custodian of samples and 
data (Yassin et al., 2010). Ownership rights, on the other hand, may be shared between 
researchers, research participants and the research institutions providing oversight of samples 
and data (O'Brien, 2009). However, these discussions are yet to be extended to the ELSI discourse 
in genomics research in Africa. Although in some recent publications (Pepper et al., 2018, Yakubu 
et al., 2018), custodianship and ownership are used simultaneously with a seeming preference 
for custodianship.  
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1.3.2c  Benefit sharing 
Benefit sharing is “the action of giving a portion of advantages/profits derived from the use of 
human genetic resources to the resource providers to achieve justice in exchange, with a 
particular emphasis on the clear provision of benefits to those who may lack reasonable access to 
resulting healthcare products and services without providing unethical inducements” (Schroeder, 
2007). Benefit sharing is a benchmark for ethical research in LMICs (Emanuel et al., 2004). It is 
embedded in the principle of justice (Beauchamp and Childress, 2001). It is also considered one 
way of building trust and promoting reciprocity between researchers and study communities 
(Knoppers, 2000). For example in 2007, the Indonesian government refused to share, with the 
WHO, avian influenza samples that were collected in Indonesia, a decision that shocked the 
global health community, as the samples were to be used for the development of an influenza 
vaccine. Indonesia had refused to share samples because it had been informed that an Australian 
pharmaceutical company was to use the samples and data to develop a vaccine, yet there were 
no clear plan for ensuring access to the vaccine by the people of Indonesia and other LMICs 
(Fidler, 2007). This caused an international outrage with many LMICs, including Libya and Nigeria, 
supporting Indonesia’s position (Vezzani, 2010, Hammond, 2009, Franklin, 2009). This highlights 
reciprocity-based expectations in global health research. Also, there was a breakdown of trust 
between Indonesia and the WHO leading to reluctance to further share samples. Indonesia then 
created a database for sharing genetic sequences which requires secondary users to consult with 
the primary researchers before they submit any publication or Intellectual property agreements 
arising from use of the data.     
Despite the importance of benefit sharing in advancing the ideals of justice in global health 
research, there are conceptual and practical challenges to the implementation of benefit sharing 
(Hugo Ethics Committee, 2000, Lairumbi et al., 2012, Schroeder et al., 2005, White, 2007). A 
question that stands out is: what constitutes a benefit in global health research. Empirical studies 
suggest that benefits could take the form of: access to healthcare; research capacity building; 
access to proven interventions; technology transfer; infrastructural development; and the 
provision of social amenities to study communities (Lairumbi et al., 2012, Munung, 2016). These 
different forms of benefits aim to advance justice at both the micro and macro-level. But it is 
debatable if benefit sharing should focus on individual needs or broader social issues that pre-
dispose populations in LMICs to exploitation. Whether benefit sharing advances justice at the 
micro or macro-level, one may argue it is more about ensuring that populations who bear the 
risk of research should also share in the benefits (Schroeder et al., 2005, Hugo Ethics Committee, 
2000). The discourse on benefit sharing will therefore benefit from explorative and conceptual 
studies that seek to identify what principles, values and norms justify benefit sharing 
arrangements and how it could be best implemented.  
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1.3.2d Intellectual property (IP)  
A convoluted ELSI in genomics relates to “innovation” arising from genomics research and 
whether or not such innovations are permissible for patenting or intellectual property. There are 
several cases (successful and otherwise) of researchers or institutions that have applied to patent 
DNA sequences or genomics related inventions (Cook-Deegan and Heaney, 2010, Hopkins et al., 
2006). Some of these include patents on: genes/gene sequences; methods for the isolation of 
DNA sequences; and healthcare products (e.g. diagnostic tests). There is also a movement against 
the patenting of DNA sequences, backed by arguments that: 1) DNA occurs naturally and 
therefore no one can claim to have “discovered” or invented them; 2) patents of DNA sequences 
will limit research and healthcare; and 3) DNA sequences do not meet legal requirements for 
patenting (NCOB, 2002). There are also parallel arguments that gene patents could fast track 
scientific discovery and innovation (Chandrasekharan and Cook-Deegan, 2009). However, a 
recent study showed that gene patenting has no important quantitative effect on scientific 
research and follow-on innovation (Sampat and Williams, 2019).  
Whether or not gene patenting benefits or restricts scientific innovation, a point of interest for 
the global health justice debate is if the benefits from patenting will be evenly distributed (Smith 
et al., 2004). Patents work best where there is a healthy economy, which unfortunately, is not 
the case in most LMICs. Therefore, though patenting may serve as an incentive for the translation 
of genomics knowledge, if care is not taken, it may stifle innovation for health problems that are 
peculiar to LMICs. This may result in limited access to genomics medicine by populations in Africa, 
despite their participation in population genomics studies (Westerhaus and Castro, 2006, Correa, 
2009).  
The UNESCO declaration on the human genome and human rights (Article 4), states that “the 
human genome in its natural state shall not give rise to financial gain” (UNESCO, 1997). Whilst a 
number of regulatory regimens and patent offices have declared that gene sequences cannot be 
patented, there is still a wave of conflicts and controversies in Europe and the USA around 
patents and commercialisation in genomics (Kean, 2011, Cook-Deegan and Heaney, 2010). 
Genomics research and biobanking consortia in Africa would need to seek for solutions to the 
dilemma of IP, especially given the gaps in patent laws in most African countries.  
The issuance of intellectual property and patents can incentivize translation efforts and 
encourage innovation. However, it will have to be done in such a way that as not to hamper 
research or limit access to proven interventions by populations in LMICs. That is, if patents and 
other IP rights are a necessity for innovation, an approach whereby access to innovation and 
other related benefits are made available for people in Africa would be need to identify in order 
to prevent a scenario whereby those provided the desired samples and data for understanding 
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human genetic variation and health, are unable to access the benefits of such research. This again 
raises issues of benefit sharing in population genomics research in Africa.  
1.3.2e Fears of exploitation of African researchers and study populations 
The final justice-related ELSI in genomics research and biobanking relates to fears of exploitation. 
Exploitation is a moral conundrum that occurs when an agent (person or group of persons) 
exploit another in a way that is considered morally wrong. Often, differences in power dynamics 
are critical for such exploitation to occur. (Brown, 2014).  
The Kantian approach to exploitation describes exploitation as the harmful, merely instrumental 
utilization of a person’s capacity for one’s own advantage or for one’s own ends. It goes beyond 
use to include harm. Morality is a central category in Kantian exploitation. In Kantian ethics, A 
exploits B when A gets a benefit from an interaction with B on a maxim that: reduces B’s rational 
agency (even if this was done with consent from B); fails to acknowledge the needs of B as a 
rational agent (beneficence) and demeans or degrades B without preserving B’s agency. Critics 
of the Kantian approach to exploitation argue that it is difficult to characterise what harm is and 
that the Kantian conception presupposes that exploitation is involuntary (Siegel, 2008) or 
degrades the weaker party (Wood, 2009), which may not necessarily always be the case. 
More contemporary approaches to exploitation tend to base their argument on the idea that one 
may be exploited even with their voluntary consent and it may sometimes be mutually beneficial, 
even in cases of vulnerability. They rely on Wertheimer’s conception of exploitation, that is: A 
exploits B when B receives an unfair level of benefits as a results of B’s interactions with A 
(Wertheimer, 1999). The moral focus is on the level of benefits and not what B receives -This 
level of benefit must be fair. Fairness is characterised by the level of burden B bears as part of 
the interaction and the benefits that A and others receive as part of their interaction with B. 
Contemporary approaches to exploitation therefore seem to have adopted the fair benefits 
argument which are more justice-inclined. An unfair advantage occurs when A takes advantage 
of B’s vulnerability and/or when A gains more than B (disproportionate benefit) as a result of 
their interaction (Ballantyne, 2005, Benatar and Fleischer, 2004).  
Exploitation has been labelled a central inequity in international health research (Hawkins and 
Emanuel, 2008). There is also general consensus on the importance to prevent the exploitation 
of research populations in LMICs (Siegel, 2008). Interestingly, however, there is no consensus on 
what exploitation in health research entails, though there is some degree of agreement as to 
when it occurs. Exploitation in clinical research occurs when: a person’s inability to provide 
consent is taken advantaged of; when the research does not address the health needs of the host 
population; and when post-trial benefits are not addressed by the sponsors of the research 
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(Emanuel et al., 2004, Ballantyne, 2005). When this happens, it can be said that the research 
sponsors have taken advantage of the vulnerability of study population to conduct research that 
offers them an unfair level of benefits. 
Cases of exploitation of African researchers and study populations in global health research 
collaborations have been widely discussed (Tangwa, 2017, Okwaro and Geissler, 2015, Angell, 
1997, Ballantyne, 2005, Freudenthal, 2019). These historical experiences have sometimes led to 
deep mistrust between HIC and African research partners; and a strong desire for equity in global 
health research collaborations (Munung, 2016, Parker and Kwiatkowski, 2016, Chu et al., 2014). 
A recent study showed that African scientists involved in genomics research in Africa had 
concerns of exploitation and expressed a desire for transparency, fairness and African leadership 
of genomics studies in Africa (Munung et al., 2017). The study also documented that African 
researchers wanted to be involved in decision-making processes with the hope that this will 
mitigate the potential of them being exploited. 
Power asymmetries between LMICs and HICs have contributed to fears of exploitation of African 
researchers and study populations who are involved in global health research collaborations. For 
example, limited local funding for health research has seen African researchers enter into global 
health research collaborations on an unequal footing, mainly to access funds for research or to 
supplement their paltry salaries (Bhutta, 2002, Chu et al., 2014). This could give HIC researchers 
the advantage of pushing their own research agenda rather than prioritising the health and 
research needs of the African country. It is also claimed that funders and HIC researchers often 
dictate the research agenda in most global health programs and that sometimes their research 
agenda is very different from the needs of the LMIC where the study is being conducted (Sridhar, 
2012, Chu et al., 2014). While global health research programs can be of benefit to both HICs and 
LIMICs, LMIC partners must be given a chance to participate in decision-making about key equity-
oriented subjects such as research priority setting (Butrous, 2015, Pratt et al., 2016b). LMIC 
researchers must also ensure that studies conducted in Africa are responsive to the health needs 
of the study population. This is relevant for genomics research and biobanking in Africa where 
there is uncertainty on future use of samples stored in biobanks or data deposited in public 
databases. It will require that African researchers and other stakeholders be involved in decision-
making on secondary uses of samples and data. Giving African stakeholders the opportunity to 
participate in decision-making making structures within global health research programs, has the 
potential to promote equitable and fair research collaborations (Munung et al., 2017).  
In recent times, significant efforts have been made to address the moral wrongs of exploitation 
in global health research. In genomics research for example, a number of initiatives are in place 
to ensure that genomics research collaborations in Africa are fair and equitable (de Vries et al., 
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2015c, Parker et al., 2009). There is no doubt that this has changed the way some global health 
programs currently operate on the continent and could possibly has led to significant changes in 
how African researchers approach global health research collaborations. However, the discussion 
has mainly leaned towards protecting African researchers from exploitation, with little being said 
about the possibility of exploiting African research populations. One of the few documented 
cases of exploitation of study populations in genomics research in Africa is that of the San people, 
where there are claims that although genomics studies on this indigenous African population 
would be of benefit to humankind as a whole, the study participants and community felt had 
been exploited by the researchers (Chennells and Steenkamp, 2018). The reasons for this vary   
including concerns that scientific publications from a particular study had reported information 
that was far removed from what it had primarily seek to address, and which could stigmatise the 
SAN people. Also, there were claims that the researchers persistently refused to meet and discuss 
the content of the consent forms. The San community considered this a show of disrespect  by 
the researchers. This subsequently led to a series of conversations on the ethics of genomics 
research on indigenous populations resulting in the San code of research ethics (SASI, 2017). The 
code insists that before any health research is carried out in the San community: the protocol 
must be designed together with the community; there must be meaningful consultation with the 
San people; the project must provide in-depth information on the benefits of the study to the 
San people; and have a defined benefit sharing arrangement. The code also states that research 
on the Sans must be aligned to their local needs and aim to improve the lives of community 
members. Other recent examples were concerns of exploitation have been voiced by study 
communities include: the use of samples collected from Ebola patients by laboratories in Europe 
without the population being informed that their samples were to be used for research or in the 
development of a commercial product (Freudenthal, 2019). Also, sex workers in Kenya have 
pointed out that their contributions to research have not been rewarded in full (Andanda and 
Lucas, 2007, Schroeder and Lucas, 2013) and therefore requesting for: meaningful involvement 
in research processes, inclusion in decision-making in research projects were they are involved; 
a code of conduct for researchers; and more practical benefits from the decades of studies that 
they have been part of (Gosling, 2017, Tukai, 2018).  
Based on the examples above, the possibility of exploitation of African researchers and study 
populations could be minimised through: prioritising research that is aligned to the health needs 
of study populations, identifying benefit and benefit sharing arrangements, building capacity for 
genomics research, having meaningful engagement with study communities; involving study 
communities and African researchers in decision-making; African leadership of research projects 
and transparency.    
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1.4 Study Rationale 
It is undeniable that data and sample sharing would have to occur within a system that promotes 
high ethical standards (Kaye et al., 2009). This is important given markedly visible inequalities in 
health and health research between HICs and African countries, as well as concerns of 
exploitation and extractive research. 
Genomics research and biobanking consortia in Africa will undoubtedly have to address ethical 
issues related to: secondary uses of samples and data; exploitation; ownership of data and 
samples; benefit sharing and intellectual property (Chen and Pang, 2015, Bull et al., 2015, de 
Vries et al., 2015c, Tangwa, 2017). To this effect, some genomics research and biobanking 
consortia in Africa have set up governance structures that would look into, on a case by case 
basis, the ethical issues raised by secondary uses of samples and data. However, it remains 
unclear how fair processes for access and use should be designed; and what principles or values 
should guide such processes.  
A number of authors have proposed different ways or approaches by which concerns of 
inequities in global health research could be possibly addressed, including: the research for 
health justice framework (Pratt and Loff, 2014); and the human development framework 
(London, 2005). These frameworks, which were principally designed to advance justice in clinical 
research, have been applied to health systems research in LMICs (Pratt et al., 2016a, Pratt and 
Hyder, 2017, Pratt and Loff, 2013). However, global health research goes beyond clinical research 
to include other forms of research such as: biomedical research; social and behavioral studies; 
epidemiology; implementation research; and genomics research amongst others. Some of these 
research types involve the use of novel technology, or requires procedures that are different 
from traditional scientific practice and which may challenge the usual day-to-day research ethics 
discourse. A good example is genomics research. Genomics research and biobanking in Africa is 
taking place amidst fears that genomics may widen global health inequities (Pang, 2002, Singer 
and Daar, 2001b, Newport and Rotimi, 2009, Van Rinsum and Tangwa, 2004). This is not only 
because it is conducted in a part of the world that disproportionately bears the global burden of 
disease and that suffers from abject poverty (Tangwa, 2017) but also because it raises unique 
ELSIs compared to other forms of global health research (de Vries et al., 2011, Nyika, 2009, 
Wonkam et al., 2011). A key question that has emerged in the bioethics discourse is whether 
genomics will improve the health of world’s people or if it will widen the technology gap between 
LMICs and HICs thereby worsening global health inequities (Singer and Daar, 2001b). With the 
recent influx of externally funded genomics research and biobanking initiatives in Africa, these 
questions need to be further explored not only for primary research studies but also for studies 
that would eventually use data and samples from African genomics studies.  
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Equally, genomics research and biobanking consortia in Africa are operating amidst a climate of 
strong fears of exploitation of genomics researchers in Africa as well as study populations 
(Munung et al., 2017, Van Rinsum and Tangwa, 2004, Wonkam et al., 2011, Chennells and 
Steenkamp, 2018). There is also a historical context to exploitation of African researchers in 
global health research collaborations (Annas and Grodin, 1998, Ballantyne, 2005, Hawkins and 
Emanuel, 2008, Okwaro and Geissler, 2015, Tangwa, 2017, Jentsch and Pilley, 2003). With the 
rise in externally funded and collaborative genomics studies in Africa, it is therefore important to 
explore the different ways by which genomics research and biobanking consortia in Africa could 
further the ideals of health justice and minimise the exploitation of study populations and African 
researchers. A keen look at the different ELSIs suggests that power and economic disparities 
between LMICs and Africa, as well as global health inequities, are the main stirrer for a majority 
of the macro-level justice-related ELSIs in genomics research and biobanking in Africa.  
There are also broad perceptions that governance will be a tool for addressing macro-level justice 
ELSIs in global health research (Lee and Mills, 2000, Pratt and Hyder, 2016, Pratt and Hyder, 2017, 
Winickoff, 2008). This is because the majority of these justice ELSIs are due to power and 
economic differences between HICs and LMICs. Therefore, effective governance mechanisms 
that: articulate health equity oriented goals, minimises the influence of more powerful 
stakeholders in decision-making; and that sets out the responsibilities of all stakeholders, is more 
likely to foster the promotion of justice in genomics research and biobanking consortia in Africa. 
This thesis seeks to fill this gap by proposing a principles-based governance framework for 
genomics research and biobanking in Africa. We hope that such a framework would appeal to 
the broad range of stakeholders involved in genomics research and biobanking projects in Africa. 
To develop the governance framework, we used a variety of methodological approaches, 
including both conceptual and empirical analysis.  
1.5 Thesis outline 
In this study, we explored how the ideals of justice could be advanced in genomics research and 
biobanking in Africa, with a focus on governance. Specifically, we explored how genomics 
research and biobanking projects in Africa should be governed such that it promotes the ideals 
of health equity and justice. To do this, we embarked on a conceptual analysis of justice theories, 
as well as empirical research that captures existing governance of genomics research programs 
in Africa. I started with a conceptual analysis of two accounts of global health justice and a 
normative analysis of the African indigenous mora theory of Ubuntu. This led to the identification 
of principles that could guide the governance of genomics research in Africa. Following the 
identification of these principles, I proposed a principles-based (or conceptual) governance 
framework for genomics research and biobanking in Africa. To test if the proposed framework 
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will meet the needs of genomics research programs in Africa and how it could be implemented, 
I used two empirical bioethics methods (reflective equilibrium and the convergence approach) 
and qualitative research methods (case study, document analysis and in-depth interviews). The 
empirical data was used to check the frameworks requirements for areas of divergence and to 
revise accordingly. 
This thesis reports on the conceptual and empirical work that was conducted. It is divided into 
eight (8) chapters:  
Chapter 1 (the present chapter) sets the stage for the conceptual and empirical work. It 
includes: a brief description of genomics research and biobanking consortia in Africa, with 
the goal of highlighting unique characteristics of population genomics research in Africa. 
I argue that these characteristics of genomics research raise justice- ELSIs (also briefly 
described) which could be addressed through governance.  
Chapter 2 is a presentation of the conceptual methods and analysis that were used to 
identify principles that could inform the governance framework. . This involved a 
conceptual analysis of three governance accounts: shared health governance; global 
governance for health; and the African moral theory of Ubuntu. Using the convergence 
approach, I identified key principles that could advance the ideals of justice and fairness 
in genomics research in Africa. These were then used to propose a principles-based 
governance framework for genomics research and biobanking in Africa. 
Chapter 3 presents the principles-based governance framework for genomics research 
and biobanking in Africa, based on the principles that were identified in Chapter 3. The 
framework makes recommendations on how the principles could be operationalized. The 
aim is to have a framework that is not far removed from practice, yet grounded in 
theoretical principles. 
Chapter 4 is a description of the empirical methods that I used to test the principles-based 
framework, mainly the reflective equilibrium approach. It involved a case study (H3Africa 
consortium); document analysis of H3Africa governance-related documents; and one-on-
one in-depth interviews with stakeholders in genomics research and biobanking in Africa 
who are involved in governance processes or have in the past been involved in the 
development of H3Africa governance policies.  
Chapter 5 is one of two chapters that report on the results of the empirical work described 
in Chapter 4. It is a presentation of the content analysis of H3Africa governance 
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documents. The interpretation of the analysis is partly informed by my experience as a 
student within the H3Africa consortium.  
Chapter 6 is the second of the two result chapters. It reports on the in-depth interviews 
that were conducted with stakeholders in genomics research and biobanking in Africa. 
The analysis is supported by quotes from the interviews.  
Chapter 7 presents the points of divergence between the principles-based framework and 
the empirical data. It also indicates revisions that will be made in the framework. The 
chapter ends with a description of how the principles-based framework could be applied 
to the justice-related ELSIs that were described in Chapter 1. 
Chapter 8 is the last chapter. It is a summary of the outcome of the entire study. It includes 
a brief discussion of the study outcome; suggestions for future research; and the 
limitations of this study. I7 conclude the chapter with a brief explanation of the impact of 
the study. 
1.6 Researcher’s Positionality  
A good part of my postgraduate research (M.Sc. and PhD) work was nested in the H3Africa 
consortium. As an H3Africa funded postgraduate student, I have observed and sometimes been 
involved in the development of some H3Africa ethics policies.. Also, one of my supervisors was 
once the chair of the H3Africa ethics and regulatory issues WG. In her role as chair of the WG, 
she led the development of some H3Africa policies. She is also part of the H3Africa steering 
committee. We therefore knew first hand, persons who have been involved in developing 
governance for genomics research and biobanking in Africa and who were likely to provide an 
informed perspective on the justice-related ELSIs. We relied heavily on this knowledge and 
experience to select potential interviewees for this study, to give context to the problem under 
study, and analyse and interpret the empirical data. 
I received a PhD student stipend from an H3Africa funded project. I do not however consider that 
this had a significant impact on the work reported in this thesis, as the funders were not involved 
in any part of the work from the design of the study to the interpretation of the empirical data. 
Neither have the funders been presented with any parts of these work for comments. I however, 
acknowledge that by receiving PhD support from an H3Africa project, it may have, to a limited 
extent had some salient and unintentional bias in the interpretation of the empirical aspects of 
                                                     
7 “I” as used in this thesis, refers to the student. 
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the work. This was minimized by having a co-supervisor who has never been involved in H3Africa 
programs and who checked the interpretation of the results for any possible clues to bias 
1.7 Research Ethics Clearance 
Research ethics clearance (Appendix 1) was obtained from the University of Cape Town, Faculty 
of Health Sciences Research Ethics Committee (HREC REF: 548/2016). This approval was obtained 
in August 2016 and renewed annually (until data collection was completed).  
1.8 Summary of Chapter 
Recent years have witnessed a heightened discourse on ethical issues in global health research 
in Africa. This is accompanied by a noticeable shift from concerns about the burdens of 
participating in research to questions of justice and fairness (Varmus and Satcher, 1997, 
Ijsselmuiden et al., 2010). This shift is nowhere more evident than in genomics research and 
biobanking in Africa where many of the key ELSIs go beyond individual participants, to include 
broader issues of justice and fairness. A challenge for genomics research and biobanking in Africa 
is to create conditions whereby African researchers can feel confident that samples and data 
entrusted in their care will be used appropriately, and that decision-making processes for their 
use are sufficiently transparent and accountable (de Vries et al., 2011). One way to achieve this 
is through governance. The research leading to this thesis principally aims to address this gap. 
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Chapter 2: Towards a Principles-based Governance 
Framework for Genomics Research and 
Biobanking in Africa 
Power and economic disparities between LMICs and HICs, as well as global health inequities 
contribute enormously to the exploitation of African Stakeholders involved in global health 
research in Africa. They also contribute substantially to the justice-ELSIs in genomics research in 
Africa. Therefore, mechanisms that could minimise the impact of these disparities, prevent 
exploitation of Africa stakeholders and build trust between all stakeholders, could be the way 
forward. In attempting to distribute power between stakeholders, and by extension resources 
and benefits, it will be advantageous to first identify shared values, norms and principles that 
should ideally inform the actions of all stakeholders. This is because if persons involved in a joint 
activity agree to abide by certain norms, principles, processes or concepts, then is there is likely 
to be a shared sense of fairness and equity amongst them (Gomez-Dants and Frenk, 2015, Kumar 
et al., 2016, Benatar, 2001).  
The impact of power disparities and its potential role in exploitation can be minimised through 
governance processes that are informed by shared values (Lee and Mills, 2000, Pratt and Hyder, 
2016, Pratt and Hyder, 2017, Winickoff, 2008). Governance is about principles, norms, values and 
institutions by which policies and decisions are made, implemented and enforced (Hufty, 2011, 
UNDP, 1997). It is also about managing power relationships within a given society (UNESCO, 
2009). This makes governance an appropriate approach to addressing macro-level (society level) 
justice issues in genomics research and biobanking in Africa.. This thesis seeks to develop a 
principles-based governance framework for genomics research and biobanking that could 
provide guidance for navigating the macro-level justice-related ELSIs in genomics research and 
biobanking consortia in Africa.  
In this chapter, I present the methodology that I used to identify the principles that could inform 
the governance of genomics research and biobanking in Africa. This involved a conceptual 
analysis of two theoretical accounts of global health justice and governance, and the African 
moral theory of Ubuntu. Drawing on empirical evidence from global health research projects in 
Africa, I also highlight what some of these principles could mean in practice. The overall goal is 
to identify principles or values that could guide the way genomics research and biobanking 
consortia in Africa address the macro-level justice ELSIs that I described in chapter 1: the 
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exploitation of African researchers and study populations, access and secondary uses of samples 
and data; ownership of samples and data; benefit-sharing and intellectual property.  
I start the chapter by explaining why effective governance for genomics research and biobanking 
is important. I then describe the different approaches that we used to identify principles and 
values that can inform the governance of genomics research and biobanking in Africa. This 
involved a conceptual analysis of: two accounts of global health justice and governance; and the 
African moral theory of Ubuntu. Principles and values that were identified using the convergence 
approach. I conclude the chapter with a list and definition of the principles that we consider 
important, based on the theoretical analysis.    
2.1 Governance of genomics research and biobanking in Africa: Why is it 
important? 
The rich human genetic diversity in African populations is a rich research resource for studies 
aimed at identifying rare gene variants and their role in health and disease (Gurdasani et al., 
2015, H3Africa Consortium, 2014). It is therefore not surprising that there is a systematic increase 
in population genomics studies in Africa, a good proportion of which involve researchers and 
funders in HICs. Many of these projects also have a biobanking component and require that 
researchers store an aliquot of their samples in biobanks; send some of the samples to 
laboratories in HICs for sequencing, and deposit the genetic data from their projects in public 
databases. Samples stored in biobanks as well as the associated clinical and genetic data may be 
used for research and/or innovation purposes by researchers from around the world.  
The success of population genomics studies depends on: the availability of large samples sizes; 
huge amounts of funding, and the availability of diverse scientific expertise required to perform 
genomics analysis. It is therefore common nowadays for genomics research projects to organise 
themselves into a network or consortium. By organizing genomics research projects in the form 
of a consortium, researchers and other stakeholders could make maximum use of limited 
resources, easily achieve statistically significant sample sizes and share expertise in ways that 
would be impossible for single projects, given Africa’s limited resources and capacity for 
genomics studies in Africa (Pang et al., 2003).  
Despite the benefits of organizing into a consortium, fears of exploitation of African researchers 
and study populations involved in population genomics research remain a major concern 
(Munung et al., 2017, Upshur et al., 2007, Chennells and Steenkamp, 2018, Moodley and Singh, 
2016) and would arguably come up in any ELSI debate on the ethics of genomics research in 
Africa. Similarly, genomics research and biobanking in Africa is taking place amidst a high disease 
burden, limited scientific capacity, and low public and private investment in health research, 
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therefore making African researchers and populations prone to exploitation by their 
collaborators in HICs (Wonkam and Mayosi, 2014, Tangwa, 2017, Benatar, 2002). Genomics 
research and biobanking consortia in Africa cannot afford to neglect these inequities and should 
put in place mechanisms to minimise the negative effects that such inequities may have on the 
bigger goal of genomics research in Africa- to prevent a genomics divide between HICs and Africa. 
A genomics divide between HICs and LMICs would likely widen global health inequities8 (Newport 
and Rotimi, 2009, Singer and Daar, 2001b, WHO, 2002).  
Exploitation in global health research is often associated with inequities in resources, research 
capacity and technological ability between Africa and HICs (Hawkins and Emanuel, 2008, Tangwa, 
2017). There is no doubt that limited or no access to local funding makes African researchers 
vulnerable when they engage in global health research collaborations. For example, African 
researchers, as a means of professional survival, sometimes engage in research collaborations on 
an agenda different from their local health priorities or personal research interest (Kok et al., 
2017). Whilst this may be beneficial for their professional development and the financial viability 
of their institutions, it may be not be contributing to improving the health of the global poor 
(Wolffers et al., 1998). In addition, the technological and research prowess of their HIC 
collaborators often mean the terms of collaboration are set by the HIC partner. When this 
happens, it can lead to avoidable tensions such as: fears of exploitation of African researchers 
and study populations, frustrations around not being consulted when research projects are 
designed; the absence of African voices in decision-making processes; and African researchers 
not being treated as equals by their HIC collaborators (Hawkins and Emanuel, 2008, Nordling, 
2012, Munung et al., 2017, Tangwa, 2017), all of which have been expressed in genomics research 
in Africa (Munung et al., 2017, Munung et al., 2018, Parker and Kwiatkowski, 2016, Staunton et 
al., 2018). It has been suggested that these tensions could be addressed through fair and 
equitable governance mechanisms (Chen and Pang, 2015, Parker and Kingori, 2016, WHO, 2002). 
Hence, the need for a governance framework for genomics research and biobanking in Africa that 
addresses ethical issues that arise due to structural inequities in health and health research 
between HICs and African countries. This chapter describes the methodological approach we 
used in developing a governance framework for genomics research and biobanking in Africa.  
                                                     
8Genomics has been described as revolutionary biotechnology and the future of medicine. However, genomics 
research is extremely expensive and there is little evidence yet, that it will have significant health benefits for the 
global population commensurate with the amount of spending or if it will be “social bubble', analogous to the 
economic bubble where investment in genomics may end up with a negative cost-benefit ratio (BALL, P. 2010. 
Bursting the genomics bubble. Nature: International Weekly Journal of Science. 31 March 2010 ed.). This broader 
justice-related question, though not discussed at length in this thesis, is crucial in discussions around the genomics 
and global health inequity.  
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2.2 Methodology: A convergence approach to identifying key principles for the 
governance of genomics research and biobanking in Africa 
Governance is a set of principles, norms, rules and decision-making processes around which the 
expectations of actors involved in a specific activity converge (Hufty, 2011). It is also the complex 
mechanisms, processes, relationships and institutions by which stakeholders engaged in a 
particular activity express their interests; exercise their rights and obligations; and mediate their 
differences (UNDP, 1997). Regulation and laws form part of governance. However, with the 
exception of international law, regulation and laws are fragmented and intended for use by the 
nation states that articulated them. Governance is broader in scope and includes principle, values 
and standards considered as good practice across nations or population groups (Shaw et al., 
2005). Therefore, developing a governance framework requires identifying a principles and 
values9 that may guide the operations between groups of people who share a common objective. 
To identify principles that could inform governance of genomics in Africa in ways that promote 
justice and fairness, I did a conceptual analysis of three theories of governance. The principles 
adopted for use in the framework were identified following the convergence approach.  
2.2.1 The Convergence Approach 
The convergence technique is a research method that entails comparing relevant theories and 
conceptual approaches with the overall aim of identifying points of convergence and divergence; 
and then pulling together the points of convergence to propose a practical solution to a problem 
(Pound and Campbell, 2015). The advantage of this method is that it leads to practical solutions 
that are less likely to be contentious, compared to solutions that are developed from a single 
theory (Bailey et al., 2015, Krubiner and Merritt, 2017). The convergence approach requires: 1) 
identifying theories that maybe relevant in addressing a moral question; 2) doing a meta-
synthesis of the selected theories with the view of identifying points of convergence and overlap; 
and 3) using the common principles (points of convergence or overlap) to propose how the moral 
problem may be practically addressed.  
                                                     
9 It may be important at this stage to define principles, values and norms. Principles are beliefs or rules that govern 
the behaviour of an agent. They are collectively agreed upon by society, and serve as a moral compass for behaviour. 
Principles tend to be concrete and provide almost immediate and very straightforward answers to ethical questions. 
Values, on the other hand, are standards of behaviour. Like principles, values can also give direction on how to 
address a moral problem. They are however less rigid than principles, and sometimes form the foundation of most 
principles. (For a detailed description, see Schroeder et al 2019, In Equitable Research Partnerships: A Global Code 
of Conduct to Counter Ethics Dumping. Cham: Springer International Publishing.  
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2.2.2 Identification of theories of justice that could inform the governance of genomics 
research and biobanking in Africa.  
The moral problem that this thesis seeks to address is: how can the ideals of justice and fairness 
be advanced in genomics research and biobanking projects in Africa? In the introductory chapter, 
I argued that one effective way could be through governance. To develop a governance 
framework for genomics research in Africa, I interrogated different accounts of global justice and 
governance and to find a convergence or overlap of different principles considered relevant for 
global health partnerships. This is because theories of global justice provide a moral structure of 
what ought to be done to achieve fairness and equity at a global level (that is beyond nation 
state). Considering, that global health research has been linked to the promotion of health justice 
(Benatar, 2001, Gostin and Friedman, 2013), and that most of the justice ELSIs are linked to 
inequities (power, resources and health) between HICs and LMICs, theories of global health 
justice will be a favourable starting point. 
There are different definitions and theories of global justice (Pogge and Moellendorf, 2008, 
Shapcott, 2011). However, in its most simplest form, global justice can be defined is a component 
of international relations that focusses on the moral obligation of the global rich to the global 
poor (Shapcott, 2014). Going by this definition, theories of global justice can be grouped into 
three broad categories: cosmopolitanism, communitarianism, and neo-realism. 
Cosmopolitanism views individuals as members of a single moral society and stresses on the need 
for individuals to detach from local or national affiliations and act as global citizens (Kleingeld and 
Brown, 2014). Communitarianism, on the other hand, is premised on the ideology that a person's 
social identity is moulded by their community, therefore shared communities values should be 
at the centre of moral judgement (Nussbaum, 2003). Neorealism emphasises the sovereignty of 
the state and the relationship between states in addressing global inequalities (Slaughter, 2011). 
These three approaches to global justice are the basis for the majority of theories of global health 
justice (Stapleton et al., 2014).  
Global health justice is concerned with: avoidable and unfair disparities in health across global 
population; and the obligations of nation states to address global health inequities. The desire to 
address health inequities has led to the articulation of different accounts of global health justice 
(Gostin and Friedman, 2013, London, 2005, Ruger, 2011, Stapleton et al., 2014). These theories 
debate issues related to who has moral responsibilities for addressing global health inequities 
(Ruger, 2012c, Stapleton et al., 2014). To this effect, there is some conceptual work, albeit 
minimal, that seeks to link global health justice to governance. Some of these include: global 
governance for health (Gostin and Friedman, 2013, Gostin and Mok, 2009, Gostin et al., 2011) 
and shared health governance. To develop a governance framework for genomics research and 
biobanking in Africa, did conceptual analysis of these two dominant accounts of global health 
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justice and governance. This was informed by three main reasons. Firstly, their development 
takes into account power differences between LMICs and HICs and the impact that it has on 
global health partnerships. Secondly, these accounts link the promotion of global health justice 
to governance and therefore propose values or principles that could promote justice and fairness 
in global health consortia. Lastly, shared health governance (SHG) has recently been applied to 
the governance of global health research (Pratt et al., 2016a, Pratt and Hyder, 2017).  
Developing governance also requires taking into consideration the values and cultures of the 
society where it will be applied. Considering that we are developing governance for genomics 
research conducted in Africa, I wanted to look at values that are common to populations across 
Africa and which could inform governance. I found the African philosophy of Ubuntu to be 
appealing. A number of African philosophies or theories of social justice exist (Kagame, 1976, 
Nyerere, 1968, Ramose, 1999, Verharen, 2008, Wiredu, 2006). However, I opted to use Ubuntu 
for a couple of reasons. Firstly, it has recently emerged in ELSI discussions on the governance of 
genomics and biobanking in Africa (Yakubu et al., 2018). Secondly, it is not only a moral theory, 
it embodies values, principles, and notions of traditional African justice and governance (Letseka, 
2014), which are key elements that we seek in developing a governance framework. Thirdly, it 
has been used to inform organisational governance in traditional African societies (Khomba et 
al., 2013, Nzimakwe, 2014). Lastly, the Ubuntu philosophy is widespread across sub-Saharan 
Africa (Metz, 2007). 
In the remainder of this chapter, I will: 1) provide a description of the three theoretical 
governance accounts; 2) highlight the principles promoted by each of them; 3) identify points of 
convergence between them and 4) use these points of convergence to select principles that could 
inform the promotion of justice in genomics research and biobanking in Africa. 
2.2.2a Global Governance of Health (GGH) 
Global Governance of Health (GGH) is a collection of norms, practices and institutions that 
collectively shape the health of the world’s population (Gostin and Friedman, 2013). It was 
developed in response to major challenges faced in the governance of global health, including 
the impact of power differentials between LMICs and HICs; the economic power of selected 
stakeholders; and the ever changing landscape of global health (Gostin and Mok, 2009). GGH 
seeks to identify ways in which the disproportionate burden of disease borne by people in poor 
regions of the world could be addressed. It suggest that one approach to addressing global health 
inequities is to support research on diseases that are prevalent amongst the global poor or 
diseases, or diseases that are common globally but for which there are specific research and 
development needs in LMICs (Gostin and Friedman, 2013). 
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GGH: Strategies for promoting health equity in global health programs 
GGH puts forth three strategies for addressing global health inequities: health systems capacity 
building; health priority setting; and stakeholder engagement (Gostin, 2007, Gostin, 2008). These 
three strategies are described below. 
Capacity building: Capacity building should be at the centre of any global health program. This is 
because by building the capacity of health systems in poor countries, global health programs will 
be empowering local health systems to better respond to the health needs of their population. 
In GGH, the recommended approach to capacity building is one that follows a bottom up 
approach, whereby poor countries are allowed to, based on empirical evidence, identify their 
capacity building needs whilst international agencies support them to address the needs.  
GGH further recommends three approaches to capacity building: 1) international agencies should 
make long term commitments to build health systems capacity in poor countries; 2) poor 
countries should take responsibility for identifying their capacity building needs; and 3) global 
health programs should measure the success of capacity building efforts. The last approach 
necessitates monitoring and evaluation of capacity building activities. Since GGH links the 
promotion of health justice to global health research, this would require that global health 
programs support research capacity building in LMICs. Obligations for research capacity building 
are assigned to both LMICs (to identify needs) and HIC stakeholders, (provide long term support 
for research capacity building). 
Health priority setting: in developing GGH, the authors argue that one of the reasons why global 
health programs have repeatedly failed in their mission to reduce global health inequities is 
because do not often align their programs to local health needs. GGH then recommends that 
LMICs take responsibility for identifying their health priorities and that international assistance 
should be directed towards those priorities. Ideally, health priorities and that this should ideally 
be informed by epidemiological parameters such as morbidity, disability and mortality rates. GGH 
also advocates for global health programs to invest in health research on diseases that are: a 
major burden to LMICs; diseases with a global burden but for which research in LMICs is required; 
or major causes of structural inequalities in health between population groups (Gostin and 
Friedman, 2013, Gostin and Taylor, 2008). Based on international law, GGH assigns the 
responsibility of identifying health priorities in LMICs to national governments. However, like 
with capacity building, it recommends that when states are unable to define local health 
priorities, international agencies have a moral obligation to assist them in identifying these 
priorities and to then direct support towards local priorities. In the context of global health 
research, this would require that LMICs articulate their health research priorities and that 
resources for global health research should be directed at the identified priorities.  
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Stakeholder engagement: The last modality for GGH is stakeholder engagement. This is based 
on the observation that there is a lack of coordination and harmonisation of the activities of the 
global health actors, leading to fragmentation and duplication of efforts. Considering that the 
number of global health actors have proliferated in recent times, each with their own agenda, 
GGH recommends that all stakeholders, through a process of engagement and consensus driven 
dialogue, should agree on an approach to solving a particular global health problem. Such an 
approach should include the involvement of marginalized populations in policy development and 
evaluation; and should seek to identify and design comprehensive interventions aimed at helping 
LMIC populations to overcome barriers that prevent them from enjoying good health (Gostin et 
al., 2013).  
GGH-Recommended norms for good governance  
Besides recommending strategies for global health programs, GGH also suggests key norms 
and/or principles that should guide the governance of global health programs. These 
norms/principles include: Honesty, transparency, deliberative decision-making, efficiency, 
accountability and monitoring and evaluation (Gostin et al., 2010, Gostin et al., 2011). 
Honesty: GGH does not define honesty. Neither does it state concisely how the honesty principle 
may advance the ideals of global health justice. However, other works by (Gostin and Mok, 2009, 
Gostin, 2008), link the honesty principle to transparency, truthfulness, open governance, free 
flow of information and civic participation.  
Transparency: Transparency in GGH is considered hallmark for good governance. It is linked to 
honesty and discussed more in terms of truthfulness. Just like the honesty principle, transparency 
is likened to activities such as: open governance, free flows of information and civic participation 
(Gostin, 2008). GGH recommends that: decision-making processes are open and comprehensible 
to all involved; that there is the free flow of information amongst stakeholders; and that 
information on the activities and processes of global health partnerships be made freely 
available. This recommendation is based on observations that there is limited transparency in 
global health programs, both at the level of decision-making and communication. Transparency 
in decision-making is important for purposes of accountability, as it allows stakeholders to 
understand the reasons for decisions and to appeal such decisions when necessary.  
Efficiency: As stated above, one of the major challenges to global health as identified by Gostin 
and colleagues is the lack of coordination between global health stakeholders involved. This lack 
of coordination has led to: missed opportunities for collaboration; increased cost; and the 
fragmentation and duplication of global health activities. Based on this, GGH recommends a 
governance structure with a coordinated architecture both at the global and local level with 
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detailed targets and concrete plans for all stakeholders. This would require defining a shared goal 
and also stating the responsibilities of each different stakeholder towards achieving that goal. 
GGH therefore calls for global health programs to articulate benchmarks for success, identify 
indicators for measuring these benchmarks; and have mechanisms in place to monitor and 
evaluate if the goals of the program are being met. The efficacy requirement therefore calls for 
monitoring and evaluation of global health programs. 
Deliberative decision-making: Deliberative decision-making is a key feature of GGH. The 
recommendation is that decision-making in global health programs should adopt a deliberative 
approach with all stakeholders genuinely listening to the views of others, especially those of 
disadvantaged groups (Gostin, 2014). This is also in line with the GGH strategy for stakeholder 
engagement, especially the involvement of disadvantaged groups in decision-making. Given that 
one of the challenges that led to the development of GGH is the difficulty in harnessing the efforts 
of the many global health actors, it may be best to first identify the different actors. Based on 
other works of Gostin (Gostin, 2007, Gostin, 2008), key actors in global health include: 
populations in LMICs, LMIC governments, HIC governments, non-governmental organisations, 
international health agencies, private industry, charity foundations, public/private hybrids, 
health researchers and the media. GGH recommends that these different stakeholders should be 
actively engaged in negotiation processes, debates and policy development and that this could 
take the form of active outreach programs (Gostin et al., 2010).  
Monitoring and accountability: GGH requires that global health develop governance 
mechanisms that embody principles such as equity and accountability. For this to happen, global 
health programs should have: clearly defined objectives; transparent decision-making systems; 
mechanisms for information dissemination; and procedures for the monitoring and evaluation of 
the program’s activities. This is because stakeholders will often demand clarity on how resources 
are being used towards the overall goal of reducing global health inequities. It is therefore 
important that global health programs identify clear equity oriented targets that: 1) will help 
improve health outcomes for all and reduce health inequities; 2) identify benchmarks and 
indicators for success; 3) have incentives and enforcement mechanisms (e.g. inducements, 
sanctions, mediation, and dispute resolution); 4) allow for interactive fora for all stakeholders 
and; 5) in the interest of transparency, make public the reasons for decisions (Gostin and 
Friedman, 2013). Accountability is therefore intertwined with the principles of efficiency, 
deliberative decision-making and transparency. 
The participation of all stakeholders in decision-making is considered a key accountability 
mechanism in GGH. This is based on arguments that standard accountability mechanisms that 
are based on monitoring only are not politically neutral and may reinforce power inequalities 
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(Gostin and Friedman, 2013, Goetz and Jenkins, 2002, Ruger, 2011, Bruen et al., 2014). GGH 
therefore supports a wider and inclusive approach to decision-making and recommends that 
global health actors should provide reasons for the decisions that they make (Gostin and Mok, 
2009). There are no suggestions on whether or not to apply sanctions when stakeholders fail to 
carry out their responsibilities, but there is the suggestion that sanctions could result in 
withdrawal of certain actors, leading to increased harm to the health of global poor mainly 
because most global health actors act on a voluntary basis (Gostin and Friedman, 2013).. Aware 
of this limitation, GGH advocates for an accountability system whereby poor and marginalised 
stakeholders are included in decision-making. This has the power of transforming traditional 
power dynamics such that powerful stakeholders having greater obligations of accountability to 
those with least political power.. Overall, GGH recommends an accountability mechanism that 
has clearer delineations of stakeholder responsibility, benchmarks and indicators of success, 
newly imagined incentives and sanctions; inclusive decision-making and effective governance 
structures at local and national levels. Figure 1 shows the different principles promoted by GGH. 
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Figure 1: Principles promoted by GGH 
 
GGH: Global health institutions, stewardship and responsibilities 
Besides suggesting strategies for promoting global health equity and principles that should guide 
the governance of global health programs, GGH also highlights the obligations of global health 
actors. In framing GGH, Gostin and colleagues begin by maintaining that nation states have the 
legal responsibility to provide essential health services to their populations. Therefore they assign 
the following responsibilities to national governments: securing the essential health package for 
their populations; setting national health priorities; effective governance through abiding to the 
norms/principles described above (Fig 1); and distributing health resources equitably (Gostin et 
al., 2010). However, the obligation to improve the health of the world’s poorest and in reducing 
global health inequities is one that cannot be limited to specific nations, especially poor countries 
(Gostin et al., 2010). Therefore, richer countries have a responsibility to support poor countries 
to secure the minimum essential health package. Also, given that poor countries are usually those 
affected by the greatest disease burden but have limited resources to address it, GGH 
recommends that HICs support health systems development in LMICs. 
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Limitations of GGH 
GGH lists honesty, transparency, effectiveness, deliberative decision-making, efficiency and 
mutual accountability as key principles for promoting justice and fairness in global health. 
However, it provides little information or guidance on the definition of these principles how they 
may be applied in practice. Equally, it is grounded in global law and assumes that there are legal 
structures in place for the implementation of global health programs, which is not always the 
case in LMICs. 
2.2.2b Shared Health Governance (SHG) 
A second theory of global health justice and governance that may provide guidance for 
developing governance for genomics research , is Jennifer Ruger’s shared health governance 
(Ruger, 2011). Shared health governance (SHG) is founded on the theory of provincial globalism. 
Provincial globalism is an intermediate position between nationalism and cosmopolitanism (see 
section 2.2.2). Like GGH, SHG was developed in response to failure by global health actors to take 
up their roles and responsibilities (Ruger, 2012b). It also situates the problem of global health 
inequity as one that is due to the failure of global health actors to take up their responsibility and 
implement policies that effectuate the public moral norm of health equity (Ruger, 2012b). The 
public moral norm is a social norm, a shared conviction by any given society on the rightness of 
lack or wrongness on a particular idea or practice. It is about moral ideas set out by society on 
what ought to be favoured or disfavoured (Ruger, 2011). Public moral norms can serve as an 
authoritative standards in the quest for global health justice (Ruger, 2012c) and require individual 
and societal commitments (Ruger, 2006). Global health inequities are morally troubling and 
requires state and non-state actors to voluntarily identify and internalise norms that would 
facilitate to attainment of global health equity. This would require relying on theories of global 
health justice for principles, policies and tools, by which these inequalities could be addressed 
(Ruger, 2008).  
Drawing on earlier works on the health capability paradigm (Ruger, 2010) and emphasising that 
health equity as a public moral norm, Ruger provides a road map for minimising global health 
injustices(Ruger, 2012a). Worthy of note is that in SHG, the public moral norm is considered as 
one that incorporates the interest on a person in relation to society, thereby suggesting a 
solidarity-based approach to global health. Also, SHG is grounded in global health law and 
therefore sees the world as a community and not a collection of individual nations (Ruger, 2008), 
thereby giving it a communitarian perspective. Although SHG is not related to conventional 
solidarity and not as communitarian as conventional solidarity (Ruger, 2011), it is “fundamentally 
synergistic with solidarity” in that it promotes solidarity at the global level, that is between 
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nations (DiStefano and Ruger, 2015)10 and more of reflective solidarity (DiStefano and Ruger, 
2015) than conventional solidarity. Reflective solidarity is the “mutual expectation of a 
responsible orientation to relationship” (Dean, 1998) and requires that consideration be given to 
individual expression instead of a “common conscience”(DiStefano and Ruger, 2015). That is to 
say the focus in reflective solidarity is more on the individual and self-regarding behaviour, than 
it is on society as a whole, compared to conventional solidarity which is about shared communal 
values. 
In considering health equity as a public moral norm, SHG makes recommendations on the 
responsibilities, motivational aspirations, and institutional arrangements that are necessary for 
promoting justice and fairness in global health. These recommendations are broadly grouped 
into 5 principles (Figure 2). 
Figure 2: Principles promoted by SHG 
 
Furthering the ideals of health justice (FIHJ) 
The first premise of SHG is that global health programs should aim to reduce global health 
inequities by improving the health of the global poor. SHG, like GGH, emphasizes the potential of 
health research to address global health inequities through the generation and translation of 
knowledge for the benefit of worst-off communities (Ruger, 2009). This could be achieved in 
three major ways: the creation of new interventions (vaccines, diagnostics etc.); management of 
                                                     
10 See page 215 
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knowledge and information (health statistics); and the development research capacity in worst-
off communities (Ruger, 2009). “Worst-off” can generally be defined as the most disadvantaged 
group. However, it is not exactly clear which population group or stakeholders SHG considers to 
be worst-off in the context of global health or how it is defined. The health capability paradigm 
however defines worst-off populations as those that experience substantial shortfalls in their 
health capabilities from the optimal level achieved worldwide (Pratt and Hyder, 2015). The 
optimal level is determined from population health indicators such as morbidity, disability 
adjusted life years (DALYs) and mortality. 
The first approach to addressing global health inequities as suggested by SHG is the creation and 
distribution of knowledge generated from research. This could broadly be categorized as the 
translation of research findings. that could improve the health of worst-off populations (Ruger, 
2012b).  
The second strategy is health systems development in LMICs. This requires: providing technical 
and financial assistance to worst-off communities; coordinating the activities of the different 
actors (to minimise redundancies); empowering individuals and groups; and building research 
capacity in LMICs. SHG argues that the obligations for global health partnerships to build research 
capacity in LMICs is grounded in the principles of social justice and health equity (Ruger, 2012b). 
Citing the 10/90 research gap11 as a major cause of health inequities, Ruger supports claims that 
there is an international obligation to help LMICs build their health research capacity, without 
which technological and scientific advancements may likely widen global health inequities (Ng 
and Ruger, 2011). As a result, there is an international obligation to support LMICs to build 
capacity for their research programmes and to access resources that could help them improve 
and maintain positive health outcomes (Ruger, 2007, Ruger, 2012b). These approaches have 
been elaborated in the context of health systems research in LMICs (Pratt and Loff, 2013).  
Shared Sovereignty or shared decision-making 
The next premise of SHG relates to decision-making. SHG depends on a group of individuals or 
institutions that come together to develop structures and procedures for decision-making; 
govern collectively; set standards for accessing success in a global health activity and for holding 
themselves accountable to one another and to society at large (Ruger, 2018). It also proposes 
that decision-making should be inclusive, deliberative and guided by acceptable public values and 
                                                     
11 The 10/90 gap was coined by the global forum for health research and refers to the fact that less than 10% of 
funding for global health research is spent research for health problems that account for 90% of the global disease 
burden 
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moral norms. Despite these recommendations, SHG is silent on how shared sovereignty may be 
actualised in practice.  
Shared Resources 
The third premise is shared resources. SHG demands that the resources of a global health 
program should be distributed fairly based on the needs and wealth of each stakeholder. It also 
requires stakeholders to make efficient and effective use of resources that are allocated to them 
(Ruger 2011; Ruger 2012). This is similar to the efficiency requirement of GGH. There are three 
components to the shared resources premise. The first component requires contributing a fair 
share to the required resources. This demands that stakeholders contribute resources based on 
their level of wealth. The second component is on resource allocation and it requires that each 
stakeholder should receive resources based on their needs. The last component calls for 
stakeholders to use the allocated resources towards achieving justice in health. In the context of 
global health research, this entails allocating resources to the following: research agenda setting, 
research capacity strengthening; and research translation (Pratt and Loff, 2013). 
Shared Responsibility  
The fourth premise of SHG is shared responsibility. Global actors have an ethical commitment to 
reduce global health inequities. In developing SHG, Ruger makes the argument that global health 
actors are usually unaware of their roles and obligations, therefore it will be inappropriate to 
hold them accountable for unspecified responsibilities (Ruger, 2013). A view that is also put forth 
in GGH through the monitoring and accountability principle. Based on that argument, Ruger 
proposes that global health programs delineate the roles and obligations of each stakeholder 
(Ruger, 2012b, Ruger, 2013) and that this should be done following the functional requirements 
principle, i.e. based on the function that a stakeholder would typically assume (Ruger, 2011). 
Delineating the roles and responsibilities of all stakeholders creates a clearer lens for mutual 
accountability, legitimacy, the sharing of resources and possible recourse in cases where 
stakeholders fail to meet their responsibilities (Ruger, 2012c).  
2.2.2c Mutual Collective Accountability (MCA) 
The fifth, and final, premise of SHG is mutual collective accountability (MCA). MCA is an 
accountability mechanism that is appropriate for institutions that are multi-layered yet the 
different stakeholders have a shared goal (Ruger, 2012c). It obliges stakeholders in global health 
to identify: important outcomes and indicators for success; have standards on how resources will 
be used; and to develop a plan to ensure meaningful participation of all stakeholders in key 
decision-making for issues that affect them (Ruger, 2012b). All three requirements are also 
promoted by GGH in its monitoring and accountability principle (section 2.2.2a). 
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Given the many stakeholders involved in global health projects, Ruger contends that it may be 
difficult to tease out the separate responsibility of any given stakeholder but that all stakeholders 
should simultaneously be held to joint standards (Ruger, 2012c). But this will require that the 
different stakeholders agree on a goal and their respective roles and responsibilities towards 
achieving the set goal(s). Without such an agreement, it will be almost impossible to demand 
some degree of accountability from the different stakeholders. SHG therefore supports a peer 
review mechanism of accountability whereby stakeholders are answerable to one another and 
not to external actors, with the exception of the populations in which they work (Ruger, 2012b). 
Ruger later suggest that where necessary, some level of external accountability may be 
permissible, in which case stakeholders may be accountable to an international non–
governmental organisation (Ruger, 2013).  
Besides delineating roles and responsibilities of all stakeholders, MCA also demands that global 
health programs articulate standards for meaningful participation by all stakeholders, especially 
vulnerable groups, in decision making. This is particularly relevant for stakeholder groups that 
may be affected by the final decision. The recommendation to have standards for meaningful 
participation in decision-making, especially for disadvantaged groups, is similar to the monitoring 
and accountability requirement of GGH. 
The last component of MCA is that global health programs should identify standards for 
distributing resources, with an emphasis on effective and efficient use of global health resources.  
The advantage being that increased accountability on the use of resources would ensure that 
resources are being used towards achieving shared equity oriented goals (Ruger, 2012c).  
In summary, mechanisms for MCA should monitor the following indicators: goal alignment; level 
of resources; mutual understanding by stakeholders of the key outcomes; meaningful 
participation of all stakeholders; efforts made to engage vulnerable groups in decision-making; 
and the effective and efficient use of resources towards achieving global health equity (Ruger, 
2012c, Ruger, 2012b, Ruger, 2013). 
2.2.2d Limitations of SHG  
SHG is a global health justice framework that suggests principles considered essential for global 
health justice. However, there is little information on how the different premises maybe 
actualized or implemented. But unlike GGH, SHG provides more details on the core principles and 
gives clues, albeit minimal, on how they may be implemented. For example there is little guidance 
on how the premise of shared sovereignty may be achieved besides stating, as part of the MCA 
requirement, that vulnerable groups should be properly engaged in decision-making. This makes 
the application of SHG to the everyday operations of global health consortia a bot challenging. 
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Overcoming some of the limitations of SHG 
Based on Ruger’s work on SHG and drawing on the work of political philosophers: Norman Daniels 
and Iris Young, Pratt and colleagues have championed work on applying the shared sovereignty 
principle to health systems research in LMICs (Pratt et al., 2016a, Pratt and Hyder, 2016, Pratt 
and Hyder, 2017, Pratt et al., 2016b). In doing so, they have developed standards for shared 
decision-making in global health research. Many of the recommendations they make are 
consistent with that suggested in GGH. Features of shared sovereignty as prescribed by Pratt and 
colleagues are presented below. 
Deliberative decision-making 
Deliberative decision-making is derived from theories of deliberative democracy (Chambers, 
2003, Cohen, 2003). Proponents of deliberative democracy argue that humans are political 
equals, and therefore ought to, as a community, deliberate with one another and to reach an 
agreement (Dryzek and Niemeyer, 2012, Cohen, 2003, Rawls, 1993). In deliberative democracy, 
all parties that may be affected by a decision should be given the opportunity to: propose 
solutions to the problem under consideration; give reasons for their position; and listen and 
consider the solutions and reasons advanced by other stakeholders (Young, 2002).. At the end of 
a deliberative process, members of a group may not necessarily agree on the final decision, but 
their perception of the problem may change, based on the reasons provided by other 
stakeholders. The idea behind deliberative democracy is to be able to reach a conclusion that will 
considered fair by all. Four major standards for fair deliberative decision-making have been 
proposed by accountability of reasonableness (A4R), a prominent theory of deliberative 
democracy. They include: relevance; appeal/revision; publicity; and enforcement (Daniels and 
Sabin, 2008a). 
The first standard for deliberative decision-making is relevance. Relevance demands that 
decisions should be based on the values and principles shared by stakeholders who may be 
affected by the decision (Daniels, 2000). A necessary step for the relevance condition is to identify 
stakeholders who may be affected by a particular decision. The second standard is appeal and 
revision and its premised on the idea that a fair decision-making process should allow for revision 
and improvement of decisions in light of new evidence or arguments (Daniels, 2000). The 
rationale for the appeal and revision standard is that it gives room for more engagement and in 
the process caters for stakeholders who may not have been involved in the initial decision-making 
process, or who may not have been clearly heard or understood, to dispute or approve the final 
decisions (Daniels, 2001). For this to happen, there should be procedures for challenging final 
decisions (Daniels and Sabin, 2008b). The third standard is publicity and it entails making final 
decisions and the reasons for them publicly available. This ensures that stakeholders understand 
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the moral basis by which final decisions are based (Daniels and Sabin, 1998, Daniels and Sabin, 
2008b). It also has the advantage of improving transparency (Daniels, 2000). Publicity, and by 
extension transparency, could be practically implemented through open meetings, circulation of 
minutes, and the use of other open communication processes (Byskov et al., 2014). The last 
standard for deliberative decision-making is enforcement. It is about monitoring and evaluating 
decision-making activities to ensure that they are in line with the first three standards described, 
which are: relevance; appeal and revision; and publicity (Daniels, 2000). The enforcement 
standard allows for decision-makers to be held accountable for the decisions that they make 
(Daniels, 2001). The enforcement component of deliberative decision-making overlaps in many 
ways with the principle of mutual collective accountability (see section 2.2.2c). 
Inclusiveness 
The second component of shared sovereignty after deliberative decision-making is inclusiveness 
(Young, 2002). Deliberative theorists recognise that although participants within an institution 
should be considered political equals, societal norms and practices may influence the ability of 
some participants to influence political decisions. Also, more powerful participants generally tend 
to dominate decision-making and to skew the final decision in their favour (Rawls, 1993).  
Inclusiveness does not only refer to including all stakeholders in decision-making. It extends to 
how and when they are involved. . Using the case of health systems research in LMICs, Pratt and 
colleagues suggest a framework for deep inclusion in decision-making in global health research 
(Pratt et al., 2016b). The framework proposes three criteria for ensuring inclusivity: breadth; 
qualitative equality; and non-elite representation. Achieving breadth requires including 
stakeholders with a wide range of relevant roles in decision making and ensuring that no one 
stakeholder group is disproportionately represented compared to the other. This is to minimise 
the possibility of any stakeholder group to dominate the decision-making process by virtue of 
their numbers. Qualitative equality, on the other hand, is about ensuring that each stakeholder 
group is not just represented but also has a chance, through reasoned argument, to influence the 
final decision (Young, 2002). For this to happen, all stakeholders should be given equal 
opportunities to: express their views; to respond to questions; and to ask questions to other 
participants (Cohen and Fung, 2004). The deliberations should also be structured in a way that 
minimises the impact of power disparities. Such an approach can create a sense of solidarity and 
increase trust amongst all actors (Valadez, 2018). 
Equally important for inclusivity is the involvement of “non-elite” stakeholder groups when 
making decisions that affect them (Smith and Wales, 2000, Cohen and Fung, 2004). This is 
because the opinions of highly educated experts are frequently (and sometimes falsely) taken to 
be the shared premise (Young, 2002). High quality non-elite participation is a function of the time 
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of engagement and the degree of involvement (Pratt et al., 2016b), it is easier to achieve more 
engagement if non-elite groups are included earlier in the research process. Pratt and colleagues 
have suggested an approach to engaging non-elite groups in decision-making (Pratt et al., 2016b, 
Pratt et al., 2018) and this includes: shared decision-making; proposal sharing; and information 
feedback. In proposal-sharing, citizens make suggestions based on what they would decide if they 
had the power to make a particular decisions (Caron-Flinterman et al., 2005). In information-
giving, citizens give their opinion on suggestions that have been provided by those who created 
the decision-making process. All three forms may take place at different phases of the study. 
Shared decision-making is thought of as the most desirable of the three, and is likely to take place 
in a collaborative partnerships. On the hand, proposal sharing and feedback of information are 
likely to take on a consultative format. Consultative decision-making involves soliciting the views 
of select individuals when making a particular decision, however the views of these individuals 
may or may not be taken into account when making the final decision (Arnstein, 1969). Usually, 
those consulted are often experts in the area of interest and in some cases may not be affected 
by the decision.  
2.2.3 Ubuntu: Application of an African moral theory to the governance of genomics 
research and biobanking in Africa. 
In the previous sections (2.2.1 and 2.2.2), I presented two accounts of global health justice and 
governance, namely GGH and SHG. However, an African perspective or moral thought will also 
be very important in framing discussions around justice and governance in genomics research 
and biobanking in Africa (Tangwa, 2017). This is because when proposing solutions to justice-
related issues, it is important to do so in ways that are sensitive to local values, beliefs and 
practices.. In this thesis I seek to develop a governance mechanism for genomics research and 
biobanking in Africa. An African perspective to governance will be important in ensuring some 
degree of buy-in by the different stakeholders.  
In this section, I describe the principles and values promulgated by an African indigenous moral 
philosophy, Ubuntu. I acknowledge that there are different African moral philosophies (Kagame, 
1976, Verharen, 2008, Wiredu, 2006). However, I am interested in Ubuntu for two main reasons. 
Firstly, Ubuntu has in recent times emerged in ELSI discussions as an African moral theory that 
could inform ELSI discussions in genomics (Pepper et al., 2018, Yakubu et al., 2018). For example, 
it featured in discussions by the H3Africa WG on Ethics and Regulatory Issues though the group 
could not reach a consensus on the role of this philosophy at the time, (Yakubu et al., 2018). . 
Ubuntu also emerged in in the process of discussions on ethics governance of genomics research 
in South Africa (Pepper et al., 2018). Secondly, although the word Ubuntu originates from 
southern Africa, it is a Bantu philosophy with equivalent concepts in many sub-Saharan African 
communities (Dauda, 2017, Metz, 2007, Oppenheim, 2012, Ramose, 1999), and therefore its 
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principles are likely to appeal to populations across Africa. Thirdly, Ubuntu (and equivalent 
concepts) has been used foundation for governance in some African countries and corporate 
bodies (Nyerere, 1968, Nzimakwe, 2014, Khoza, 2012, Mbigi and Maree, 1995). I therefore 
envisaged that by exploring Ubuntu alongside other accounts of social justice and governance, 
we would be able to incorporate an African perspective to the governance of global health 
research in general and genomics research and biobanking in particular.  
2.2.3a An African world-view of humanity12 
Ubuntu is an African indigenous moral theory for humanness (Metz, 2007, Tutu, 2012, Ramose, 
1999). It is the philosophical foundation by which African people think and act towards each other 
(Sulamoyo, 2010). The word Ubuntu originates from two Nguni languages, Zulu and Ndebele, and 
is captured in the phrase, umuntu ngumuntu ngabantu, which literally translates to: A person is 
a person because of another person. Ubuntu upholds the principle of solidarity and emphasises 
that members of a community have a responsibility to share, support and care for one another, 
so that each may achieve their full capability (Nzimakwe, 2014). The interdependence of the 
individual on her community is therefore at the centre of Ubuntu (Ramose, 1999, Dauda, 2017).  
Equivalent concepts of Ubuntu exist in other communities in sub-Saharan Africa. For example, 
the Yoruba of Nigeria, express humanism in the phrase Omoluwabi, which literally means, one 
who is of high integrity and probity (Dauda, 2017). The Koms of Bamenda Cameroon say wa ghi 
wul i.e. you are a person (Tosam 2014). In Kiswahili, an East African language, it is termed utu, 
and is derived from an indigenous governing concept which advises that every action should be 
done for the benefit of the community (Oppenheim, 2012). Across the different cultures, one can 
arguably say that Ubuntu ethics is about value systems and social contracts of mutual respect, 
responsibility and accountability (Venter, 2004).  
Ubuntu is a purely communitarian ethics and is said to be the way of life of African people (Biko, 
1987, Mbigi and Maree, 1995, Mkhize, 2008, Ramose, 1999). Members of a community are 
expected to put communal values first before those of the individual (Callahan, 2003, Du Toit, 
2005). The expectation is that the individual, though autonomous, is in a mediated relationship 
with his/her society and that communitarian values, such as reciprocity, trust and solidarity 
supersede individual choice (Tauber, 2002, Ramose, 1999). This communitarian conception of a 
person is what the phrase, A person is a person because of another person captures (Mbiti, 1968). 
                                                     
12 It is again important to emphasise that whilst I write of Africa as if it is a homogenous continent, it is quite diverse 
culturally. However, the foundations of most African cultures, particular sub-Saharan Africa are arguably very similar 
if not the same.  
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It is an epistemology that begins with the community and then moves to the individual (Battle, 
2009). 
The values and principles promoted by Ubuntu have been applied to governance in different 
sectors including: business, conflict resolution, corporate management and education (Lutz, 
2009, Mbigi and Maree, 1995, Msila, 2015, Shanyanana and Waghid, 2016). However, its 
application to health and health research remains minimal (Tosam et al., 2017). In the following 
paragraphs, I will tease out the values and principles promoted by Ubuntu that could inform the 
governance of genomics research in Africa. This is particularly relevant given recent calls for an 
African-informed governance for ELSIs in genomics research and biobanking in Africa (Pepper et 
al., 2018, Tangwa, 2017, Yakubu et al., 2018). The core principles promoted by Ubuntu are 
described, in general terms, below. 
Solidarity 
Solidarity is a key value in African communitarianism (Wiredu, 2000). Broadly, solidarity can be 
defined as unity based on shared values, objectives and standards (Prainsack and Buyx, 2012, 
Mbigi and Maree, 1995). It is a realisation that one’s capability depends on others and the 
common good should be pursued rather than the individual good. Ubuntu is the capacity in 
African culture to express compassion, reciprocity, dignity, harmony and humanity to others 
(Nussbaum, 2003). Group solidarity is therefore a key aspect of Ubuntu and is central to the 
survival of a community (Mbigi and Maree, 1995). This transcends reflective solidarity promoted 
by SHG (DiStefano and Ruger, 2015) to include communal solidarity that promotes the flourishing 
of all members of a society, irrespective of their ideologies, viewpoints and personal values. Given 
that solidarity is a key principle in African communitarianism and that the two global health 
justice theories do not directly refer to solidarity, it is worth highlighting how this principle may 
apply to the governance of genomics research and biobanking, lest in becomes too abstract.  
Solidarity is manifest in the ethics discourse in genomics research and biobanking in Africa in 
different ways. For example, empirical evidence shows that motivation to participate in genomics 
studies in Africa are often linked to a desire to contribute towards finding health solutions to the 
disease under study, as well as a desire of the research participant to know about their health 
status (Masiye et al., 2017, Tindana et al., 2012, Moodley et al., 2014, Ogunrin et al., 2018). Yet, 
even when it was done for the advancement of science, research participants have raised issues 
of benefit sharing (Moodley et al., 2014) and the desire to receive information on secondary uses 
of their samples and data (Ogunrin et al., 2018, Tindana et al., 2012, Igbe and Adebamowo, 2012). 
This will suggest that motivations to participate in genomics research and biobanking studies are 
grounded in reciprocity-based solidarity (supported by Ubuntu). Secondly, although studies have 
shown that there is a willingness amongst African researchers to share samples and data, there 
are guarded concerns around the exploitation of African researchers and research participants 
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that may hinder open sharing (Munung et al., 2017, Okeke, 2016, Wonkam et al., 2011). This has 
led to calls for genomics research in Africa: to be aligned with national health priorities; to adopt 
shared decision-making processes; to promote opportunities that will build trust amongst 
stakeholders; and to support research capacity building in Africa (Barchi et al., 2015, de Vries et 
al., 2015a, Moodley and Singh, 2016, Munung et al., 2017, Munung et al., 2018, Ramsay et al., 
2014).  
Reciprocity 
The principle of solidarity is intertwined with the principle of reciprocity. Reciprocity is the 
awareness that that human interactions are generally contingent upon mutual exchange 
whereby people continuously give and receive as part of daily life (Metz, 2007). Reciprocity is 
forthrightly expressed in many African cultures and life is seen as mutual aid. It is for this reason 
that most African societies have an expression for the aphorism “the right arm washes the left 
arm and the left arm washes the right arm”. Julius Nyerere captures reciprocity as such “In our 
traditional African society, we were individuals within a community. We took care of the 
community, and the community took care of us. We neither needed nor wished to exploit our 
fellow men” (Nyerere, 1968). Ubuntu highlights this interconnectedness and calls for people to 
be responsive to the needs of others, not necessarily in terms of the exchange of goods but 
through one’s attitude to the community (Mkhize, 2008).. Reciprocity, in the African worldview, 
is therefore about expressing concern for the welfare of others. Like solidarity, the principle of 
reciprocity has not been widely discussed in global health research, therefore it may be important 
to give examples of how it could be applied to genomics research in Africa.  
As stated in the section on solidarity, some empirical studies have shown that those who bear 
the risk of participating in genomics research and biobanking studies in Africa, do so on grounds 
that their samples and data would be used for future research to advance science and to find 
health solutions to certain diseases. Also, there is some level of expectation that as one 
contributes to a research cause, they will, in return receive some health benefits either 
individually or at the community level. Another relationship for which there are expectation of 
reciprocity is that between African researchers and secondary users of samples and data. There 
are concerns that African researchers who collected samples and data as part of primary studies 
may not be able to use the data as much as their counterparts in well-resourced settings (de Vries 
et al., 2015c, Munung et al., 2017, Walport and Brest, 2011). This ignites fears of exploitation 
leading to an inertia by African researchers to share samples and data. There is a need to balance 
the risk and benefits of sharing samples and data whilst taking into consideration the limited 
research capacity in LMICs. Many suggestions have been made including the need to build 
capacity for genomics research in Africa and to recognise the efforts of primary researchers and 
data generators (Bezuidenhout, 2018, Bull et al., 2015).  
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Reciprocity is about mutual relationships characterised by trust, respect, transparency, and 
shared responsibility (Mkhize, 2008, Nyerere, 1968). Trust is important in the relationships for 
which reciprocity is expected. For example between researchers/research institutions and 
research participant; and between data generators and secondary users of data (Merson et al., 
2015). But being trustworthy requires that one takes responsibility for certain actions and these 
responsibilities will have to be defined and agreed upon by all stakeholders. SHG makes a similar 
recommendations with a preference for using the functional requirement principle in assigning 
responsibilities (See section 2.2.2b section “shared responsibility”). However, Ubuntu, like GGH, 
does not state how responsibilities should be assigned. 
Deliberative and consensus decision-making  
The third feature of Ubuntu is deliberative decision-making. Deliberative democracy has 
dominated decision-making in African traditional settings (Wiredu, 2002). An example is 
Nyerere’s Ujamaa, where best practices for governance are likened to decision-making processes 
that involves community elders sitting under a tree and discussing freely until they reach an 
agreement (Nyerere, 1968). Consensus is key in decision-making in African settings and “every 
person is regarded as a fountain of knowledge who has valuable things to contribute to society 
as a whole” (Blankenberg, 1999). This explains the African saying: “Knowledge is like a baobab 
tree; no one person can embrace it with both arms”. Collective decision-making is at therefore at 
the centre of an Ubuntu society and like in SHG, it is characterised by respect for each other, 
listening intently to others and making efforts to understand what others are saying (Msila, 
2015). The advantage of collective decision-making is that it has the power to build trust and 
strengthen the communal spirit within a society. 
The decision-making process in traditional African settings has also been described as 
participatory consensus (Ayittey, 2010) . It often involves town or community meetings e.g. 
Indaba (Zulus, South Africa), Ama-ala (Igbo, Nigeria) and Durbar (Northern Ghana). During these 
town meetings, an idea is put forth for discussion by a leader to the elders. Once the idea has 
been discussed by the elders, it is then opened up for discussion by the community. Usually the 
public is encouraged to speak and ask questions and this is followed by deliberations until a 
consensus is reached (indicated by hand-clapping and nodding of heads). In the African 
traditional system, governance is, as a rule, characterised by persuasion and consensus driven 
dialogue as opposed to majoritarian rule (Osabu-Kle, 2000, Wiredu, 2000). When it is difficult to 
reach consensus on a particular point, meetings are rescheduled and deliberations continue at a 
later stage until consensus is reached. Voting is avoided at all cost so as to prevent majoritarian 
rule and the oppression of minority opinions. In this way, consensus can be considered an 
expression of solidarity. That is, though we differ in our views, we choose to unite for the good 
of the community. This points to the aspect of reflective solidarity supported by SHG (section 
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2.2.2b). Even with the hierarchal nature of African traditional governance where certain groups 
(for example elders or the chief priest) could have more powers and therefore dominate 
decision-making, there are always mechanisms in place to ensure that every person has an equal 
chance to speak (Louw, 2001). In cases where agreement cannot be reached, the matter is 
dropped for a while to allow for more engagement (Horne, 2004).  
Consensus as a decision-making procedure also requires, in principle, that each representative 
be persuaded, if not of the optimality of the final decision, but at least of its practical necessity 
(Wiredu, 2000). This is similar to the approach suggested in GGH and SHG that global health 
actors provide reasons for their decisions. Many Africanist writers have endorsed consensus 
decision-making as the sole normative paradigm through which the common good is obtained in 
the African value system (Ramose, 1999, Osabu-Kle, 2000, Wiredu, 2002). For example, in 
describing fair decision-making in traditional African settings, President Kenneth Kaunda states 
that “In our original societies, we operated by consensus. An issue was talked out in solemn 
conclave until such time as an agreement could be achieved” (Wiredu, 2006). This is to say the 
community will agree to proceed with a certain approach even if they disagree with the reasons 
(notion or morality) for adopting that particular approach. This has been described as the willing 
suspension of disagreement (Wiredu, 2000).  
This approach to decision-making while beneficial has some disadvantages. For example, 
reaching consensus with a large group can be time consuming. However, many have argued that 
the length of time is often compensated for by a readiness to accept and implement decisions by 
all within a society (Ayittey, 2010).  
Inclusiveness 
Also of importance in African traditional system is representation. Two aspects of representation 
are important: the representation of all stakeholder groups (formal representation); and the 
representation of the will of all stakeholder groups (substantive representation) (Wiredu, 2000, 
Shanyanana and Waghid, 2016). Based on this classification, there can be formal representation 
without substantive representation, in which case a group is represented but their voices are not 
heard and taken into account. Substantive representation is what is considered a legitimate 
approach to decision-making in African traditional system (Osabu-Kle, 2000, Wiredu, 2000, 
Horne, 2004, Ramose, 1999). Also, to minimise the effect of one group having a disproportionate 
influence on decision-making, power is distributed between the different communal groups 
(Sesay, 2014). 
The value of inclusivity is consciously encouraged and promoted in decision-making processes 
communitarian setting in and it is believed that inclusivity in decision-making embodies key 
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aspects of good governance such as: trust, transparency, accountability and equality (Burgess, 
2017, Nzimakwe, 2014, Shanyanana and Waghid, 2016, Khomba et al., 2013). 
Accountability 
Accountability in Ubuntu-style governance accountability is seen more in terms of participatory 
governance and takes the form of going into a community and engaging with them, not just as 
key informants but also as agents of change who are capable of addressing concerns and issues 
that affect their community (Burgess, 2017). Reporting back to the community on shared 
activities is important but that should be done not just for the sake of reporting back but with 
the goal of receiving and implementing feedback from the community. In which case, a 
community meeting (Ayittey, 2010) could be used as vehicle for sharing information and 
receiving feedback from meeting participants. It is therefore about accountability to the different 
stakeholders, as is the case in SHG. There is however very little information in the literature on 
Ubuntu and accountability. 
Trust 
Another principle that is important in Ubuntu societies is trust. Trust is the expectation that one 
can rely on another person’s words and actions and that the person has good intentions to carry 
out their promises (Bligh, 2017). It is a relational concept and has more meaning in a scenario 
whereby one party is vulnerable to the other. Ubuntu is based on a system of mutual trust and 
respect for members in a society. Trust is gained when there is respect and recognition of the 
contribution of all members of the community (Mbigi and Maree, 1995). In African cultures, trust 
is built through long-term consistency in words and actions (Ting-Toomey, 2012). 
Figure 3 provides a representation of the principles and values espoused by Ubuntu and how they 
are all centred on solidarity as an overarching principle. 
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Figure 3: Principles promulgated by Ubuntu 
 
2.2.3b Ubuntu and Governance 
Ubuntu has several implications for governance. A number of African political leaders have 
appealed to its use or that of equivalent moral theories or concepts, in the development of 
national policies. An example is Julius Nyerere’s, socio-political ideology, Ujamaa (Swahili for 
family-hood), whereby best practices for governance were likened to the custom of African 
elders sitting under a tree and having a free discussion on a particular dilemma or problem until 
they agree (Nyerere, 1968). Proponents of Ubuntu argue that institutions that reflect this manner 
of deliberativeness are undoubtedly democratic and consultative, and in many ways promote 
principles of justice and fairness such as: solidarity, reciprocity and mutual benefits (Khoza, 2006, 
Tutu, 2012).  
Ubuntu also theorises a collective humanist existence, that is, I am because you are. That is not 
to say a person’s responsibility is concealed through group effort. Rather, each person is expected 
to, while pursuing their own good, participate in community activities in ways that foster the 
common good (Lutz, 2009). Equally, values such as social cooperation, sharing, open society, 
transparency and deliberation are enshrined in African moral theories (Louw, 2002, Mandela, 
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2006, Nussbaum, 2003). It also emphasises the importance of open sharing and equitable use of 
resources in ways that had been agreed by the community (Khomba et al., 2013, Khoza, 
2012).These principles have been successfully applied to the management of organisations in 
Africa (Khomba et al., 2013, Lutz, 2009, Mbigi and Maree, 1995), and may be extended to global 
health research.  
 Limitations of Ubuntu 
The rationale for including Ubuntu as an African philosophy that could inform the governance of 
genomics research was because my aim was to develop a governance framework that is informed 
by African values, principles and norms. However, unlike SHG and GGH, Ubuntu was not 
developed to address challenges in global health and the application of some of its principles will 
require much wider discussion. 
2.2.4 Points of Convergence and Divergence: Ubuntu, GGH and SHG 
In analysing SHG, GGH and Ubuntu, five (5) principles emerged as common in all three theoretical 
accounts. These five principles are: shared decision-making, transparency, shared resources, 
shared responsibility and accountability. (Table 2). 
Table 2: Points of convergence (and divergence) between GGH, SHG and Ubuntu 
Principle Ubuntu GGH SHG 
Furthering the ideals 
of health justice ( FIHJ) 
Possibly   
Honesty Not included  Not included 
Solidarity  Not included Synergistic to solidarity 
(reflective solidarity 
Deliberativeness    
Transparency    
Accountability    
Trust   (honesty) Indirectly (through 
deliberative decision-making, 
transparency, accountability 
and shared responsibility 
Shared resources  (Indirectly: efficiency 
requirement) 
 
Efficiency Not included  Not included 
Reciprocity  Not included Not included 
Shared responsibility   (accountability 
principle 
 
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Solidarity and reciprocity are directly promoted by Ubuntu only. However, as stated in section 
2.2.2b, SHG is synergistic with solidarity. The principles of trust, efficiency and FIHJ are promoted 
in at least two of the governance accounts. The outliers are: solidarity, reciprocity and honesty. 
The first two are directly promoted by Ubuntu only and the last by GGH.  
FIHJ appears in GGH and SHG but not in Ubuntu. This could be expected given that Ubuntu, as an 
African moral theory, does not primarily set out to address issues of global health. In contrast, 
SHG and GGH aim to address the ills of global health inequity. Nonetheless, Ubuntu advocates 
for communities to work together to advance the common good or a shared goal. Therefore, if it 
was construed within the confines of global health, Ubuntu will likely speak to furthering global 
health justice, given that Ubuntu is characterised by a deep sense of solidarity and consideration 
for others.  
The principle of trust is not directly promoted by SHG. But in advocating for shared sovereignty, 
transparency, accountability and shared responsibility, SHG suggests that these different 
principles are essential in promoting trust between stakeholders. Also SHG is in line with the 
plural subject theory, a consciousness of unity amongst a group of individuals jointly committed 
to a shared objective (Ruger, 2011) and that trust is based on the reciprocity of others, i.e. the 
consciousness of unity.  
The principles of honesty and efficiency are directly supported by GGH only. Efficiency is about 
effective use of research resources in ways that address the ills of global health equity. It is also 
about effective coordination of the different stakeholders to avoid duplication of efforts and that 
stakeholders are carrying out responsibilities assigned to them. It can therefore be linked to the 
principles of shared resources, shared responsibility and accountability. Honesty, on the other 
hand, is about transparency, free flow of information and civic participation in global health. It 
therefore speaks to the principles of trust, transparency and shared decision-making. The 
principles of honesty and efficiency would not be taken forward as they are related to principles 
that are found in all three theoretical accounts. 
Solidarity and reciprocity are promoted, at least directly, by Ubuntu only. The principles of 
solidarity and reciprocity are intricately linked and it is sometimes difficult to talk about one 
without referring to the other. Although solidarity is not stated upfront as a component of SHG, 
Ruger considers reflexive solidarity as a compliment to SHG but noting that that unlike 
conventional solidarity, the focus is on the individual and not the community (DiStefano and 
Ruger, 2015). I had sought to provide an African voice to the governance in global health 
research. Despite the lack of outright convergence on the principles of solidarity and reciprocity, 
I included them in the framework as a way of ensuring that African values and principles are 
promoted in the governance of genomics research and biobanking.  
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Some of the principles are defined or described differently in the three accounts, but in ways that 
are complimentary. For example, in SHG and GGH, the equality of all stakeholders is important. 
Ubuntu, on the hand, recognises the class structure in most African communities but then 
highlights the importance of substantive representation, which is about giving equal voice of all 
members of the community by ensuring that the perspectives of the different groups (age, clan, 
social status) are taken into account during decision-making. Accountability is another area 
where there is a slight difference in the definition. GGH and SHG suggests that accountability 
could be achieved through monitoring and increased participation of all stakeholders in decision-
making, and by clearly delineating the responsibilities of all stakeholders. Ubuntu speaks of 
accountability more in terms of participatory governance and the need to report back to 
communities, not just for the sake of informing them, but also to allow them provide feedback. 
In all accounts, however, inclusive participation and transparency are necessary requirements for 
accountability. All three accounts also support a peer review accountability mechanism (mutual 
collective accountability) whereby stakeholders are accountable to each other rather than to an 
external body.  
Generally, most of the principles are defined or described in detail by SHG only (except solidarity, 
reciprocity and trust). GGH tends to give practical information on how the principles could be 
implemented, without necessarily defining the principle or providing sufficient information on 
what it entails. For example. GGH supports monitoring and evaluation as a means of ensuring 
accountability. However, it doesn’t describe or define accountability. The same can be said for 
Ubuntu I will therefore adopt definitions provided by SHG and lean to the different accounts for 
practical ways by which they may be implemented. In the case of solidarity, reciprocity and trust, 
I will use the definitions from Ubuntu. 
2.2.5 Principles adopted in the governance framework 
Based on the convergence approach, I adopted nine (09) principles for use in developing the 
framework. These principles and their definition/description are shown in Table 3.  
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Table 3: Principles that will inform the development of a governance framework for genomics research 
and biobanking in Africa. 
No Principle Brief description 
1 Solidarity Communal unity based on shared goals, values, 
responsibilities and standards  
 
Global health research should improve the health of all 
but should also address the health and research needs of 
the global poor 
2 Reciprocity Human interactions are generally contingent upon mutual 
exchange  
 
The expectation that as one contributes to a cause, then 
some health benefits will come back to them or to their 
communities 
 
3 Furthering the ideals of 
health justice ( FIHJ)  
Global health projects should improving the health of 
people in poor regions and reduce global health inequities 
 
This includes prioritising the health needs of populations 
in LMICs; building research capacity in LMICs; and 
supporting the translation of research findings. 
4 Shared sovereignty Procedural justice is important 
 
Decision-making should follow a deliberative process 
 
Decisions should ideally be reached via consensus  
 
Democratic and substantive representation of all 
stakeholders i.e. giving equal voice to all stakeholders 
6 Shared resources  Resources should be fairly distributed towards equity 
oriented goals.  
 
Stakeholders should receive a fair share of resources 
based on their needs 
 
7 Shared responsibility Responsibilities of stakeholders should be clearly 
delineated 
 
Assign responsibilities based on the functions they 
typically assume 
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8 Mutual accountability Stakeholders should be simultaneously held to joint 
standards and must agree to their respective roles and 
responsibilities.  
 
Identify outcomes and indicators of success.  
 
Mutual understanding by stakeholders of the key 
outcomes of the project. 
 
Have standards on how resources would be used 
 
Develop a plan for meaningful participation of all 
stakeholders in decision-making, especially the 
participation of vulnerable groups 
 
Monitoring and evaluation of program goals.  
9 Transparency  Decisions and activities of projects should be available to 
all stakeholders 
 
Free flow of information 
 
Civic participation in consortium’s activities 
10 Trust The expectation that one can rely on another person’s 
words and actions and that the person has good 
intentions to carry out their promises.  
 
A relational concept and has more meaning in cases 
whereby one party is vulnerable to the other.  
 
Respect and recognition of the contribution of all 
stakeholders 
 
2.3 Chapter Summary 
In this chapter, I presented the conceptual work leading to the identification of principles that 
could inform the governance of genomics research and biobanking in Africa. Two accounts of 
global health justice and governance (GGH, SHG) and the African moral theory of Ubuntu 
informed our conceptual analysis. Based on the convergence approach, A total of nine principles 
were selected for use in the developing a governance framework for genomics research and 
biobanking in Africa.  
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In the next chapter, I will propose a principles-based governance framework genomics research 
and biobanking in Africa. This framework will be based on the principles presented in Table 2. It 
also takes into account that most of the macro-level justice issues in genomics research and 
biobanking in Africa often evolve around the sharing of samples and data.  
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Chapter 3:  A Principles-based Framework for the 
Governance of Genomics Research and 
Biobanking in Africa 
Principles-based governance provides a common frame of reference on the values of by which 
decisions ought to be made or how institutions need to conduct themselves (Black et al., 2007, 
Honderich, 1995). Governance models that adopt a principle-based approach often have more 
latitude and flexibility (Laurie and Sethi, 2013) and serve more as pointers for the relevant values 
and norms that stakeholders ought to consider when designing and implementing programs.  
In this chapter, I present a principles-based framework for the governance of genomics research 
and biobanking in Africa. The proposed framework is informed by GGH, SHG and Ubuntu. Based 
on the convergence approach, reported in the previous chapter, we identified nine (09) principles 
that could inform governance of genomics and biobanking. These principles include: furthering 
the ideals of health justice (FIHJ); solidarity, transparency, reciprocity, mutual collective 
accountability; shared sovereignty, trust, shared resources and shared responsibility. I presented 
a description of the different principles in the previous chapter (summarised in Table 3).  
For each principle I provide make recommendations for its implementation. The aim is not to be 
too prescriptive, but rather to provide context on how the principles may be operationalised 
(Sethi, 2018). In proposing this framework, the assumption is that all samples and data would 
have been collected and stored with the informed consent of the research participants and that 
there are mechanisms in place to safeguard their privacy and confidentiality. Also, some of the 
principles and/or recommendations may apply to other forms of global health research. 
3.1 Furthering the Ideals of Health Justice (FIHJ) 
Genomics research and biobanking consortia in Africa should aim to further the ideals of health 
justice. This could be done through improving the health of populations in poor regions and 
reducing global health inequities. It has been suggested that the contribution of genomics to 
improving population health will occur in three inter-related steps (Collins et al., 2003): genomics 
to biology (elucidating the structure and functions of genes); genomics to health (translate 
knowledge generated to heath); and genomics to society (promoting the use of genomics to 
maximize health benefits and minimize harms). All three steps are key and may be embedded in 
genomics projects at different stages. However the impact that genomics research would have 
on global health inequities would depend on how they promote the three global health equity 
objectives which we described in chapter 2 (section 2.2.2a and 2.2.2b). The three equity oriented 
objectives include: research priority setting; research capacity building; and research translation  
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3.1.1 Research Priority Setting 
Disparities in health and wealth between countries and limited resources for health and health 
research in Africa raises questions of justice and fairness in genomics research and biobanking in 
Africa (de Vries et al., 2015c, Munung et al., 2017). A common concern is the possibility of 
exploitation of study populations and that African researchers tend to work on the research 
agenda of their HIC partners rather than on local health priorities. 
Establishing research priorities for genomics research and biobanking in Africa (including 
secondary uses of samples and data) can serve as a good approach to ensuring that limited 
research resources are directed to the health needs of African populations and that concerns of 
exploitation of African populations are minimized. Also, identifying research priorities for 
genomics research in Africa will help funders, researchers and policy makers to direct limited 
research resources towards health conditions that are likely to yield maximum public health 
benefits. It would also facilitate the transformation of a donor-driven research agenda to one 
that is driven by the health needs of study populations. However, the process for research priority 
setting would have to be guided by the following principles: transparency, shared responsibility 
and shared sovereignty (Pratt and Loff, 2014). 
 Genomics research and biobanking consortia in Africa should prioritise diseases that: 1) 
are a major contributor to the disease burden in Africa; 2) has a strong evidence of 
genomics aetiology; 3) there is limited ability to modify exposure or risk factors through 
environmental or lifestyle changes and 4) diseases for which the use of genomics could 
have a high public health impact. This is because not all diseases or health conditions that 
are of a major cause of morbidity and mortality in Africa will necessarily need to be 
addressed using genomics.. Secondly, it will be ethically problematic to divert scare 
research resources to explore health conditions for which cheaper and more feasible 
options are likely to be successfully applied in resource limited settings. Epidemiological 
parameters such as mortality, morbidity and disability adjusted life years (DALYs) should 
serve as a guide for research priority setting for genomics research in Africa. 
 
 At the initiation stage, genomics research and biobanking consortia should decide on the 
stakeholders that would be involved in identifying research priorities, provide reasons for 
including them in the process; and state the role of the different stakeholders. Ideally, it 
should include: funders, African researchers, healthcare providers in Africa, study 
population, African governments, as these different groups have a shared interest in 
driving a successful genomics research agenda in Africa. 
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 To minimise the influence of unequal power dynamics that may influence research 
priority setting in Africa in favour of more powerful stakeholders, the research priority 
process should be initiated and led by African stakeholders with the support of HIC 
partners and should follow a deliberative process. Where there is limited capacity, by 
African stakeholders to identify and set genomics research priorities, international 
agencies and professional organisations, such as the WHO should play a facilitative role 
by providing technical and financial support to African countries to help them identify 
their genomics research priorities.  
 
 Funders should prioritise genomics research projects that are aligned with the health and 
health research needs of African populations or more generally, health conditions that 
would be of benefit globally but for which research on African populations is required. 
This applies to both primary studies and projects that will use samples or dataset from 
the primary studies. 
 
 Data and biospecimen access committees (or the equivalent) should give priority for 
access to samples and data to research projects that are aligned to local research 
priorities. 
 
3.1.2 Research capacity strengthening 
Capacity building is one of the core ways by which global health research consortia may advance 
the ideals of global health justice (See sections 2.2.2a and 2.2.2b). The aim is to strengthen the 
capacity of African countries to independently conduct research on the health needs of their 
populations. Capacity building should be evidence-based and occur at different levels (project, 
institution and national level) over a long period of time to allow for African researchers to have 
the capability to conduct independent research. It may therefore involve: providing technical and 
financial assistance for genomics research in Africa; coordinating the activities of the different 
actors (to minimise redundancies); and empowering individuals and groups that are engaged in 
genomics research and biobanking in Africa. 
 Research capacity building is key to achieving equitable research partnerships in Africa. 
Genomics research and biobanking in Africa should clearly articulate plans to build 
genomics research capacity in Africa. This should include capacity building for: 
researchers (junior and senior); research users (communities, healthcare providers, policy 
makers, etc.); and research institutions.  
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 Research capacity building should be evidenced-based and directed by the African 
partners. This will ensure that capacity building efforts are tailored to the needs of African 
partners, thereby supporting them to carry out research that is of relevance to their 
communities. Capacity building activities should be done in collaboration with local 
institutions and coordinated with the needs of the populations where the studies would 
be carried out. African partners should be given a greater voice in deciding what capacity 
building is required. 
 
 African researchers should lead primary genomics research projects in Africa. This would 
mitigate the unequal influences that powerful partners may have on key processes such 
as decisions around research priorities, secondary uses of data and samples and resource 
allocation.  
 
 The impact of genomics for study populations, lies more in how it would be used to 
improve health and healthcare of African populations. Genomics research and biobanking 
consortia in Africa should develop the capacity of African institutions, researchers and 
physicians in genomics medicine. . This will include: the training of medical geneticists, 
genetic counsellors; providing support for genetic medicine units; and supporting the 
development of interventions for genomics medicine in Africa. 
 
 African governments should take responsibility for building their capacity in genomics 
research. Where they are unable to do so, funders, HIC researchers and other 
international agencies should support them through a long term commitment to build 
research capacity including more long-term research collaborations  
 
 For projects that would use datasets from genomics studies conducted in Africa, funders 
and data and biospecimen access committees should prioritise resource allocation to 
projects that have plans to collaborate with researchers in Africa on a long term basis. 
This will ensure sustainability of genomics research in Africa  
 
3.1.3 Research Translation 
The most direct way in which genomics could impact on the future of medicine in Africa is 
through the availability of genomics medicine in healthcare settings in Africa. This would require 
the translation of research results to practical health interventions/policies (Collins et al., 2003, 
Khoury, 2003, Seguin et al., 2008, Singer and Daar, 2001b). Translation can sometimes come with 
the need to secure patents and Intellectual Property (IP) rights. Patents and IPs often serve as 
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incentives for promoting innovation in health (Eisenberg, 1990). On the other hand, it can 
increase the cost of health inventions, impose restrictions on research and development and 
impede the transfer of existing tools and technologies (Williams, 2010). Many African countries 
do not have the capacity to translate research findings and to support innovation in biomedical 
research and healthcare. For this reasons, genomics research consortia should develop 
mechanisms that would ensure the equitable distribution of knowledge and resources generated 
from the projects and how the knowledge from these projects would be used to support the 
development of interventions.  
 Genomics research and biobanking consortia in Africa should clearly articulate a 
translation strategy for population genomics studies in Africa, including how they will 
promote translation of research results in ways that will benefit populations in Africa. In 
cases where an intervention is developed from the study, there should be mechanisms in 
place to ensure sustained access to the intervention  
 
 Where genomics research in Africa leads to new knowledge that could refine health policy 
or practice, African researchers should liaise with healthcare providers, national 
governments and funders to advocate for such new knowledge to be incorporated into 
clinical care and practice.  
 
 To facilitate the translation of research findings as well as the uptake of interventions by 
study populations, significant stakeholder engagement is required. Genomics research 
and biobanking projects should at early stages, design research, educational and 
stakeholder engagement programs to facilitate the training of healthcare workers, policy 
makers and the general public on genomics medicine. This has the potential to achieve a 
level of genomic literacy amongst stakeholders as well as facilitate the integration of 
genomics into healthcare.  
 
 African researchers, research institutions (through patent offices), national governments 
and research participants should identify the kind of patents that would be acceptable for 
genomics research in Africa. Researchers and research institutions that file for patents or 
IP rights for innovations arising from the use of genomic datasets should publicly disclose 
their intentions to do so and how the plan to ensure that any products developed from 
the innovation will be made accessible to study populations.  
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 Innovations from genomics research projects in Africa that are suitable for use in the 
African context and which addresses local health needs should be prioritised for 
translation. 
 
 Funders and research institutions should develop a mechanism for tracking how the 
outcome of genomics studies are being used to improve healthcare for populations in 
Africa and if there is access to proven interventions by study population.  
 
3.2 Solidarity 
The principle of solidarity places prominence on the community over the individual. When study 
populations in Africa agree to provide samples and data for genomics studies, they do so more 
for communitarian-based solidarity reasons, especially as little or no immediate benefits may 
accrue to a study participants and/ or their communities (van Schalkwyk et al., 2012, Igbe and 
Adebamowo, 2012). By donating samples to biobank and participating in genomics research, 
research participants hope to contribute to the common good, that is improving human health 
through scientific and medical advancement (Igbe and Adebamowo, 2012). Empirical evidence 
shows that motivations to participate in genomics studies in Africa vary but are often associated 
with a desire to contribute towards finding solutions to the disease under study at the time as 
well as to know their individual health status (Masiye et al., 2017, Tindana et al., 2012, Moodley 
et al., 2014, Ogunrin et al., 2018). Therefore, it is important that genomics research in Africa: 
aligns to the health needs of populations in Africa and also ensure that study communities benefit 
from their participation in genomics research.  
 In participating in genomics research, study populations hope that their samples and data 
would be used to advance science and medicine for the benefit of the world’s population. 
However, to prevent a genomics divide between HICs and Africa, which may eventually widen 
global health inequities despite the participation of African populations in genomics research, 
genomics research in Africa should prioritise research on health conditions that are a major 
contributor to the disease burden in the study population. The same applies for future uses 
of samples and data from genomics research and biobanking projects in Africa. The idea is to 
promote with communal values, whereby one supports the other to allow for human 
flourishing.  
 
 Biobanks and genetic databases have an obligation to share samples and data with other 
researchers in ways that allow for maximum use of samples and data.. Therefore, datasets 
from genomics research and biobanking projects in Africa should be made available for 
research on the health needs of African populations. The responsibility for this lies with a 
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broad range of stakeholders, including but not limited to: researchers, research participants, 
funders, journal editors, data access committees, research institutions and policy makers.  
 
 Given the possibility that African researchers may not have adequate resources and capacity 
to use samples stored in biobanks and genomics datasets. Data access committees, biobanks 
and funders should prioritise research projects that involve African researchers and research 
institutions. This would ensure that African researchers are supported to use samples that 
were collected in primary projects and the data generated thereof to pursue research on the 
health needs of African populations. 
 
 Participation in genomics research and biobanking projects provide little or no direct benefits 
to study populations. However it is premised on the promise that it will facilitate science and, 
in the long run, improve the health of populations in Africa. Also our conceptual analysis as 
well as empirical evidence (Masiye et al., 2017, Moodley et al., 2014, Ogunrin et al., 2018) 
suggests that motivations to participate in genomics research and biobanking studies are 
grounded in reciprocity-based solidarity as well as the desire to contribute to the 
advancement of science. Because genomic research is still at the developmental stages and 
it is unlikely that the benefits of such research will accrue to current biobank donors, 
genomics research and biobanking consortia in Africa establish appropriate benefit sharing 
agreements with study communities and LMIC researchers either at the project level or at 
the level of the consortium. This could for example be through continuously communicating 
research findings and progress to research participants and host communities, including 
information on the uses of samples and data. This also has the potential of building trust. 
 
3.3 Mutual Trust 
Trust is a person’s reliance on someone or something to carry out their responsibilities or keep 
to their promises (Beauchamp and Childress, 2001). It is a necessary precondition of solidarity 
and it is difficult to imagine solidarity-based relationships that are void of trust. Trust is 
characterized by openness, reliability, accountability, dependability, and consistency (Bligh, 
2017, Hardin, 2002, Michael et al., 2008). The success of any genomics research and biobanking 
project in Africa will depend not only on the quality of samples collected or the researchers and 
institutions involved, but to a large extent on building and maintaining the trust and support of 
all stakeholders (Carr and Littler, 2015, Bull et al., 2015). For example, there are broad 
perceptions that the expertise and contributions of African partners involved in international 
collaborations are not recognised and that HIC partners are seen as self-sufficient collaborators 
(Parker and Kingori, 2016). This is a call to recognise the interdependence of all stakeholders 
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within a research collaboration and an acknowledgement that each is making a significant 
contribution to the success of the project (Munung et al., 2017), without which there may be a 
breakdown of trust, leading to refusal to participate in studies or to share samples and data. This 
could have severe implications for the sustainability of genomics studies in Africa. 
 Genomics research and biobanking consortia in Africa should develop data and sample 
sharing policies that recognises the contributions of African researchers, study 
populations and primary data producers. This may include: recognition in publications 
emanating from the use of data, access to patents and IP rights; and informing 
stakeholders of how samples and data have been shared and used for the advancement 
of science and healthcare. The lack of this could weaken partnership bonds and break 
trust between collaborators. 
 African researchers should identify ways of engaging study communities on the purposes 
and outcome of their studies and the social and ethical implications. This shows respect 
for study communities and likely to build trust between researchers, research institutions 
and study communities. It would also empower study communities to effectively 
participate in deliberative decision-making on sample and data sharing in particular and 
genomics research and biobanking general.  
 For reasons of trust and trustworthiness, research institutions involved in primary studies 
should serve as custodians for samples and data stored in biobanks and databases 
respectively. This will imply their involvement in making decisions on access to samples 
and data. Ideally a committee such as the data and biospecimen access committee (DBAC) 
could be asked to take on such a role. Such a committee should include all stakeholders 
who may be affected by decisions related to sample and data sharing, including: 
representative of participants, community representatives, REC members and 
researchers in LMICs. 
 
 Research that demonstrate long-term research collaborations or plans for long term 
collaborations should be prioritised by DBACs when the make decisions on access to 
samples and data. Funders should also prioritise projects that demonstrate or has a plan 
for long term collaborations. Long term collaborations tend to build a system of trust that 
may incentivise data sharing. Also solidarity is stronger within inner circles. There are 
already observations that researchers in Africa are more likely to share data with 
researchers with whom they have an established and trusted research collaboration (Carr 
and Littler, 2015, Bull et al., 2015).  
 
 65 
 
3.4 Reciprocity 
Reciprocity refers to the symmetrical arrangement of giving and receiving, not in terms of giving 
back, in kind, what one has received, but in terms of the value of what has received. Whilst 
participants in biobanking and genomics research maybe aware that no direct benefits are likely 
to accrue to them as a result of their participation in genomics research and biobanking projects, 
yet they opt in to studies (altruism) for the benefit of mankind (Igbe and Adebamowo, 2012, 
Moodley et al., 2014, van Schalkwyk et al., 2012). However, a potential exchange (incidental 
reciprocity) may apply in cases where benefits arise in the future. In this case, reciprocity is 
reflected more as a communal value where research participants take responsibility for the 
health of others (I am, therefore you are), and their altruism should be matched by similar moves 
from institutions hosting biobanks.  
 Genomics research and biobanking consortia should clearly articulate appropriate benefit 
sharing policies either at the project level or at the level of the consortium. This may 
include possibilities for: health development projects, capacity building, feedback of 
research results, public education in genomics and access to genomic medicine or 
interventions derived from population genomics studies in Africa.  
 
 Genomics research and biobanking consortia should develop plans for ensuring 
sustainable access to proven interventions or products that may arise from genomics 
research projects in Africa or the use of samples and data from these projects. 
 
 Genomics research and biobanking consortia in Africa should state: what kind of benefits 
are likely to accrue to study communities; who would have access to these benefits 
(individual participants, research groups, and study communities, public; and how they 
will be made available. At the minimum, key findings emanating from primary and 
secondary research studies should be communicated to study communities. African 
researchers/research institutions and secondary users of data and samples should 
identify possible mechanisms of communicating these findings to the study community.  
 
 Reciprocity also requires acknowledging the contributions of the samples and data 
providers. Secondary users of samples and data should acknowledge the contributions of 
primary researchers who made samples and data available for research. Scientific 
journals, publishers and funders should identify ways of recognising the contribution of 
different African researchers who are involved in the generation of the primary data or 
collection of samples stored in biobanks. This may take several forms including but not 
limited to: collaboration, citations, acknowledgements and co-authorship. 
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Genomics has the potential to improve knowledge on human heredity and health. It is important 
that countries who contribute samples and data for this purpose are empowered to carry out 
research that is responsive to the health needs of their societies. For biobank donors, this may 
be through doing research that is responsive to the health needs of their communities. However, 
another stakeholder group whose interest needs to be considered are the African researchers. 
Given the limited research capacity in Africa, especially for high-through-put genomics studies, 
the efforts by African researchers should be matched by parallel activities to build their 
capabilities to use these samples and data to answer research questions of interest to them. 
Without which, fears of exploitation of African researchers in global health collaborations will 
persist, leading to an inertia for data and sample sharing. Therefore, it is recommended that: 
 Funders and HIC partners of genomics research and biobanking projects in Africa, by 
virtue of mutual reciprocity, should support capacity building activities so as enable 
African researchers participate in, and contribute to, world class genomics research. This 
will also ensure that all partners are able to equitably contribute in scientific 
collaborations. Capacity building should take the form of individual and infrastructural 
capacity building and the fostering of long term research partnerships. 
 
Reciprocity is also about mutual respect and exchange of information (Nzimakwe, 2014, Ramose, 
1999). It requires that all stakeholders should be able to listen to the viewpoints of others, to 
acknowledge their contributions and to be willing to change their initial viewpoint following a 
reasoned argument.  
 Genomics research and biobanking consortia must develop approaches and platforms 
that allow all stakeholders affected by a decision to make a contribution to policies and 
procedures on the access and use of samples and data.  
 
3.5 Shared Responsibility 
Shared responsibility is about assigning responsibilities to different stakeholders based on the 
roles that they normally perform. Shared responsibility adopts a cooperative approach that is 
based on the equitable sharing of responsibility amongst all stakeholders. This will imply that the 
more powerful stakeholder be assigned more responsibilities than the less powerful stakeholder. 
In table 4 below, we present the different stakeholder groups in genomics research and 
biobanking and possible roles and responsibilities. This is based on the functions such stakeholder 
groups assume in genomics research and biobanking consortia in Africa (functional requirement 
principle). 
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Table 4: Roles and responsibilities of stakeholders in genomics research and biobanking in Africa  
Stakeholder Description of stakeholder group Roles and Responsibilities 
African Researchers  Researchers based at institutions in 
Africa and who are directly involved 
in genomics and biobanking 
projects.  
 Directly responsible for designing 
and implementing projects that 
addresses the health needs of 
African populations. 
  
 Contribute samples and clinical 
data to the biobank. 
 
  Generation of primary datasets. 
Data may include: clinical 
information, phenotypic genetic 
variation and microbiome 
sequence data.  
 
 Ensure that study populations 
benefit from their participation in 
genomics studies including access 
top proven interventions that may 
arise from the use of samples and 
data.  
 
 Identify what kind of patents may 
be acceptable for innovations that 
arise from genomics and 
biobanking projects in Africa. 
Researchers in HICs Researchers based at institutions in 
HICs and who are directly involved 
in genomics research projects in 
Africa. 
 Involved in design of the study 
 
 Provide research support to 
partners in Africa. 
Funders Organisations in HICs and LMICs 
who fund genomics research 
projects. 
 Provide financial support for 
project. 
 
 Allocate research resources based 
on the needs of stakeholders and 
towards health equity oriented 
goals (research capacity building, 
research that addresses the health 
needs of populations in Africa). 
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Governing body within 
the consortium 
Should be made up of all 
stakeholders who are likely to be 
affected by decisions taken at the 
level of the governing body. It 
should at the very least include 
representatives of African 
researchers; study populations; 
funders.  
 
Representative of each stakeholder 
group should be proportionate and 
should capture the diversity within 
the stakeholder group (for example 
representative of African 
researchers at the level of data 
access committees should include 
both junior and senior researchers). 
 
 Take major decisions on behalf of 
the consortium 
 
 Advise stakeholders on project 
related activities 
 
 Ensure that genomics research in 
Africa furthers the ideal of health 
justice 
Data and bio specimen 
access committees 
(DBAC) 
An independent advisory group 
responsible for making decisions on 
access to samples and data. 
 
 Review request for access to data 
and samples. 
 
 Ensure that access to samples are 
provided to projects with clearly 
health equity oriented goals. 
 
 Prioritise projects that have plans 
for long term collaboration with 
African researchers. 
Independent 
organisation 
Should be made of experts in 
genomics research and biobanking 
but who are not part of the 
consortium.  
 Peer review of the consortiums 
scientific program funders 
 
 Check that a consortium is 
achieving its equity oriented goals 
by for example doing monitoring 
and evaluation of the consortium 
in cases where accountability 
mechanism where peer 
accountability is not sufficient.  
 
 Provide project-related advice to 
the consortium 
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Policy Makers Ministries of Health, Science and 
Technology in Africa. 
 
Regional and global organisations 
with health and health research 
mandates. For example WHO, 
NEPAD, African Union. 
 Support the development of best 
practices for genomics and 
biobanking including benefit 
sharing mechanisms. 
 
 Identify genomics research 
priorities for Africa. 
 
 Fund genomics research. 
 
 Support research translation. 
 
 Support research capacity building. 
 
 Ensure sustainability of genomics 
research in Africa. 
 
Data and sample users. Consortium members: This includes 
project PIs, their co-investigators 
and student and staff members 
named on grant proposals. 
 
 Submit new data generated to the 
consortium’s database. 
 
 Submit annual reports on how data 
and samples have been used. 
 
 Collaborate with and/or 
acknowledge African researchers 
who collected samples or 
generated the data of interest. 
 
 Ensure that their research is align 
with genomics research priorities 
of study community or to diseases 
that are common globally but for 
which there are specific research 
and development needs in LMICs.  
External users: Any other person,  
not directly involved in primary 
projects. 
Healthcare 
practitioners 
Doctors, nurses, laboratory 
technicians, and genetic 
counsellors. 
 Implementation of proven 
interventions. 
 
 Participate in research priority 
setting. 
 
 Support the implementation of 
genomics research.  
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Continent wide 
scientific societies 
Professional bodies with interest in 
promoting genomics research in 
Africa. For example: African Society 
of Human Genetics and the African 
Academy of Sciences.  
 Identify genomics research 
priorities for Africa. 
 
 Serve as an educational and 
organisational forum for African 
scientists. 
 
 Advice genomics research and 
biobanking consortia in Africa.  
 
 Support the development of 
policies for genomics research. 
Project Coordinating 
Centres  
Designated entity that provides 
administrative support to the 
consortium. 
 Day to day management of 
projects. 
 
 Administrative oversight and 
support.  
 
 Monitor consortium’s activities to 
ensure that they are achieving 
equity-related goals. This may 
include: monitoring capacity 
building activities; involvement of 
African researchers in projects that 
use data and samples from the 
consortium.  
Research Participants Diverse group of individuals who 
voluntary provide samples and/or 
data to research projects and/or 
biobanks.  
 Initial “providers” of sample and 
data. 
 
 Participate in decision-making on 
use of samples and data 
Study communities  Populations where research 
participants are recruited from. It 
may be patient groups.  
 Initial “providers” of sample and 
data. 
 
 Participate in decision-making on 
use of samples and data. 
Research Institutions  Universities, research organisations, 
and hospitals 
 Provide infrastructural support for 
genomics and biobanking projects. 
 
 Develop public engagement 
activities to ensure that study 
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communities are aware of use of 
their samples and data. 
 
 Identify what kind of patents may 
be acceptable for innovations that 
arise from genomics and 
biobanking projects in Africa and 
ensuring that African researchers 
are part of patents and IP 
applications where necessary. 
Research ethics 
committees.  
Committees made up of people of 
diverse disciplinary backgrounds 
who undertake the ethical review of 
research projects involving humans. 
 Review and approve research 
studies with the aim of protecting 
research participants and ensuring 
that research is of social value to 
participants or study communities. 
 
 Oversee the safety, rights and 
welfare of research participants. 
Journals Intermediary between investigators 
who gather data and write research 
reports and readers of research 
results (healthcare professional, 
scientists and lay people).  
 Publish outcomes of research to 
improve scientific knowledge, 
patient care, and health outcomes. 
 
 Ensure that articles published in 
journals acknowledge the 
contributions of researchers who 
generated the data e.g. 
acknowledgement of data 
providers, or citeable datasets. 
 
In addition to the roles and responsibilities assigned to the various stakeholders, some 
stakeholders have additional moral obligations for promoting justice in genomics research and 
biobanking in Africa 
 
 Researchers and research institutions in Africa have an obligation to design projects that 
address the health needs of study populations. In doing so, they should involve all 
stakeholders who may be affected by this. This may require doing stakeholder mapping to 
identify key stakeholders for the different projects. Particular efforts should be made in 
including African policy makers in decisions about research priorities for genomics research 
and biobanking.  
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 Funders should ensure that funding schemes for genomics research and biobanking in Africa 
are designed to further the ideals of health justice, that is: genomics research should be 
aligned to health needs of study populations, have defined plans for translation of research 
findings; and build research capacity in Africa. Also resources should be assigned to the 
different stakeholders based on their needs. 
 
 Policy makers in Africa have an obligation to articulate their national research priorities and 
earmark those that genomics research is likely to make a significant contribution in improving 
the health of populations in Africa. Where they are unable to do so, international agencies 
such as the WHO could support them in this role. Where national health research priorities 
exist, funders should align calls for funding for genomics research with these priorities. 
 
 Institution(s) or persons responsible for implementing benefit sharing should be identified by 
the consortium, and their roles and responsibilities clearly defined. The role of other 
stakeholders who may be involved in the process such as researchers, funders, commercial 
bodies and research institutions should also be spelled out. 
 
3.6 Shared Sovereignty 
Knowledge is like a baobab tree; no one person can embrace it with both arms 
Governance is about the processes and interactions of stakeholders who share a common goal. 
It allows for members of a society to live together and to cooperate. In deciding who should be 
involved in decision-making, genomics research and biobanking consortia should identify key 
stakeholders (see section 3.5, “Shared responsibility”). All stakeholders who may be may be 
affected by the decision and the influence they have on the decision-making process. Given the 
power differences between stakeholders in genomics research and biobanking programs in 
Africa, it is essential that in setting up decision-making structures and processes, attention should 
be given to the power dynamics, for example which stakeholder group are likely to have more 
influence on decision-making. Shared decision-making is characterised by: inclusivity; relevance; 
deliberativeness; consensus decision-making and publicity. 
3.6.1 Inclusivity 
Genomics research and biobanking consortia should be cognisant that whilst deliberative 
processes consider stakeholders within an institution as political equals, societal norms and 
practices may influence the ability of some participants to effect decisions and outcomes. Also, 
the more powerful participant tends to dominate the decision-making process and this may skew 
the final decision in their favour (Rawls, 1993). Given the diversity of stakeholders involved in 
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genomics research and biobanking in Africa, all stakeholders whose basic interests are affected 
by decision should be included in decision-making processes, especially marginalised and 
vulnerable stakeholders. This has the advantage of enabling different stakeholders to refine their 
personal opinions and also ensures that research serves the interests of study communities (Pratt 
et al., 2016). Generally, processes that are designed to be deeply inclusive are more likely to 
produce decisions that reflect the needs and interests of society as a whole. Excluding any one 
group of stakeholder may weaken the legitimacy of governance mechanisms.  
 
 In developing policies for genomics research and biobanking in Africa, genomics research 
and biobanking consortia should identify all stakeholders who may be affected by the 
policies and include them in the decision-making process. In doing so, they should into 
account: power differentials between stakeholders, how it may influence on decision-
making and develop mechanisms to minimise one stakeholder group dominating the 
decision-making process.  
 
 There is a need to capture the diverse voices within genomics research and biobanking 
projects in Africa. Each stakeholder affected by a decision should be given agency and 
should have an equal chance to voice their opinion. Particularly important is the need to 
include voices of disadvantaged groups and stakeholders who are more vulnerable to 
exploitation. In the case of genomics research and biobanking in Africa, this will include 
primary sample and data providers (African researchers, junior researchers and research 
participants). This could be achieved through a variety of means including: consultations, 
collaborations, focus group discussions and public engagement activities. By ensuring 
substantive representation (i.e. including the voices of all stakeholder groups), genomics 
research and biobanking projects will be allowing for power and influence to be 
distributed to stakeholder groups who often have a curtailed voice in research programs. 
 
 In deciding who should be involved in a particular decision-making process, genomics 
research and biobanking consortia should categorise different stakeholders based on the 
influence they have in the decision-making process and on the final decision. This may 
ensure that decision-making is free from unequal power distortions between 
stakeholder’s distortions. Stakeholders who have sufficient power to disrupt or influence 
a particular decision-making process should take on a consultative or advisory role and 
should therefore not be given voting rights as they already have sufficient bargaining 
power. 
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 To enable all stakeholders to make contributions to decision-making and policy, genomics 
research and biobanking consortia should identify factors that suppress people's 
opportunities to participate equally in decision-making (for example structural barriers, 
limited capacity and norms of discourse), and then develop mechanisms that will 
empower them, and optimise their participation in decision-making. This may include 
building their capacity in genomics and biobanking through research, public literacy and 
having appropriate resource allocation mechanisms. 
 
 To minimise the potential of one stakeholder group having considerable influence in 
decision-making processes is important, it is important that the affected stakeholder 
groups are not only represented, but that that no one group is disproportionately 
represented compared to the others. 
 
 Achieving inclusivity also requires going beyond stakeholder representation to include 
how and when they are involved. Genomics research and biobanking consortia in Africa 
should develop mechanisms of including sample donors and their communities in every 
phase or stage of the projects including: research agenda setting, design and secondary 
uses of data and samples, policy development etc. While there maybe conceptual 
challenges to achieving this in practice, they may be overcome through designing 
appropriate community and public engagement activities. 
3.6.2 Relevance  
The third requirement of shared sovereignty is that decision-making should appeal to the values 
of all stakeholder groups.  
 Solidarity, reciprocity, shared sovereignty and trust are key principles in African settings and 
therefore to minimise the possibility of fears of exploitation, these principles should guide 
the development policies.  
 
 The values and principles that would guide decision-making should be stated upfront by 
genomics research and biobanking consortia in Africa. These would ensure that these values 
and principles are promulgated when designing policies for genomics research and 
biobanking in Africa. Final decisions should reflect the values and principles of all stakeholders 
who may affected by the decision. 
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 Genomics research and biobanking consortia should develop accountability policies that 
involve communicating study communities about the progress and outcome of research 
projects in which they are involved. 
 
3.6.3 Deliberativeness and consensus decision-making 
The importance of reasoned deliberative dialogue lies in the fact that it creates an enabling 
environment to make decisions that are relevant for communities, and to resolve issues amicably 
(Fishkin, 2011, Pratt et al., 2016b, Valadez, 2018, Nyerere, 1968). Also, powerful partners always 
tend to present their views as norms but if less powerful stakeholders are given a voice, the 
deliberative process may reveal salient biases and may subsequently influence the more 
powerful partners to change or revise their positions (Young, 2001, Young, 2002). Given the 
diverse stakeholder groups that are involved in genomics research and biobanking in Africa and 
the power differences between them, efforts should be made to adopt a deliberative approach 
to decision-making that seeks to mitigate those power dynamics. Each stakeholder group should 
be given a chance to present their case and to give reasons for their positions.  
 Decision-making within genomics research and biobanking governance structures (steering 
committees, data access committees etc.) should adopt a deliberative process. This applies 
to processes for making decisions such as research priorities, policy development and 
decisions on access to data and samples.  
 
 Stakeholder groups who may be affected by a decision should be given a chance to present 
and give reasons for their own points of view; listen to the reasons of others and debate on 
issues in which they disagree or have conflicting ideas. By giving a chance for reasoned 
argument, the voices of the all stakeholders would have been considered by the different. At 
the end of the process, the different stakeholders may not necessarily agree on the final 
decision, but their perception of the problem may change. The idea is to be able to reach a 
conclusion that is acceptable or considered fair by all. 
 
 Genomics research and biobanking projects in Africa should develop mechanisms for 
engaging and deliberating with the public on key issues around genomics and biobanking. 
This may be done through: consultancy, feedback or the use of participatory approaches to 
stakeholder engagement. 
 
 Decision-making should be by consensus. The voices of all stakeholders who may be affected 
by the decision should be represented in policies and decision-making. There should also be 
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a substantive representation of the voices of all stakeholders. That is, physical representation 
of the stakeholders is not sufficient. 
 
 There should be mechanisms in place to revise decisions that have been made especially in 
light of new evidence.  
3.6.4 Publicity 
Publicity and entails making final decisions and the reasons for them publicly available. This 
ensures that stakeholders understand the moral basis by which final decisions are based (Daniels 
and Sabin, 1998, Daniels and Sabin, 2008b). It also has the advantage of improving transparency 
(Daniels, 2000). Publicity, and by extension transparency, could be practically implemented 
through open meetings, circulation of minutes and the use of other open communication 
processes (Byskov et al., 2014). 
 The reasons for final decisions should be made publicly available as this gives room for 
stakeholders who were not involved in the original process and who may want to appeal 
the decision to have an idea on the basis for which the decision was made. 
 
 Minutes or reports of meetings should be made available to all stakeholders who may be 
affected by the decisions taken at meetings.  
 
 Study populations should be informed of the outcome of decisions that will affect them 
and the reasons for such decisions. Appropriate means of communicating with these 
stakeholder groups should be identified and may include public engagement activities or 
other methods that were used for engaging research participants. 
3.7 Shared Resources 
Resource allocation is a major area of conflict in global health research and raises a range of 
ethical issues related to justice and fairness (Chi and Bump, 2018, Daniels, 2016). One key 
question relates to the equitable distribution research resources between LMIC and HIC partners 
(Pratt and Loff, 2011, Pratt and Loff, 2014, Benatar, 2001, de Vries et al., 2015b). Some of the 
ELSIs in genomics research and biobanking (e.g. exploitation of African researchers and study 
populations, ownerships of samples and data, IP rights and patents) are associated with the 
allocation of resources in global health research. SHG suggest that the distribution of resources 
should be such that a high proportion of the project resources are used to support the research 
of the LMIC partner (Pratt and Hyder, 2016, Pratt and Hyder, 2017).  
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 Genomics research and biobanking consortia in Africa should develop collaborative 
models that are equitable in nature and that ensure that a majority of the resources 
(funding, samples, data etc.) are controlled by African researchers and research 
institutions, unless doing will present a challenge to the overall conduct or 
implementation of the studyThis is because inequalities in resources tend to confer more 
benefit to the HIC partner and have tremendous impact on key research procedures and 
outcomes such as: ownership of data and samples, publication outputs; intellectual 
property rights, and access to the benefits of research.  
 
 Data should be made more widely available to the research community as this may 
accelerate and enhance health research globally. However, given the history of 
exploitation and limited health research capacity in Africa, there is need to recognise that 
whilst open sharing is important, it may also have negative impact on African researchers, 
unless there are mechanisms in place to ensure that they have the capacity to analyse the 
data (sections 1.3.2a and 1.3.2e).  
 
 Samples and data are a valuable resource in genomics research and biobanking. Priority 
for secondary use of samples and data should be given to research that: 1)addresses the 
health neds of population groups in Africa; 2)have a strategy that promotes uptake of 
research findings in ways that benefit study populations; and 3)has plans to develop the 
capacity for LMIC institutions and researchers. Decisions on what to prioritise for funding 
and for secondary use of data and samples should include, at the minimum, 
representatives from the following stakeholder group: funders, African researchers (both 
junior and senior to capture the views different levels of researchers), HIC researchers, 
research participants and policy makers in Africa.  
 
 Authorship of research publications, patents and intellectual property are key resources 
and a major point of contention amongst genomics researchers. Research institutions and 
journals should identify ways of assigning authorship, IP rights such that they are 
equitably distributed. A way around this is to develop and implement fair and transparent 
practices on authorship, benefit sharing, intellectual property and ownership and to 
ensure that the policies recognise the contributions of data producers and sample 
providers.  
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3.8 Transparency 
Transparency is a hallmark for good governance. Whilst it is a difficult concept to define, in global 
health, it has been likened to activities such as: open governance, free flow of information and 
civic participation (Gostin, 2008). This requires: that institutional and decision-making processes 
are open and comprehensible to all stakeholders; that there is the free flow of information 
amongst stakeholders; and that such information is accessible to all stakeholders. This 
recommendation is based on observations that there is limited transparency in global health 
programs, both at the level of decision-making and communication between the different actors. 
This often presents as a major challenge to global health efforts. Researchers in Africa have also 
called for transparency in decision-making processes within genomics research and biobanking 
consortia in Africa, arguing that it is key in fostering equitable global health research partnerships 
(Munung et al., 2017, Okeke, 2016). Open communication between research partners can also 
foster trust amongst stakeholders (Munung et al., 2017). It also shows that partners in a 
collaboration have nothing to hide from each other and are open to constructive criticism, which 
is a value that is critical in deliberative decision-making.  
 Transparency in the governance of genomics databases and biobanks is critical for 
accountability purposes and for building and fostering trust between stakeholders. As a 
result, reasons for decisions on governance policies should be made publicly available. 
This makes it possible to hold decision makers accountable for the decisions that they 
make. Therefore, in the interest of transparency and public accountability, biobanks and 
databases ought to make publicly available, information about their activities and 
policies.  
 
 Genomics research and biobanking consortia in Africa should develop mechanisms for 
reviewing requests for access to samples and data. The principles, procedures and policies 
for access to samples and data should be made publicly available. Such mechanisms 
should describe what samples and data can and cannot be used for. 
 
 Genomics research and biobanking consortia should make public, information on how 
samples and data will be used and by whom. While it is difficult to clearly predict how 
data will be used, these projects should state this information upfront, to the best of 
current knowledge at the time. Once samples and data have been made available for use 
to requestors, the information about actual use should be made available. 
 
 Transparency in decision-making processes is also vital. Consortia should make public the 
processes for which decisions on key ethical issues are made. For example, information 
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of how a consortium decides on who has custodianship of data and how IP rights and 
patents would be distributed in the case of an innovation. The ideal will be to make the 
decisions and the reasons for them publicly available.  
 
3.9 Mutual Collective Accountability (MCA) 
Accountability and transparency are hallmarks of fairness. MCA demands that stakeholders 
within a global health program should be answerable to one another and to other external 
bodies. Firstly, stakeholders must agree on a shared goal; have a common understanding of the 
goal; identify the important outcomes and indicators for measuring if they are achieving set 
goals; have standards of how resources will be used; and the how the plan to ensure meaningful 
participation of all stakeholder groups including in key decision-making processes that affect 
them (Ruger, 2012b). Genomics research and biobanking consortia in Africa should therefore 
establish ways for ensuring: that shared sovereignty is achieved; that resources are being used 
towards promoting health justice and that all actors are performing their roles and 
responsibilities. This could be done through setting standards for decision-making processes 
within the consortium; identifying indicators and benchmarks that may be used determine if 
these processes are inclusive and deliberative; and how resources have been allocated.  
 Genomics research and biobanking consortia in Africa should state the specific 
responsibilities of the different stakeholders. This is because the responsibility for fair, 
efficient and equitable partnerships lies in a broad range of stakeholders including: 
researchers, research participants, funders, journal editors, data access committees, 
research institutions and policy makers. A list of stakeholders and their possible roles and 
responsibilities was presented in table 4; section 3.5. 
 
 Given that the overall goal of population genomics studies in Africa is to use genomics as 
a tool to address global health inequities, Genomics research and biobanking consortia 
should clearly specific their equity oriented goals (see section 3.1) as well as detailed and 
realistic indicators of how the goals will be achieved. This would involve stating outcomes 
for equity related activities such as capacity building; research priority setting and 
research translation. 
 Genomics research and biobanking collaborations should consistently monitor and 
evaluate the equity-oriented goals of the consortium. Monitoring and evaluation should 
provide a situation analysis of the consortium at the beginning of the project; document 
how the consortium is working towards achieving its goal of reducing global health 
inequities. These may include outputs related to: number of approved request for access 
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to data and samples; research that has been carried out using stored samples and data; 
number of research publication; authorship of papers by African authors, number of 
graduates; fellowships that have been offered; patents awarded; new interventions; 
policy impact; feedback of study findings to communities; and compliance with the 
agreement of secondary use of data and samples should be monitored. Outputs and 
metrics for evaluation should be elaborated by researchers, funders, study communities 
and policy makers.  
 MCA also requires establishing ways for ensuring that shared sovereignty is achieved 
within a research consortium. That is, they should have standards for decision-making 
processes within the consortium as well as identify indicators of how to determine or 
evaluate if these processes are inclusive and deliberative.  
 
 MCA is also about engaging study populations, not just as key informants but also as 
agents of change that that have the potential to address concerns and issues that affect 
their community. There should be a mechanism to engage biobank donors and to address 
the concerns that may have related to the consortiums polices and processes.  
 
 Given that accountability is not just about how stakeholders are carrying out the 
responsibilities assigned to them but also about engaging communities about the 
outcome and progress of research studies, genomics research and biobanking consortia 
should develop mechanisms of disseminating the outcome of research projects; 
informing stakeholders on how samples and data have been used; and how the activities 
are contributing towards achieving the consortium’s goal of reducing global health 
inequities. This may require public engagement activities between host communities, 
research institutions and researchers. This accountability mechanism also has the 
potential to foster trust between researchers and study communities. 
  
3.10 Chapter Summary 
Governance is about the processes and interaction of stakeholders who share a common goal 
and who are involved in collective action to address a moral problem. In this chapter, we 
proposed a principles-based approach to governance of genomics research and biobanking in 
Africa. Principles-based governance focusses on the values of the organisation and how it may 
guide action. Based on the principles (Figure 4) identified in Chapter 2 through the conceptual 
analysis and the convergence approach, we proposed a principles-based governance framework 
for genomics research and biobanking in Africa.  
 81 
 
Figure 4: Key principles that will support the governance of genomics research and biobanking in Africa 
 
 
In the next chapters, I will use empirical methods to explore how these principles have been 
upheld in genomics research and biobanking in Africa. This will be through empirical analysis 
involving the reflective equilibrium approach involving: analysis of policy and governance 
documents for genomics and biobanking in Africa; and one-one in-depth interviews with 
different stakeholders in genomics research and biobanking in Africa.  
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Chapter 4: Methodology for Testing the Principles-
Based Governance framework  
The overall aim of our study was to propose a governance mechanism for genomics research and 
biobanking in Africa that will address structural inequalities and justice-related ELSIs in genomics 
research collaborations in Africa. In the previous chapter, I proposed a principles-based 
(conceptual) governance framework for genomics research and biobanking in Africa. This 
framework was developed using normative policy or practice oriented bioethics approach. This 
involved combining both normative and empirical. In this chapter, I will present the empirical 
methods that we used to test the principles and recommendations developed that informed our 
governance framework. This include a case study of H3Africa (section 1.2.2b) and data collection 
processes which consisted of 1) thematic analysis of H3Africa governance-related policies and 2) 
one-on-one, in-depth interviews with stakeholders in genomics research in Africa. The aim of the 
empirical study was to the framework against current governance practices of genomics research 
consortia in Africa, as well against the expectations of the different stakeholders, and to revise 
where necessary (reflective equilibrium) against the ethical intuitions of stakeholders in 
genomics research and biobanking in Africa, and to a lesser extent gain a practical understanding 
of how the principles are, or could be, implemented in everyday genomics research projects in 
Africa. The empirical arm of this work used the reflective equilibrium approach.  
4.1 Empirical Methodology 
Empirical bioethics (Ives et al., 2016, Musschenga, 2005) is becoming common practice in applied 
ethics owing to arguments that understanding people’s moral beliefs, ethical intuitions, 
behaviour and reasoning in a specific area of practice can yield information that is meaningful for 
ethics (Borry et al., 2004, Davies et al., 2015). Empirical bioethics is in inter-disciplinary activity in 
which scientific methods of enquiry (qualitative and/or quantitative) are integrated into ethical 
analysis with the hope of reaching a conclusion that is not too abstract or far removed from 
realities (Davies et al., 2015). There are different approaches to empirical bioethics (Davies et al., 
2015). Two prominent ones are normative policy or practice oriented bioethics (NPOB) and 
descriptive policy or practice oriented bioethics (DPOB) (Ives and Draper, 2009). NPOB is 
normative work on what policy or a practice ought to achieve and it involves combining 
philosophical bioethics to produce a rigorous and consistent analysis of an ethical problem and 
using empirical methods to gain a practical understanding of the ethical issue. DPOB, on the other 
hand is about using empirical method to gain an understanding of how bioethical reasoning 
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would take place in different context, what Ives and Draper, 2009, describes as the sociology of 
bioethics. We used the NPOB approach to achieve our study objectives. The conceptual analysis 
and the outcome of the process were presented in chapters 2 and 3 respectively.  
The empirical part of this study used the reflective equilibrium approach. Reflective equilibrium 
principally consists in working back and forth between a theoretical considerations or principle 
that one believes in and revising it wherever necessary in order to achieve some degree of 
coherence (equilibrium) between the theoretical considerations.13 The rationale behind 
reflective equilibrium is to “test” one’s belief systems (values, principles etc.) against other beliefs 
or value systems that one may have, and constantly revising and refining these values or belief 
systems in cases challenges arise, with the overall goal of reaching an acceptable level coherence 
among the widest set of beliefs.  
 
Figure 5: Diagrammatic representation of reflective equilibrium14 
 
In this study, the idea was to check if the principles and recommendations in the proposed 
framework fit the actual circumstances surrounding genomics research in Africa and where 
possible/required, to tailor the recommendations to the actual circumstances of genomics 
                                                     
13 https://plato.stanford.edu/entries/reflective-equilibrium/ accessed 08 October 2019 
14 https://www.bu.edu/wcp/Papers/TEth/TEthBulg.htm Accessed 08 October 2019. 
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research in Africa. The aim is to have a framework whose principles and recommendations can 
be considered binding for all rational agents and also not too abstract and far removed from 
reality (Davies et al., 2015). This is why I had started by developing a principles-based framework 
for genomics and biobanking in Africa (theory) and then used empirical methods to explore how 
the Framework aligns with the governance policies of genomics research consortia in Africa, as 
well as with the views and experiences of different stakeholders group. The empirical data was 
used to revise the theory as appropriate (reflective equilibrium). The empirical method that I 
used was the case study approach (Starman, 2013, Yin, 2003, Stake, 1995) and the case of interest 
to us is the H3Africa Consortium (section 1.2.2).  
A number of methodologies have been used by researchers who seek to use empirical data to 
inform normative ethical work (Davies et al., 2015, De Vries and Van Leeuwen, 2010). These 
methodologies can be broadly categorised into dialogical and consultative (Davies et al., 2015). 
Dialogical approaches focus on the experiences of an identified group of people, not just as a 
source for reflection but also as part of the process of reflection and analysis (Widdershoven et 
al., 2009). It usually requires a combination of methods including: in-depth interviews and 
deliberative discussions. Consensus is central, but not a requirement for dialogical 
methodologies, and the conclusions of deliberations are taken as the findings of the 
investigation. Consultative approaches, on the other hand, involve using methods of scientific 
inquiry to test normative conclusions. In which case the participants or persons consulted where 
not involved in the normative theorising. Rather an external thinker (the researcher) developed 
the theory and then “consulted” with other stakeholders (Draper and Ives, 2007). Key to 
consultative approaches is going back and forth between the theory and the empirical data, and 
revising the theory until there is some level of coherence between the empirical data and the 
theory of interest (reflective equilibrium). The approach I used for this study was the consultative 
approach.  
4.1.1 The Case Study Approach 
A case study is a research design that offers a researcher an opportunity to probe, a phenomenon 
within its real-life context. It enables exploration of how and why a complex social phenomenon 
works and can bring out important contextual features. Case studies typically use a variety of 
qualitative research methods such as in-depth interviews, document analysis, and participant 
observations (Baxter and Jack, 2008, Patton, 1990, Yin, 2003). It enables the researcher to answer 
“how” and “why” type of questions while taking into consideration how the phenomenon is 
influenced by the case (Baxter and Jack, 2008). Different types of case study designs exist (Stake, 
1995, Yin, 2003). In this study, I used the instrumental case study design (Stake, 1995). 
Instrumental case studies are research designs that help the researcher to refine a theory or a 
phenomenon of interest. The case is not the primary focus, rather it plays a supportive or 
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facilitative role in enabling the researcher to understand or refine the theory of interest. A benefit 
of the instrumental case studies is that there is a close collaboration, or at least there is some 
level of rapport between the researcher and research participants, thereby enabling research 
participants to freely express their views (Baxter and Jack, 2008). I am a student in the H3Africa 
consortium and once worked as a part time research assistant for H3Africa exploring issues of 
consent and regulation for genomics research in Africa. I was also involved, as a participant, in 
the development of the H3Africa “ethics and governance framework for best practice in genomic 
research and biobanking in Africa”. I had therefore established some rapport with H3Africa 
activities and potential interviews. 
4.1.2 The Case: H3Africa and the governance of justice-related ELSIs 
A case is a bounded entity that is of interest to the researcher (Miles et al., 1994). In our study, 
the case is H3Africa governance policies and the phenomenon of interest to us is how H3Africa, 
as a genomics research and biobanking consortia in Africa, has upheld the principles 
recommended in our framework and what are the possible points of divergence. The aims and 
objectives of the H3Africa consortium have been described (Section 1.2.2). I will now present 
albeit briefly, H3Africa’s governance structures and policy documents.  
4.1.2a Governance structures in H3Africa  
The main decision-making body of the H3Africa consortium is the steering committee (SC). The 
SC is made up of all principal investigators of H3Africa projects, and representatives of the two 
funders. All H3Africa principal investigators have a primary affiliation to a research institution in 
Africa. At the time of this study, there were 42 projects listed on the H3Africa website.15 A 
number of these projects have been completed and others are new projects that received 
funding in 2018. Also, some researchers are principal investigators of more than one H3Africa 
project. Projects are nested in 14 African countries, with a majority being in South Africa.  
While the steering committee is the major decision-making body, other key governance 
structures exist within the consortium including: an independent expert committee, working 
groups (WGs), the data and biospecimen access committee (DBAC) and the H3Africa coordinating 
center (H3ACC). These different structures report directly to the steering committee. Figure 6, 
shows the different governance structures within H3Africa and how they are managed. 
 
 
                                                     
15 https://h3africa.org/consortium/projects (accessed 10 Oct.2018). 
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Figure 6: H3Africa Management Structure (Mulder et al 2018)16 
 
H3Africa has an independent expert committee (IEC) which is made up of international experts 
of different disciplinary brackgrounds. Members of the IEC are not affiliated to any H3Africa 
project. Their role is to oversee the H3Africa consortium as a whole and to advise H3Africa 
funders. To do this, they meet quarterly and attend H3Africa meetings (biannual). Members of 
the IEC are appointed by the funders. Its current membership stands at ten, eight of whom are 
based in institutions in HICs, one in an African institution and one in an international agency.  
In terms of the working groups (WGs), H3Africa currently has 12 WGs. These WGS (Figure 7) are 
organized around particular topics or areas of work and will generally have a defined deliverable 
that is in line with the consortium’s activities. WGs are made up of researchers affiliated to an 
H3Africa project and nominated by their principal investigator to represent the project in the 
WG. Most WGs are led by chairs and co-chairs and meet regularly.  
 
                                                     
16https://www.slideshare.net/AfricanOpenSciencePl/h3africah3abionet-case-studynicola-mulder (Accessed 20 
October 2018) 
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Figure 7: Working Groups in the H3Africa Consortium17 
 
The activities of some H3Africa WGs have led to the development of policies or guidelines that 
are relevant for our study. For example, the ethics and regulatory issues WG has developed a 
number of ELSI guidelines for genomics research and biobanking in Africa The data and 
biospecimen WG has also developed best practices for sample and data sharing in H3Africa. 
Membership to WGs is not static and changes depending on availability of nominated members 
and project dynamics (active or completed projects).  
The H3Africa Data and Biospecimen Access Committee (DBAC) is responsible for implementing 
H3Africa data and sample sharing policies. Members of the DBAC are appointed by the steering 
committee and are not (current) members of the H3Africa consortium. The DBAC is administered 
by the Alliance for the Acceleration of Excellence in Science in Africa (AESA), which also 
distributes some of the H3Africa funding (see Figure 6). AESA is an entity of the African Academy 
of Sciences. The DBAC can co-opt principal investigators, funders and the independent expert 
committee in when they need advice to make a decision on access to samples and data. However, 
these three stakeholder groups are considered ex-officio members.  
                                                     
17 https://h3africa.org/consortium/working-groups Accessed 20 October 2018) 
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4.1.3 Data Collection and Analysis 
In this study, I used qualitative research methods to test our principles-based governance 
framework against the governance policies of the H3Africa consortium as well as ethical 
intuitions of the different H3Africa stakeholders. The data collection phase was divided in three 
parts: 1) desktop analysis of H3Africa governance-related documents; 2) one-on-one, in-depth 
interviews with persons who have been involved in the development of H3Africa governance 
policies and; 3) observations, which were mainly a retrospective reflection of the process that 
led to the development of some H3Africa governance mechanisms.    
4.1.3a Data Collection: H3Africa policy and governance–related documents  
A consortium’s policy documents and publications can provide rich information on its decision-
making activities and the norms and principles that guide the governance of the consortium. We 
collected publicly available H3Africa governance related documents. This included: H3Africa 
policies; guidelines; and relevant publications by members of the H3Africa consortium. Table 5 
shows the list of H3Africa publications that we included in this study. These documents were 
selected because they 1) specifically discussed or addressed issues pertaining to fairness and 
justice in genomics research and biobanking in Africa, and 2) because they were written or 
published by the H3Africa consortium or persons affiliated to it. 
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Table 5: H3Africa Governance-Related Documents 
Document Year Code Brief Description 
Enabling the genomic revolution 
in Africa ( H3Africa, 2014) 
2014 H3Africa 2014 A journal article published in Science. It can be considered as a marker 
paper for the consortium. The article is authored by a number of H3Africa 
consortium members and provides information on the goals of H3Africa 
and anticipated activities of the consortium.  
H3Africa guidelines for informed 
consent (2nd edition) 
2014 IC Guidelines A guide for developing informed consent for H3Africa projects. However, 
also recommended for use by non-H3Africa investigators planning to set 
up genomics research and biobanking projects in Africa.  
Application for access to 
H3Africa data and biospecimen 
NA DBAC 
application 
Application form to be used by researchers and other entities who plan to 
access and use samples stored in H3Africa biobanks and/or data 
generated from H3Africa projects. 
Ethics and governance 
framework for best practice in 
genomic research and 
biobanking in Africa 
2017  Best practice 
guidelines 
The document list pertinent ethical principles and best ethical practices 
for genomic research and biobanking in Africa. 
H3Africa data and biospecimen 
access committee guidelines 
NA DBAC 
guidelines 
Provides information on the composition, working and procedures of the 
H3Africa data and biospecimen access committee (DBAC) 
H3Africa biospecimen deposit 
material transfer agreement  
NA MTA This form is used to record the transfer of biospecimen from H3Africa 
projects to an H3Africa biobank.  
H3Africa data sharing, access 
and release policy 
NA DARP This document lays out principles that the consortium considers 
important in striking an appropriate balance between ensuring that there 
are safeguards in place to protect biobank donors, while at the same time 
maximizing the ability of researchers to use samples and data stored in 
biobanks and databases 
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H3Africa data access agreement  
 
NA DAA This document sets out the terms by which access to samples and data 
will be granted. 
NIH-H3Africa request for 
application on ELSIs 
2012 RFA-ELSI Funding Opportunity Announcement for studies on ELSIs in human 
genomics research in African populations. It is complementary to funding 
announcements for H3Africa research projects and coordinating centres.  
 
2012 RFA-Research 
Projects 
Funding Opportunity Announcement human genomics research in African 
populations. It is complementary to funding announcements for H3Africa 
research projects and coordinating centres 
Harnessing genomic 
technologies towards improving 
health in Africa: opportunities 
and challenges  
2011 White-Paper A community-generated document outlining recommendations to the 
two H3Africa funders: Wellcome Trust and NIH. It is authored by members 
of two of H3Africa working groups: The WG on communicable diseases 
and the WG on non-communicable diseases. 
Policy and guidance for 
managing conflicts of interest 
related to data and biospecimen 
access committee (DBAC) 
decisions 
NA DBAC Document describes the processes for disclosing, identifying and 
managing conflicts of interest in the DBAC and to promote quality 
decision-making when conflicts of interest arise. 
The H3Africa policy framework: 
negotiating fairness in genomics 
(de Vries et al., 2015c) 
2015 De-Vries et al, 
2015b  
A peer-reviewed journal article authored by several H3Africa investigators 
and representatives of funders. The article discusses how fears of 
exploitation of African scientists prompted the development of policies for 
collaborative genomics research and biobanking in Africa.  
Model framework for 
governance of genomic research 
and biobanking in Africa – a 
content description (Yakubu et 
al., 2018) 
2018 Yakubu et al A content description of the best practice guidelines for genomics 
research and biobanking in Africa. 
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4.1.3b Analysis of H3Africa governance documents 
The predominant method of analysis was deductive thematic coding based on the principles and 
recommendations in the principles based governance framework (Chapter 3). The idea was to 
test the conceptual principles-based framework against the existing governance practices of a 
genomics research consortia in Africa. The aim was to explore how our proposed framework fits 
with current governance policies of genomics research consortia in Africa and where it is far 
removed from reality. The empirical data from the thematic analysis to revise the framework 
where necessary (reflective equilibrium). Despite doing deductive coding, there was minimal 
inductive coding in the case of new principles emerging from the document analysis. We then 
checked these new principles against our frameworks; principles to see if they were in any way 
related to the framework’s principles or if they framework should be revised to include them as 
new principles.  
To facilitate the process of analysis, all the documents were imported into the qualitative 
research software NVivo 12 (QSR International, 2018). To enable the inclusion of information on 
websites but which is not downloadable, I used NCapture (an extension file on Google Chrome 
that is supported by NVivo to get a pdf version of a website). I then thematically coded by NSM18 
using a pre-defined coding scheme (Appendix 4) which basically comprises of the principles from 
governance framework. The first few coding were checked with one of the supervisors for 
consistency and inconsistencies were resolved.  
4.1.4 One-on-one In-depth interviews 
The second part consist of one-on-one in-depth interviews with different H3Africa stakeholders.  
4.1.4a Sampling 
Purposive sampling was used to select research participants. Purposive sampling is a non-
probability-based sampling strategy where particular settings, persons or activities are selected 
deliberately so as to obtain information that cannot be obtained in other ways (Devers and 
Frankel, 2000). This entails identifying and selecting research participants that are knowledgeable 
about the phenomenon of interest and who can give rich information about the subject matter 
(Creswell and Poth, 2016, Sargeant, 2012). In addition to having an informed perspective, 
research participants were also selected based on their availability and willingness to be 
interviewed (Bernard, 2017, Miles and Huberman, 1994). The advantage of this sampling strategy 
is that it provides the researcher with the opportunity to gain an in-depth understanding of the 
topic of interest (Patton, 1990).  
                                                     
18 The student 
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4.1.4b Research Participants 
Study participants were either persons who: 1) had participated in the development of 
governance policies 2) are involved in governance processes or; 3) had inside information on the 
functioning of the consortium, by virtue of their role within the consortium. Drawing on our 
knowledge of the processes of H3Africa policy and guidelines development, we made a list of 
persons fit into one of the three criteria mentioned above. These potential participants could be 
categorised into different stakeholder groups: African researchers, researchers from HICS, 
research ethics committee members, DBAC members, policy makers and funders (Table 4). 
Efforts were made to involve at least one person in each stakeholder group.  
Emails were sent to potential research participants to invite them to be part of the study. The 
email had a description of the objectives of the project and why they were selected to be part of 
the study. Emails were sent to all identified persons (n= 28) as per the inclusion criteria stated 
above. A response was received from 19 persons, giving a response rate of 67.86%. Of these, 
three declined to be part of the study either because of time constraints, a conflict of interest or 
being unhappy with the study procedures. Of the 16 persons who accepted, 15 were interviewed. 
Repeated efforts to schedule an interview with one of the 16 persons failed. Table 6 gives a 
description of the 15 interviewees. 
Table 6: Characteristics of Interviewees (n=15) 
Group Characteristics Profile of Interviewees Number 
Gender Female 5 
Male 10 
   
Stakeholder Group REC 5 
Data access committee 2 
Policymakers 2 
African Researchers 4 
Funders 1 
Independent Expert Committee 1 
 
While some of the interviewees fit into a particular stakeholder group, a number of them 
belonged to more than one stakeholder group. For example, there are researchers who are also 
policy makers or members of RECs. Members of the DBAC also belonged to different stakeholder 
groups. As a result, it was possible to have an interviewee who is an ethics committee member, 
a member of the DBAC and an African researcher. Therefore, during the interviews, it was 
common for some interviewees to draw on their experiences from the different roles they 
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occupy. However, for the purposes of this study, interviewees were classified based on their 
primary role within H3Africa. Questions were often directed towards that specific role.  
4.1.5 One-on-one in-depth interviews 
The one-on-one in-depth interviews were semi-structured (Mack et al., 2005). All questions were 
open ended (Annex 3: Interview guide). Open ended questions in qualitative research allows for 
the research participant to openly articulate their views in-depth and with little restrictions 
(Jacob and Furgerson, 2012, Kvale, 1996). It also allows for probing and/or follow-up questions 
(Denzin and Lincoln, 2005). The questions were related to the principles and requirements of our 
conceptual principles-based governance framework. The idea was to explore whether and how 
the framework’s principles and recommendations were considered ideal by the different 
stakeholder groups and how they were promoted in H3Africa. Like in the document analysis we 
were searching for a level of coherence between practice and the theory of interest (reflective 
equilibrium). Before the interviews, I did an initial analysis of how the principles in our 
governance framework were upheld in H3Africa governance governance-related documents. I 
integrated some of the outcome from the document analysis into the topic guide. For example, 
sometimes interviewees were asked about a particular H3Africa policy and how that promotes 
fairness. 
4.1.5a Pilot interviews 
The interview guide was pilot-tested in December 2017 with a researcher who has been involved 
in the development of ethics frameworks for global health research, but who is not part of 
H3Africa. The main aim was to check for clarity of questions. Following the pilot, some questions 
were revised for clarity. These were mainly questions that where too theoretical in nature, 
including questions containing words like equity, reciprocity and solidarity. This was because 
some interviewees, based on their disciplinary background, were likely to struggle with questions 
containing these terms or may consider it too theoretical or philosophical. For example, in the 
pilot interview, the researcher had asked what reciprocity meant, though when the question was 
framed differently, his response indicated that he would expect some reciprocity-based actions.  
4.1.5b Main Interviews 
An interview guide was used for all the interviews. However not all questions on the guide where 
asked to every interviewee. As is normal with qualitative research, the interview guide was not 
rigidly followed (Patton, 1990, Dumay and Qu, 2011), rather it served as a pool where questions 
could be selected based on the stakeholder group, their discipline or their particular experience. 
For example, questions related to decisions on funding projects were not appropriate for REC 
members. 
 94 
 
Interviews were conducted using different approaches: face-to-face meetings; Skype; telephone; 
and written interviews (Table 7). We used these different means because our interviewees were 
based in different countries around the world. All interviews were audio recorded. Before the 
start of each interview, informed consent was obtained from the interviewee. This included 
consent to audio record the interview. The purpose of recording was to ensure accurate 
transcription and to facilitate the process of data familiarisation. Interviews were conducted 
between December 2017 and November 2018. 
Table 7: Approaches used for one-on-one interviews 
Mode of Interview Number of interviews 
Face to face 03 
Telephone 04 
Skype 06 
Written 02 
Total 15 
 
4.1.6 Observation  
Observation forms a major part of qualitative research (Kawulich, 2005). In this study, I reflected, 
retrospectively, on the process that was used in developing an H3Africa governance and best 
practice framework (Yakubu et al., 2018). The development of the policy took place before the 
conception of this study. The process involved a number of virtual and physical meetings. Physical 
meetings took place in South Africa and Senegal. I was involved in the organisation of these 
meetings and sat through all the meetings. I had also followed the development of the guidelines 
up until when they were approved for use as a policy document for the consortium. This 
experience informed some of the interviews as well as analysis of the data though it didn’t form 
part of the coding process. Also, one of my supervisors is a previous chair of the H3Africa ethics 
and regulatory issues WG. Discussions with this supervisor also helped add context during data 
analysis and interpretation. 
4.2 Data Analysis 
The first stage of data analysis began with the transcription of interviews. This was done verbatim 
from the audio recordings. To ensure accuracy , each transcript was reviewed at least once , to 
identify any errors or missing text. Where the recording was inaudible, “…” was used to signify 
that there was no sound or missing information. In addition to reading printed copies of the 
transcripts, I also listened to all the recordings at least twice. The purpose was to familiarise 
myself with the dataset (Charmaz, 2006, Creswell and Poth, 2016, Patton, 1990). 
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4.2.1 Coding 
The data analysis was similar to that used for the thematic analysis of H3Africa governance-
related documents. Firstly, all transcripts were imported into the qualitative research software 
NVivo 12 (QSR International, 2018). Deductive thematic coding (Vaismoradi et al., 2013) was used 
to analyse the transcripts, as codes were already pre-determined (principles that informed the 
framework). Deductive coding is a method of qualitative data analysis that uses a predetermined 
framework to analyse the data (interview transcripts, field notes, pictures). It is therefore a 
theory-driven approach, whereby themes or codes selected are predetermined by an existing 
theory, in our case, the principles in our governance Framework. Minimal Inductive coding was 
done for interview transcripts, mainly where the interviewee was articulating a point related to 
governance which did not form part of the Framework’s principles.  
Like in the document analysis, I did the first round of coding. The coding was checked with one 
of my supervisors and discrepancies were resolved. Following that, I coded the rest of the 
transcripts. Because deductive coding was principally used in this study, the codes (principles of 
the framework) had been jointly agreed upon with my supervisors during the development of 
the governance framework and the analysis of H3Afrca governance documents. Therefore, only 
differences in the actual coding were discussed and resolved and not the codes themselves. In 
cases of new codes (inductive coding), the content of the codes were discussed with supervisors 
to see if the constitute a new principle or if they inform one or more of the principles in the 
Framework. 
4.3 Ethical Considerations 
Research ethics clearance was obtained from the University of Cape Town, Faculty of Health 
Science Research Ethics Committee, HREC REF: 548/2016 (Annex 1). 
Before the interviews, informed consent (Annex 2) was obtained from all participants. Consent 
documentation was sent by email to potential participants in the study invitation email. The aim 
of sending information sheet to research participants prior to the interviews was so that they 
could make an informed decision of whether or not they would like to be part of the study. Before 
the interviews, I also re-iterated the content of the information sheet and confirmed their 
willingness to be part of the study. Permission to audio record was also obtained from all 
participants. Audio recordings and informed consent forms were available only to the student 
and the supervisors. Once the interviews were transcribed, the transcripts were anonymised and 
all sources of identification replaced with codes and pseudonyms. This was to ensure that 
confidentiality was maintained at the highest possible standard. 
 96 
 
In reporting the results of the in-depth interviews, names of interviewees have been replaced 
with pseudonyms to limit the chances of identification of study participants. Also, in some cases, 
slight edits were made to the quotes, mainly to remove repetitive words/phrases or 
exclamations. The purpose was to improve readability. No new words were added.  
4.4 Limitations of the empirical study 
The empirical part of this study aimed at testing our principles-based framework against 
governance-related documents of the H3Africa consortium, as well as the governance 
expectations and views of different stakeholders in genomics research and biobanking in Africa. 
Though a list of stakeholders had been identified in our governance framework, it was not easy 
to get a fine balance of all stakeholder groups. For instance, whilst we strived to interview people 
across different genders, age groups and levels of professional seniority, our interviews ended 
up being skewed towards senior males in academia. I acknowledge that greater diversity could 
have further enriched the study. However, I endeavoured to reach out to the different 
stakeholder groups and also to persons across the different management structures of the 
consortium but did not get any response from some potential participants. Also many of the 
consortium members who had participated in policy development or involved in governance 
structures are professionally senior and some stakeholder groups had not been involved in the 
development of policies.  
Also, it was difficult in a single interview to explore in depth on all aspects of the framework, 
given that most the framework principles are quite multi-layered. For example, a governance 
requirement such as inclusiveness is broad and involves a range of requirements such that it will 
require a full study, to fully explore, what it really means for genomics and biobanking in Africa. 
This work will benefit from future studies that specifically seek to explore, in depth, separate 
elements of the framework.  
This study would have benefited from a review of minutes of some H3Africa governance 
structures, for example minutes of steering committee meetings, or working group meetings 
where policy decisions were made or discussed. Attempts to get the minutes were unsuccessful. 
We did not want to use our insider access to obtain these documents, but we were also unable 
to receive copies of the minutes through formal channels.  
4.5 Chapter Summary 
In this chapter, I discussed the empirical methods that were used to test our proposed 
governance framework against the current governance practices of a genomics research and 
biobanking consortia in Africa, as well as against the ethical intuitions of different H3Africa 
 97 
 
stakeholder groups. This involved the use of empirical bioethics approaches and qualitative 
research methods (document analysis and one-on-one in-depth interviews). The aim was to 
achieve some coherence between the principles-based framework and practical realities. In the 
next two chapters, I present the findings of the empirical study. 
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Chapter 5: Assessing Existing Governance Practices of a 
Genomics Research and Biobanking Consortia: The 
Case of the H3Africa Consortium 
In Chapter 3, I proposed a principles-based governance framework for genomics research and 
biobanking in Africa. This was based on a conceptual analysis of: two accounts of global health 
justice and governance (SHG and GGH); and the African moral theory of Ubuntu. To investigate 
how the principles and recommendations proposed in the governance framework compare to 
the existing governance approaches of a genomics research and biobanking consortia in Africa, I 
used empirical bioethics approaches (normative policy or practice oriented bioethics, 
consultative approaches and reflective equilibrium). This involved qualitative research methods 
(Case study, thematic analysis of H3Africa governance-related documents and one-on-one in-
depth interviews with stakeholders in genomics research and biobanking in Africa.  
In this chapter, I present the results of the thematic analysis of H3Africa governance documents 
and how the upheld, aligned or diverged from the principles promoted in our governance 
framework. In presenting the results, I will provide a brief context to each principle, then state 
what was obtained in the data and end with an analysis and/or interpretation of the data and 
whether or not the policies align or diverged from the principles promoted in our governance 
framework. The results of the analysis are presented according to the nine principles promoted 
in the governance framework (Chapter 3). This includes: shared sovereignty, furthering the ideals 
of health justice (FIHJ), solidarity, reciprocity, transparency, shared resources, shared 
responsibility, mutual trust and mutual collective accountability. 
5.1 Shared sovereignty or shared decision-making 
Shared sovereignty (shared decision-making) is about democratic governance. It allows 
stakeholders to express agency and to ensure that their needs and perspectives are captured in 
decision-making. The advantage of shared sovereignty is that if properly done, it could address 
concerns of inequality in decision-making. Key indicators of shared sovereignty include: 
deliberativeness; inclusiveness; consensus; relevance; appeal and revision; publicity and conflict 
management. Voting may be used in deliberative decision-making, but attention must be on the 
quality of the decision-making process, ensuring that it is not elitist and that it captures the voices 
of all who may be affected by it (Pratt et al., 2016b, Young, 2002). In the review of H3Africa 
governance documents, I checked for these different indicators.  
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5.1.1 Decision-making structures within H3Africa  
Two major decision-making structures emerged from the documents that were reviewed: The 
steering committee (SC); and the data and biospecimen access committee (DBAC). The SC is the 
main decision-making body (See Figure 6). While the DBAC is charged with making decisions on 
access to samples and data from H3Africa projects. However, a number of working groups (WGs) 
exist within the consortium, each tasked with a different activity but expected to report directly 
to the steering committee.  
The SC comprises of African researchers and funders, mainly: Principal investigators of H3Africa 
projects and two representatives of the funders. However, “additional funding members may join 
the meetings but do not have voting rights” (de Vries et al., 2015c). These additional funding 
members are program scientists19. Program scientists are employees of the funders and are 
responsible for administering grant portfolios and working with principal investigators to 
negotiate the goals of their projects.20 These program scientists take part in SC meetings and in 
the deliberations but do not have voting rights. 
The DBAC is the second major decision-making body in H3Africa. It is an independent committee 
made primarily of non-H3Africa members. The DBAC is tasked with the responsibility to “review 
and approve or reject all requests from the research community…..for access to datasets and/or 
biospecimens” (DBAC guidelines). Members of the DBAC are appointed by the steering 
committee and it is said that the “steering committee will consult more broadly to identify 
appropriate members of the DBAC” (DBAC Guidelines). However, it is not stated who, or which 
stakeholder group, would be consulted. The majority of DBAC members are based in institutions 
in Africa. Its current voting membership stands at nine. Details of its composition is shown in 
Figure 8. Of the four scientists who are part of the committee, one is from a HIC but with research 
experience in Africa. The DBAC also has four ex-officio members: a member of the independent 
expert committee (IEC); a representative of each of H3Africa’s major funders; and an H3Africa 
principal investigator. The size of the ex-officio members is almost half that of the voting 
members. The criteria for selecting members of the DBAC are not stated in any of the 
consortium’s documents. 
                                                     
19 In some documents (e.g. RFA ELSI and RFA research) Program scientists are also referred to as program officers or 
project scientists. 
20 https://www.niaid.nih.gov/research/program-officers  
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Figure 8: Composition of the H3Africa Data and Biospecimen Access Committee (DBAC)21 
 
A third decision-making structure is the working groups (RFA-Research projects). As stated in 
chapter 4 (figure 7) there are currently 12 working groups (WGs) in H3Africa. The WGs may be 
considered decision-making structures, though indirectly. This is because some WGs are have in 
the past led the development of governance policies for the consortium. However policies 
developed by the WGs would have to be endorsed by the steering committee. WGs are ideally 
made of representatives from the different H3Africa projects and representatives are appointed 
by an H3Africa principal investigator. However, from our personal experience, membership in 
WGs is quite fluid, with some WGs having representatives of funders (program scientists).  
After identifying the major decision-making bodies, we checked core H3Africa governance 
documents (Chapter 4; Table 5) to investigate whether the key indicators of shared sovereignty 
(deliberativeness, relevance inclusivity, consensus, publicity and appeal and revision) were 
reflected in H3Africa’s decision-making structures.  
5.1.2 Inclusivity  
One way to promote equity in decision-making is through ensuring that decision-making 
processes are deeply inclusive of the different stakeholder groups, especially marginalised or 
                                                     
21 https://h3africa.org/wp-content/uploads/2018/05/App-D-H3Africa-Data-and-Biospecimen-Access-Committee-
Guidelines-final-10-July-2017.pdf Accessed 08 October 2019 
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disadvantaged groups and that no one group is disproportionally represented. There are three 
components of inclusivity are: breadth, qualitative equality and non-elite participation (Pratt et 
al., 2016b, Ruger, 2011).  
5.1.2a Breadth of Stakeholders 
Breadth is about the range and mass of stakeholders that are involved in decision-making. It 
should be such that each affected stakeholder group is proportionally represented so as to 
capture the diversity of perspectives within the research program.  
Stakeholders that are typically involved in decision-making in H3Africa, as per the documents 
reviewed include: researchers (African and HICs), funders, community representatives, 
independent experts and program scientists. Compared to the other H3Africa decision-making 
structures, the DBAC is the most inclusive in terms of breadth. It is composed of African 
researchers (in the majority), HIC researchers, a representative of independent expert committee 
(IEC), funders and a community representative. It equally has a wider representation in terms of 
scientific discipline. The DBAC is also the only decision-making structure that has a representative 
a community representative (patient advocate). The steering committee, on the other hand, is 
made up of African researchers, members of the IECs and the funders. No other stakeholder 
group is represented in the steering committee. WG are predominantly made of researchers and 
funders (program scientists). 
Decision-making in H3Africa is dominated by three stakeholder groups: funders, HIC researchers 
and African researchers, as these stakeholder groups dominate the steering committee and the 
DBAC. Whilst community representatives form part of the DBAC, their participation in decision-
making is limited to reviewing request for access to data and samples.  
5.1.2b Qualitative equality 
To achieve inclusivity, all stakeholders affected by a decision should have an equal chance to 
influence the final decision-. Although the range and mass requirement are largely not met within 
the SC, there are measures in place to ensure that decision-making is not dominated by 
historically powerful stakeholders such as funders and HIC researchers. For example, in the SC, 
the greater number of African researchers vis-à-vis HIC researchers and funders could be 
understood to have the effect of promoting the voices of African researchers, thereby minimising 
the possibility of exploitation of African researchers. Also, some representatives of the funders 
on the SC do not have voting rights and may therefore be taking on a supportive role. This is in 
line with the qualitative equality requirement of shared sovereignty, which recommends that HIC 
partners play a rather supportive role in decision-making, allowing a greater number of 
representatives from LMIC institutions to be included relative to HIC partners (Pratt and Hyder, 
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2017). The same can be said of the DBAC which is made of 14 members, 9 of which have voting 
rights, whilst four are non-voting. The four non-voting members include: an H3Africa principal 
investigator, 2 representatives of the funders and a representative of the IEC (see figure 8). 
However, the number of community representatives or patient advocates compared to the 
expert groups and other stakeholders is relatively small and this may influence their ability to 
influence decision-making.  
 Qualitative equality is also about including the voices of each stakeholder group represented 
(substantive representation) in decision-making. That is, there must be some level of qualitative 
equality whereby all individuals have a fair opportunity to voice their opinion and to influence 
the decision-making process. It was difficult to determine from the document analysis, how this 
was promoted within H3Africa besides the dominance of African researchers in key decision-
making structures. However, in a recent study, a genomics researcher in Africa called for 
“regulatory procedures that will make sure that the African scientists are involved and are central 
to any decision involving the use of the samples and are actually involved in the publications and 
the intellectual property that emanates from such processes. African scientists should be at the 
centre of all of this. So it is not disadvantaging anyone” (Munung et al., 2017). This may suggest 
that at the time of the study (2015-2016), there were perceptions that African researchers did 
not have an equal chance to influence decision-making compared to stakeholders from HICs. This 
is despite some of them being principal investigators.. 
Also, in developing some H3Africa policies, the ethics and regulatory issues WG adopted a 
consultative process, especially when engaging stakeholders who were non H3Africa members 
(de Vries et al., 2015a, Ramsay et al., 2014, Yakubu et al., 2018). My observation of some of the 
WG processes is that decision making followed a deliberative process. However, it will be 
important to interrogate how the different stakeholders who participated at these meetings feel 
about the engagement and deliberative processes that were adopted by some WGs, and if they 
found their voice in the overall process and in the final decision. It will also be important to 
explore how the qualitative equality component plays out at the level of the steering committee 
and the DBAC, given that though these structures are dominated by African researchers, a 
substantial number of representatives of the funders (including project scientists) and members 
of the IEC take part in deliberations. Overall, substantive representation was more visible within 
the WGs than at the broader level of the consortium.  
5.1.2c Non-elite participation 
Equally important in shared sovereignty is the participation of “non-elite” groups in decision-
making. Besides the representation of African researchers, who can be considered historically 
disadvantaged within global health research programs, only the DBAC involves another 
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historically disadvantaged group, representatives of study communities (Best practice guidelines 
and DBAC guidelines). The DBAC has non-science experts such as fraternity and legal persons (see 
Figure 8). However, whether these non-expert members have an opportunity to impact on 
decision-making (substantive equality) is unclear, given their relatively small number compared 
to the expert group. For example, having single individuals representing study communities may 
not always be ideal especially when the rest of the DBAC is made up of experts. It may be worth 
having an additional patient group representative as part of the DBAC. This may limit the chances 
of supressing the voice of this stakeholder group.  
5.1.3 Relevance 
The second key requirement for shared decision-making, after inclusivity, is the relevance 
principle. The relevance condition demands that decision-making processes, and final decisions 
should appeal to the values and principles of stakeholders who may be affected by the decision.  
The H3Africa best practice guidelines speaks to the relevance principle, stating clearly that the 
document is “inspired by communal or solidarity-based worldviews that are important in many 
African countries. Such worldviews recognize that individuals are shaped by their relations to 
people around them, and emphasize respectful and harmonious relationships between 
individuals. It places central importance on reciprocity, consultation and accountability as key 
ethical values”. This suggest that principles such as solidarity and reciprocity and respect which 
are important in African communities and other parts of the world, were taken into consideration 
when developing this particular H3Africa policy. The guideline further mentions, with reference 
to informed consent and community engagement practices, that there is need for an African 
approach to decision-making stating that “In many African contexts, individuals often take 
decisions in consultation with family, friends and community members. Frequently, there are also 
clear authority structures that must be respected in the engagement process such as permission 
from village chiefs and elders. In genomic research and biobanking, community engagement 
offers an important opportunity to build respect and trust between research teams and the 
respective communities”. Here the document again highlights respect, as well as trust as 
important principles and/values that are necessary when implementing genomics studies in 
Africa. The quotes above therefore shows that some of the principles promoted in our 
governance framework (solidarity, reciprocity, trust, accountability) are also considered 
important by the H3Africa consortium. A principle not in our framework but which is considered 
by the consortium to be important is respect. However, there is little detail in the documents 
reviewed about what the principle of respect entails.  
5.1.4 Deliberativeness 
Deliberativeness is the third requirement of shared sovereignty. Deliberative democracy 
demands that all stakeholders who may be affected by a decision should be given the opportunity 
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to propose solutions to the shared problem, give reasons for their position and be open to 
criticism (Young, 2002). None of the documents that were reviewed suggested if this was an 
approach to decision-making, although consultation was used in some cases. However, from our 
experience, the WGs (made primarily of one or two stakeholder groups), used deliberative 
processes when developing policies (personal observation). Usually, when developing a policy, 
the ethics and regulatory issue WG would first deliberate about certain policies at the level of 
WG meetings and would come up with draft policies that they consider to be fair and just. Once 
these policies have been identified, other stakeholder groups (mainly RECs and other African 
researchers) were consulted to discuss the proposed policies. In most cases therefore, persons 
invited to meetings to discuss guidelines where presented with draft policies for discussion. 
5.1.5 Consensus decision-making 
Following deliberative discussions, shared sovereignty demands that the final decision should be 
reached by consensus. Consensus decision-making is a form of group decision-making process 
whereby group members agree to support a particular resolution in the best interest of a group. 
For a consensus driven process to be considered fair, it must be: inclusive, deliberative and 
agreement seeking. 
From the document review, voting is the main form of reaching final decisions in H3Africa, both 
at the level of the DBAC and steering committee. In the steering committee, each funded project 
and funding agency is entitled to one vote. At the level of the DBAC, final decisions will also be 
reached by voting (DBAC guidelines). It is also stated that decisions may be reached without 
discussions at a DBAC meeting but that in cases where the vote is not unanimous, the chair will 
make the final decision. It is not stated if voting is preceded by deliberations, however there has 
been some minimal use of structured group interactions and consensus-driven dialogue (de Vries 
et al., 2015a, Ramsay et al., 2014, Yakubu et al., 2018). Voting can form part of consensus 
decision-making. However, it must be preceded by deliberative discussions with the intention of 
reaching group agreement. This therefore aligns with our framework principle of shared 
sovereignty and the requirement for consensus-based decision making. However, further work 
is needed to establish whether voting was and/or preceded by deliberation.  
5.1.6 Appeals and revision 
The appeals and revision condition of shared sovereignty states that there should be mechanisms 
in place to appeal decisions and to revise the decisions in line with new evidence. The DBAC fulfils 
this requirement by making provisions for researchers to appeal a decision to reject their request 
to access samples and data. In the DBAC guidelines, it is stated that “If a requester wishes to 
contest the H3Africa DBAC decision…….the requester may contact the H3Africa DBAC chair to 
discuss the issues or resubmit her/his request. The H3Africa DBAC Chair may approach the 
 105 
 
H3Africa steering committee for their advice in problematic cases”. Besides this, there is no 
information on processes for appeal and revision, for example are requestors required to provide 
a detailed reasons for why their applications will be considered, will they appeal be discussed at 
a DBAC meeting or does the chair have the sole decision-making right, what kind of decisions can 
be appealed and how long is the appeal process? There is no mention of a process to appeal and 
revise decisions that are made by the steering committee.  
5.1.6a Conflict management 
The sixth requirement for shared sovereignty is that global health research consortia should have 
mechanisms in place to address conflicts.. Two major ways of managing conflict are discussed in 
H3Africa governance documents: mediation and the use of independent committees. Both are 
linked to the functioning of the DBAC and to the sharing of research resources (samples and 
data). The DBAC is an independent committee, therefore, no H3Africa researcher is part of the 
DBAC. The idea for an independent DBAC stems from arguments that despite the advantages of 
having primary researchers populate DBACs as they potentially have greater knowledge of the 
wishes of sample donors, they often want to exercise ownership and control over their data 
(Fecher et al., 2015, Kaye et al., 2009), rather than allowing maximum use of samples and data 
for the advancement of research. The approach by H3Africa for an independent DBAC therefore 
seems appropriate in addressing that level of conflict. 
The H3Africa defines a conflict of interest as any situation whereby the personal interest or 
loyalties of a DBAC member may influence or affect the decision of the committee. The DBAC 
requires that members communicate with the H3Africa coordinating centre, or the Africa Alliance 
for Accelerating Excellence in Science in Africa (AESA), in advance, of any conflict of interest they 
may have for an application under review. AESA is an initiative of the African academy of Sciences 
and has an H3Africa portfolio which manages Wellcome Trust funded H3Africa projects. The 
DBAC member with a conflict of interest will then have to recuse themselves from discussion and 
voting on all applications for which they had indicated a conflict of interest.  
Conflicts are also predicted to arise in cases where data and samples are used in ways that do 
not conform to the data access agreement (DAA) and in assigning intellectual property rights 
(H3Africa MTA). It is expected that this will be solved via mediation or adjudication by an ad-hoc 
committee made of approximately seven members and with a balanced representation of the: 
steering committee; funders; the provider or host biorepository; and the local research ethics 
committee. There are no indicators of what the mediation process will take into consideration.  
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5.1.7 Publicity 
The last of the shared sovereignty requirement is publicity. The recommendation is that global 
health research projects should make publicly available, information on decisions that affect 
stakeholders; and the procedures by which the decision was reached. This allows all stakeholders 
to easily interrogate decisions made by the consortium, should the wish to do so. In H3Africa, 
reference to the publicity requirement is only made in relation to access to samples and data. 
The DBAC guidelines state that the H3Africa coordinating centre will publish ( on the H3Africa 
website), a list of projects that have been granted access to samples and data samples. This, 
however, is in contrast to the data access release policy (DARP) which states that “the 
coordinating centre will keep records of who gained access, and when, to ensure that the terms 
of access and the conditions of the publication embargo are complied with. These records will not 
be made publicly available, but will be available to the H3Africa steering committee for oversight 
purposes”. The quote above shows that information on access to samples and data will not be 
made available, thereby contrasting the DBAC guidelines. The DBAC guidelines (but not the 
DARB) align with our framework requirement for shared sovereignty that decisions, and the 
reasons for them, should be made available to all affected stakeholders.  
5.2 Solidarity 
The second principle promoted in our framework, after shared sovereignty is solidarity. Solidarity 
is a key principle in African communitarianism. It is about unity, based on shared values, 
objectives and standards (Wiredu, 2000). It supports an approach whereby members of a 
community work towards achieving a common goal even when they may have different personal 
values and opinions (Msila, 2015). The principle of solidarity overlaps with the principles of 
reciprocity and trust.  
Solidarity is represented in H3Africa governance documents in two major ways. Firstly, there is 
the solidarity of HICs with populations in Africa. This is motivated by fears of a potential genomics 
divide which may worsen global health inequities (H3Africa White-Paper). The goal of H3Africa is 
to prevent this genomic divide thereby contribute to reducing global health inequities (H3Africa 
Consortium, 2014) . It is hoped that this could be achieved through the participation of African 
populations in genomic variation studies as well as through equipping African researchers with 
the tools and skills needed to carry out population genomics studies. This has led some funding 
agencies (US-NIH and the Wellcome Trust) in HICs to invest in population genomics research and 
biobanking in Africa, with the goal of preventing a genomics divide. The second is a call for 
solidarity from African populations to the global community. This is framed in line with the idea 
that understanding Africa’s rich genetic diversity offers significant insights into a range of 
diseases as well as treatment strategies that could benefit populations not only in Africa, 
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worldwide (White-Paper, H3Africa, 2014). Population genomics studies on African populations 
could be facilitated through collaborative research and the sharing of samples, data and expertise 
between researchers. However, entrenched systemic and structural inequalities in health, 
research capacity and resources between HICs and Africa and a history of extractive research 
practices in global health programs in Africa, also requires that parallel attention be given to 
social justice and fears of exploitation of African populations and researchers in global health 
research. To this effect, H3Africa developed a number of policies for access to data and samples 
from H3Africa projects. Some of these policies include: the data access release policy (DARP) and 
the DBAC guidelines. These policies all support the sharing of samples and data (through the 
European genomics archive) with researcher from around the world, but with access being 
controlled by the H3Africa DBAC. However, priority for access would be given to researchers in 
Africa, especially those who were involved in the initial studies (DARP). The idea is to ensure that 
African researchers have more control of data and samples, thereby addressing concerns of 
exploitation of African researchers. This shows the adoption of solidarity based values by the 
H3Africa but in ways that are limited to ensure fairness and to curb the exploitation of African 
researchers.  
Based on the document review, the responsibility for promoting solidarity-based action in 
H3Africa lies with four stakeholder groups: populations in LMICs; researchers in LMICs; 
researchers in HICs; and H3Africa funders. African researchers and research participants are 
expected to show their solidarity towards health for all, by allowing for the sharing of samples 
and data so as to allow for maximum research utility. Whilst HICs would show solidarity to African 
populations by funding genomics studies on African populations and building the capacity of 
African researchers to independently perform genomics studies. It is stated that the consortium 
embraces an ethos of the common good and therefore the consortiums research resource 
(samples, and data) would be used not only in Africa but also globally (H3Africa 2015).  
Another demonstration of solidarity that could be deciphered from the review of the documents 
relates to patents, IP and subsequent access to proven interventions that may arise from the use 
of samples and data. The consortium argues that if care is not taken, IP claims may unnecessarily 
limit research and innovation. H3Africa adopts the NIH stance on IPs stating that “H3Africa 
discourages any premature claims on precompetitive information that may impede research, 
though it encourages patenting of technology suitable for subsequent private investment that 
may lead to the development of products that address healthcare needs” (H3Africa DARP). The 
H3Africa DARP takes this a step further and notes that the “filling of patent applications and/or 
the enforcement of resultant patents in a manner that might restrict use of the H3Africa 
genotype-phenotype data could diminish the potential public benefit they could provide”. And in 
cases where this is unavoidable and for the purposes of innovation, “preferential access [to 
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intervention] be given to communities that contributed the samples from which the data in the 
H3Africa database is derived”. Equally, users of samples and data are advised to opt for a non-
exclusive license to LMICs should they determine that their innovation could provide solutions to 
Africa’s burning health problems. (H3Africa DAA). This is ensure that LMIC populations have 
affordable access to the innovation and by extension, genomics technologies.  
H3Africa policies are in line with the proposed Framework’s principle of solidarity. They also 
speak to the principle of furthering the ideals of health justice (FIHJ).  
5.3 Furthering the ideals of health justice (FIHJ) 
The third requirement of the Framework speaks to the obligation of genomics research in Africa 
to further the ideals of health justice. That is, they should aim at reducing global health inequities. 
Generally, the argument for large scale genomics research projects in Africa has been fuelled by 
fears of a possible genomics divide that could widen global health inequities between LMICs and 
HICs (Gurdasani et al., 2015, H3Africa Consortium, 2014, Singer and Daar, 2001b). Global health 
research can further the ideals of health justice by: 1) ensuring that research addresses the health 
needs of worst-off populations; 2) building research capacity in LMICs and 3) promoting the 
translation and uptake of research findings.  
In all the documents that were reviewed, there was recurred emphasis that genomics research 
in Africa “should promote the goals of reducing global health inequality and exploitation of and 
strengthening the research system in the country where the samples are collected” (Best practice 
guidelines). Below, I present how the three requirements of FIHJ were promoted by the H3Africa 
consortium. 
5.3.1 Research priority setting 
Research priority setting in global health research has the advantage of guiding research 
investment and by extension, ensuring that research is of potential public health benefit to study 
populations (Viergever et al., 2010, COHRED, 2000). Our framework requirement for the principle 
is that genomics research and biobanking consortia should prioritise diseases or health 
conditions that are a major contributor to the disease burden in Africa, have a genetic aetiology 
and for which genomics could provide maximum public health benefit.  
The H3Africa research funding announcement (RFA) states that “H3Africa is designed to provide 
new opportunities to African scientists to lead research on the genetic and environmental 
contributors to health and disease issues of importance to Africa through the use of genomics and 
other cutting-edge approaches”. The consortium’s whitepaper also emphasises that H3Africa 
funders would “support a number of focussed research projects that could address questions of 
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significant scientific and medical importance to African Populations” or as would be later 
described in an article on H3Africa’s approach to fairness, the “H3Africa consortium seeks to 
harness genomics technology to investigate diseases pertinent to African populations.....and 
responsive to local health needs”(de Vries et al., 2015c). Based on information on the H3Africa 
website, current projects span both communicable and non-communicable diseases including: 
tuberculosis, rheumatic heart disease, trypanosomiasis, stroke, respiratory infections, breast 
cancer, schizophrenia, sickle cell anaemia and neurological disorder. It is unclear how H3Africa 
decided on what diseases /health conditions to focus on, but the H3Africa White-Paper makes 
reference to the United Nations millennium development goals, as well as diseases that are a 
major cause of morbidity and mortality in Africa. There is also reference to WHO statistics on 
DALYs and mortality estimates in Africa, to justify why the consortium will also focus on chronic 
diseases. It is also stated in the White-Paper that following an agreement between the African 
Society of Human Genetics (AfSHG) and H3Africa funders, the consortium opted for a model 
whereby population genomics studies in Africa are tied to specific diseases. This is to ensure that 
these studies yield maximum benefit to African populations.  
The H3Africa White-Paper specifically lists: tuberculosis; human African trypanosomiasis; cancer 
due to infectious diseases; sickle cell disease; hypertension; type 2 diabetes; stroke; cancer; and 
other Mendelian conditions (for example non syndromic deafness) as research priority areas for 
genomics in Africa. The list above contains diseases that are major drivers of morbidity or 
mortality in Africa and/or which may be considered diseases of the poor. Some diseases on the 
H3Africa’s priority areas such as sickle cell disease and syndromic deafness may not be major 
contributors to the disease burden in Africa, however they have a strong genetic aetiology and 
genomics could therefore propose solutions with a high public health impact. The consortium 
also stresses the need for secondary users of data to address questions of health importance to 
African and African diaspora populations” (H3Africa White-Paper).  
H3Africa research priority areas therefore align line with our framework principle for FIHJ that 
genomics research in Africa , including secondary uses of samples and data should prioritise 
diseases that are: a major driver contributor to the disease burden in Africa; have a strong genetic 
aetiology; and for which there is limited ability to ability to modify exposure to risk factors 
through environmental or life style changes; and which the use of genomics could have a high 
public health impact in resource limited settings. The data also suggest that research priorities 
for H3Africa were determined by African researchers and funders and this aligns with the 
framework’s principle of shared sovereignty. 
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5.3.2 Research Capacity Building 
A second requirement of the FIHJ principle is research capacity building. H3Africa acknowledges 
that the limited capacity for genomics research in Africa may worsen global health inequities (de 
Vries et al., 2015c). Research capacity building is a central component of H3Africa and is 
emphasized in all H3Africa governance- documents. The consortium adopted recommendations 
by the African Union and the New Partnership for Africa's Development (NEPAD) to build capacity 
for science and technology in Africa as well as public awareness of science (White-Paper). It hopes 
to achieve this through a multiplicity of approaches mainly: the training of African researchers 
(both senior and junior); skills development; support for genomics infrastructure; public 
engagement in genomics; and African leadership of H3Africa projects. These measures have the 
potential of creating equitable research partnerships and generating knowledge and 
interventions that are critical to addressing Africa’s health needs. For example, the DAA states 
that “H3Africa should support the training of Africans in the field of genetic epidemiology, 
bioinformatics, statistical analysis, high-throughput technologies, genomics data analysis, clinical 
research, and ELSI research to address current disparities in expertise and enable African 
researchers to participate fully in the generation, interpretation, and utilisation of data and 
discoveries from the samples donated”. This reliance on the recommendations from the African 
union and NEPAD highlights the role of this stakeholder group (policy makers) in decision-making  
A highly desirable feature of consortia governance is ensuring that HIC partners assist LMIC 
partners with limited capacity to do independent research (Pratt and Hyder, 2017). To enable 
LMIC researchers carry out independent research, H3Africa funding is awarded directly to African 
researchers. Equally, the initiative has supported the establishment of African centres of 
excellence for genomics research and is funding the training of African researchers at multiple 
levels including: skills development; training of postgraduate and postdoctoral scientist (Munung 
et al., 2017). H3Africa data governance policies (DARP and DSA) also advocate for African 
researchers to be given priority access to samples and data. Collectively, and in the long run, this 
will definitely facilitate independent genomics research projects by African researchers. This also 
aligns with the Framework requirements that African researchers should lead genomics projects 
in Africa and that when researchers request to use samples and data, the DBAC and funders 
should prioritise those projects that involve African researchers as collaborators.  
The capacity building component of the proposed framework also requires that African 
researchers should be supported to become independent researchers and that this is likely to 
happen through long term collaborations. The H3Africa program was initially set up as a 5 year 
project. The first round of funding ended in 2016. In 2017, a second call for applications was 
launched. Some of the projects in the first rounds phased out while others received a second 
round of funding, together with new projects. Overall, the consortium does not have a defined 
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mechanism for long term sustainability of genomics research on the continent or H3Africa 
projects. However, in the RFA, African researchers are expected to provide support letters stating 
how their institutions will ensure sustainability of projects as well as retain, where possible, junior 
scientists that are trained as part of H3Africa. In its White-Paper, the consortium also makes a 
call to African governments and regional policy organisations (such as the African union and 
NEPAD) to ensure the sustainability of genomics projects in Africa by committing funding for 
genomics research. This approach supports the Framework requirements. 
5.3.3 Translation of research findings 
The last of the three ways by which the principle of FIHJ could be advanced, is through having a 
mechanism for the translation of research findings and ensuring that study populations have 
access to proven interventions.  
Overall, there is minimal reference to research translation in H3Africa consortium documents. 
Only two of the documents directly refer to translation. These are: the White-Paper and the 
governance and best practice guidelines. In the governance and best practice guidelines, there is 
a firm recommendation that “efforts should be made to ensure that pertinent research findings 
are translated into population specific diagnostic assays/tests in cases where current and often 
Euro-centric assays/tests are inadequate in the African setting” However, in the White-Paper, the 
consortium appears cautious in talking about translation stating that “translation has been the 
greatest challenge of molecular genomics” and that even though conventional studies are 
focusing more on identifying rare gene variants and their role in health and disease, translating 
those findings into medical practice seems overwhelming at this point”. 
Like most basic sciences, it is likely that it will take a while (including multiple studies) for the 
outcome of population genomics studies in Africa to be translated into clinical and /or policy 
interventions. This may explain why the consortium applies caution in talking about translation 
of research findings. While the proposed Framework requires that genomics research and 
biobanking consortia have a clear plan for the translation of research findings and for ensuring 
that study populations are able to access proven interventions emanating from these studies, 
H3Africaseems to be very cautious about discussing translation and did not detail what may 
happen in cases where products are developed from studies that use samples and data from 
H3Africa projects. However there is a general acknowledgement on the importance of public-
private partnerships that could support translation of research findings. Also, the consortium 
encourages researchers to opt for non-exclusive licence to LMICs to ensure access to proven 
interventions preferential access [to intervention] be given to communities that contributed the 
samples from which the data in the H3Africa database is derived (section 5.2 “Solidarity). 
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5.4 Reciprocity 
Reciprocity is the awareness that human interactions are contingent upon mutual exchange. The 
term reciprocity features in one of H3Africa’s policy documents: the best practice guidelines for 
governance of genomics and biobanking in Africa. In the document, it is stated that the guidelines 
are informed, in part, by reciprocity and solidarity. Otherwise, expectations for reciprocal 
relationships range from: study populations opting to share samples and data from genomics 
research and biobanking projects in Africa with researchers in other parts of the world so as to 
contribute towards health for all; developing benefit sharing arrangements; acknowledging 
primary data producers; and research capacity building. 
The first reciprocal relationship is between study populations and the global community. By 
participating in genomics research and biobanking projects, African populations are contributing 
Africa’s rich genetic diversity to foster genomics research and genomics medicine globally. 
However, the consortium is called upon to ensure that that samples are not only exported out of 
Africa, for the global good, but that genomics research in Africa is “responsive to the health needs 
of African populations, ……and that there is a stronger avenue for implementation of research 
findings into clinical practice” (Best practice guidelines). This also applies to secondary uses of 
samples and data where requestors are expected to state how their studies will be addressing 
the health needs of African populations as well as how their projects would contribute to 
research capacity in Africa (White-Paper; de Vries et al 2015).  
In terms of benefit sharing, the H3Africa ethics and governance framework for best practice in 
genomics research and biobanking in Africa, states that “the main benefit of genomics research 
and biobanking should be health and welfare benefits to African populations as they are 
shouldering the research burdens and risk, [therefore] benefit sharing regulates that benefits are 
burden are distributed fairly and it is therefore key to ensuring that research collaboration is fair”. 
It also recommends that researchers “disseminate information on genomic research and provide 
feedback of research results” as this stands as a key benefit for African research participants. 
The last aspect is acknowledging African researchers in publications arising from the use of 
H3Africa samples and data. The H3Africa whitepaper recommends the development of policies 
that will guarantee African researchers full credit for their primary work. This recommendation 
is reflected in the H3Africa DARP where is it stated that “investigators who access H3Africa data 
[should] acknowledge the consortium and relevant project(s) appropriately in any oral or written 
presentations, disclosures or publications…..and intellectual property” as a way of “recognising 
the scientific contributions of researchers who generated the data”  
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5.5 Transparency 
Transparency is about openness and sharing of information in ways that are accessible and 
understandable to all stakeholders. It is about making available, information on the consortium’s 
operations, policies and decision-making processes.  
H3Africa policies are available through its website. Also the DBAC guidelines and DARP provide 
detailed information on the processes for accessing samples and data, as well as how request for 
access to samples and data would be evaluated. These two documents also state that the 
consortium will provide details of entities that have used samples or data from H3Africa projects. 
This information will be made available either to the public to the SC (See 5.1.7 Publicity). This 
aligns with our framework requirements for shared sovereignty that information on how samples 
and data have been used should be made publicly available to all affected stakeholders.  
Transparency however does not only apply to decision-making processes. It is also about 
providing detailed and comprehensible information about the consortium’s activities to study 
communities. The H3Africa informed consent guidelines state that “it is important that the 
development of a consent process is informed by a wider community engagement effort aiming 
to meaningfully engage with prospective research participants and their communities to identify 
and discuss the ethical aspects of the research”. Also, one of the three capacity building 
approaches in H3Africa, as stated in its White-Paper is public engagement. Though not much said 
with respect to public engagement, some projects on public understanding of science projects 
(Mboowa et al., 2018) as well as community engagement (Staunton et al., 2018) has been 
ongoing within the H3Africa consortium. This shows that the Frameworks recommendation for 
transparency and accountability could be implemented. There was however no information on 
whether and how the consortium will inform other stakeholders (excluding funders) of how it is 
achieving its equity oriented goal of preventing a genomics divide in Africa.  
5.6 Shared resources 
The shared resources component of the Framework demands that consortia partners should 
receive a fair share of the consortium’s resources and that the bulk of it should be allocated to 
the African partner. Also, stakeholders should contribute resources based on their wealth. Four 
major kinds of resources could be identified from H3Africa governance-related documents: 
human resources; samples and data; financial resources and patents/intellectual property. Table 
8, provides a description of these resources. 
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Table 8: Resources in genomics research and biobanking in Africa 
Resource Description of how resources will be used 
Samples To be shared globally for use in research that could improve 
global health.  
 
Material transfer agreements provide fair terms of exchange 
and the idea is to minimise the possibility of exploitation of 
African researchers and study population  
Data Data generated from H3Africa projects will be made 
available to researchers via the European Genome Archive. 
 
A data sharing agreement between the data and sample 
provider (H3Africa or H3Africa PI is mandatory). 
 
Access to H3Africa data must be approved by the DBAC. 
Indicating that while it is available for use by researchers 
around the world, it will be controlled and not freely 
available. 
Financial resources Funds for H3Africa projects would be held by a researcher 
affiliated to an African institution. 
 
Majority (51%) of the funding is to be spent in institutions in 
Africa. 
Research publications There is a nine months embargo period to allow primary data 
producers to analyse and publish their findings before the 
data is made available via the European genome archive 
 
Primary data producers should be acknowledged in all 
publications emanating from the use of their data. 
 
The H3Africa coordinating centre will track publications to 
ensure that primary data producers and the consortium are 
acknowledged. 
Intellectual property and 
patents 
Awardees will retain copyright for software developed as 
part of awards. 
 
Patents that may limit research use of data is discouraged.  
 
When the outcomes of study that used samples and data 
from H3Africa leads to tangible products or services, 
innovators are encouraged to opt for non-exclusive licences 
 115 
 
so as to ensure that study communities have access to the 
health intervention. 
Research Infrastructure Laboratories, research equipment, centres of excellence, 
biobanks. 
 
African institutions will provide infrastructural support for 
projects.  
 
H3Africa will support the development of African centres of 
excellence for genomics research. 
 
Infrastructural development will be guided by a needs 
assessment of what already exist in the continent.  
Human resources Researchers, administrative staff, funders, clinical staff 
 
Majority of project partners (co-PIs) are to be based in an 
African institution. 
 
One of the key recommendations for promoting justice in global health research consortia is that 
stakeholders should contribute resources based on their wealth and that the majority of 
resources should be assigned to the LMIC partner as this allows them to carry on research that is 
of relevance to the health needs of their populations. In terms of funding, the main funders of 
H3Africa, the NIH and Wellcome trust, are institutions in HICs. H3Africa projects are led by 
researchers based in African institutions and funding is directly allocated to their institutions. Of 
the total funding, at least 51% has to be used in an African institution (RFA-Research). Also, the 
overall expectation is that H3Africa will seek ways of ensuring that the research partnerships are 
structured such that African researchers have “preferential access to samples and data” (de Vries 
et al., 2015). The H3Africa MTA also emphasises the need for African researchers and institutions 
to retain ownership of samples and data and this has implications for intellectual property and 
the filing of patents. H3Africa largely follows recommendations that global health research 
consortia assign more resources to the less resourced partner. Therefore, it can be said that these 
policies are consistent with the principle of shared resources.  
5.7 Mutual Trust 
Trust is a relational concept and is based on the expectation that one can rely on another person’s 
words or actions and that the person has good intentions to carry out their promises. (Bligh, 
2017). Trust is also a necessary requirement for solidarity and has great value in instances where 
one party is vulnerable to the other and therefore at risk of exploitation by the more influential 
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party. In our governance framework we had suggested that trust could be fostered in genomics 
research through long term collaborations, recognising the contribution of each stakeholder 
group and through public engagement activities. 
Statements in H3Africa documents on the importance of building trust between stakeholders 
suggest that trust is required at two levels: trust between African researchers and their 
collaborators in HICs and between study communities and African researchers/research 
institutions. For the former, the consortium hopes that trust could be built through fostering 
equitable relationships between HICs and African researchers (de Vries et al., 2015c). This has 
the advantage of countering fears of exploitation of African scientist. In terms of trust between 
study participants or communities and African researchers and institutions, it is hoped that trust 
could be built in three major ways: community engagement, return of results and re-contact with 
research participants (Best practice guidelines and RFA research). Concerns of exploitation of 
African populations and researchers may perhaps explain why only these three group of 
stakeholders and not the others, were specifically targeted as stakeholder groups for which it is 
important to build trustworthy relationships, It also shows that reciprocity-based actions, respect 
for values and norms of African populations, and accountability are necessary for building trust. 
H3Africa policies therefore support our framework principles of trust and by extension, 
reciprocity, shared decision-making and accountability.  
5.8 Shared Responsibility 
The shared responsibility principle demands that responsibilities should be assigned to 
stakeholders based on the function that they typically assume. In H3Africa activities and decision-
making are likely to happen in groups, for example: WGs, steering committee, the DBAC and the 
IEC. A look at membership in the different groups or committees identifies the following 
stakeholders: African researchers, data experts, bioethicists, fraternity persons with legal 
expertise, study populations, funders, researchers in HICs and members of ethics committees. 
Other stakeholders, in genomics research in Africa who may not be part of the consortium but 
who are sometimes referred to in the documents are: study communities; European nucleotide 
archive; European genome archive; commercial enterprises and journal editors. Table 9, shows 
the different stakeholder groups in H3africa and their corresponding responsibilities as per 
H3Africa governance documents.  
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Table 9: Roles and responsibilities of different H3Africa stakeholders 
Stakeholder Roles and responsibilities 
Researchers in Africa  Outline how their work will contribute to reducing 
global health inequities  
 
 Be involved in community engagement activities with 
the goal of building trust between study communities 
and researchers 
 
 Identify research priorities that are relevant to study 
populations 
 
 Make publicly available resources that are developed 
with the use of H3Africa resources 
 
 Take part in key decision-making  
 
 Provide scientific and technical leadership for projects 
DBAC  Provides oversight of data collected and/or generated 
by H3Africa projects. This includes review of request 
for access to data 
 
 Gives feedback on approved request for data use to 
RECs that approved the primary studies 
Steering committee  Made of H3Africa PIs ( African researchers) and 
funders 
 
 Major decision-making body of the consortium. 
 
 Advices stakeholders of major project related 
activities 
 
Collaborating researchers in 
HICs 
 Support capacity building efforts of the consortium 
especially in projects where the serve as co-P.Is or 
collaborators 
Funders  Research priority setting 
 
 decision-making (steering committee) 
 
 funding for H3Africa projects 
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 monitor and evaluate projects through a peer review 
process ( with inputs from the IEC) 
African research institutions   Provide infrastructural support for H3Africa projects. 
 
 Make a commitment to share samples and data from 
H3Africa projects. 
 
 Provide logistic and administrative support to 
H3Africa projects. 
 
 Organise community engagement activities, in line 
with cultural and context specific dynamics, with the 
goal of building trust between research institutions 
and study communities. 
 
 Ensure sustainability of projects and retain, where 
possible, junior scientist trained as part of H3Africa  
Policy makers/national 
governments 
 Ensure sustainability of projects  
 
 Provide research infrastructure for approved projects 
Regional networks and 
organisations 
 Sustainability of genomics research through the 
provision of funding.  
Research Ethics 
Committees 
 Safeguard the interest of research participants. 
 
 Provide oversight of samples, with the aim of 
ensuring responsible use of samples for future 
studies. 
Independent Expert 
committee 
 Review and evaluate the progress H3Africa  
 
 Advice funders on the progress and achievements of 
the consortium. 
 
 Participate in key decision-making (as part of the 
steering committee) but with non-voting rights. 
Program Scientist  Negotiate program goals with H3Africa PIs 
 
 Participate in decision-making (within the steering 
committee) but with non-voting rights. 
Healthcare professionals 
(medical geneticist, 
physicians, nurses, 
phlebotomist, nurses) 
 Feedback of genetic findings 
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 Develop guidelines for the feedback back of incidental 
findings  
 
 Management of patients. 
 
 Sample collection and identification of phenotypes. 
Secondary users of samples 
and data 
 Ensure that their proposed studies contribute to 
efforts aimed at reducing global health inequities. 
 
 Submit annual reports to the DBAC stating how they 
have complied with the DAA. 
Research 
communities/Research 
Participants 
 Primary resource for samples and data. 
 
 Maybe involved in decision-making (as part of DBAC). 
H3Africa coordinating 
Centre (based at HIC and an 
African research 
institution).  
 Monitor use of data and samples. 
 
 Advice secondary users of samples and data on access 
procedures. 
 
 Provide administrative support to the consortium. 
European Genome Archive 
 
European nucleotide 
archive 
 Store data generated from H3Africa projects.  
 
 Make data available following approval from the 
DBAC. 
 
Shared responsibility demands that the responsibility for stakeholders should follow the 
functional requirement principle that is stakeholders should be assigned responsibilities based 
on the function that they would typically assume (see section 2.2.2b). The roles and 
responsibilities assigned to the various stakeholders by H3Africa fit with the with the functional 
requirement principle, and therefore with the Framework requirement (Chapter 3; table 4). The 
document review however reveals stakeholders such as the European genome archive, which 
was not included in our governance framework. However, the framework had broadly indicated 
that African research institutions would ensure that data is submitted to the consortium’s 
database, without specifically mentioning any genomics database. On the other hand, the 
framework includes RECs and journals, which are not assigned specific functions in H3Africa 
documents, although reference may have been made to them. For example, the DBAC is 
expected to draw the attention of journals in cases of breach of data use (H3Africa DARP). This is 
certainly in the hope that journals will withdraw these articles or ask authors to comply when 
possible. The DBAC is also expected to communicate RECs who provided initial oversight of 
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samples and data to inform them of how samples and data have been used (Best practice 
guidelines). These responsibilities of the DBAC and scientific journals where not captured in the 
proposed Framework. It will be considered when revising the Framework.  
5.9 Mutual Collective Accountability (MCA) 
Mutual collective accountability (MCA) is the last principle promoted in our framework. Three 
things are key in MCA: identifying benchmarks for measuring success; participation of all 
stakeholders in setting and evaluating benchmarks (process, output, and outcome indicators) 
and publicity of decisions. Also key in MCA is monitoring and evaluation, and the principles of 
transparency and trust.  
The H3Africa best practice guidelines for the governance of genomics research and biobanking 
recommends that the “impact of community engagement efforts should be evaluated”. However 
it is not stated how this will be done and by who. It is also stated that H3Africa would be evaluated 
after five years (RFA-Research) and the following are listed as indicators for measuring the 
consortium’s success: publications in high impact journals; first and senior authorship by H3Africa 
investigators; operation of a pan–African bioinformatics network, operational biorepositories; 
availability of funding for genomics projects, reversal of brain drain (H3Africa 2014, White-Paper). 
These indicators and benchmarks for success are published in documents that were jointly 
written by African researchers and H3Africa funders, suggesting therefore that these two 
stakeholder groups decided on how the success of the consortium will be measured. The IEC is 
expected to regularly advice project funders on the progress of the consortium, though it is 
unclear if the IEC will be using the stated benchmarks. 
Monitoring and evaluation is a necessary pre-condition for accountability. Three major H3Africa 
activities will be monitored: 1) project outcomes, 2) community engagement activities; and 3) 
access to samples and data (best practice guidelines and DBAC guidelines). The Chair of the DBAC 
is expected to submit an annual report to the steering committee. The DBAC is expected to 
“communicate regularly with the ethics review committees with primary oversight of the samples 
and data being overseen…….this enabling the ethics committee to know what is happening with 
the samples” (Best practice guidelines). One can therefore say that secondary users of data are 
accountable to the DBAC and the DBAC is accountable to the primary ethics committees and the 
steering committee. While the researchers are accountable to the ethics committees and to 
study communities.  
The best practice guidelines further recommends that the consortium should monitor the use of 
samples, including: number of samples exported; recipients of the samples; reasons for exporting 
samples; number of archived or destroyed samples. The H3Africa coordinating centre will also 
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“keep records of who gain[ed] access, and when, to ensure that the terms of access and the 
conditions of the publication embargo are complied with” (H3Africa DARP). Secondary users of 
data and samples, on the other hand, are expected to submit annual reports to the DBAC stating 
how they have complied with the DAA. Secondary users are therefore directly accountable to the 
DBAC. It is only this level (secondary users to DBAC) of accountability that has an enforcement 
mechanism in place, which is the suspension of access to data (H3Africa DARP). Equally, future 
access may also be denied to individuals found responsible for a previous breach of the conditions 
of the DAA”. And in the case where the publication embargo was not respected the “H3A steering 
committee or DBAC may contact the appropriate journal editor with evidence that data use 
conditions have been breached and to request that any manuscripts be withdrawn” (H3Africa 
DARP). This would suggest that the consortium has to work together with publishers or journal 
editors to define processes and agreeable reasons for withdrawing a published article.  
It is also expected that H3Africa, through the coordinating centre, will track publications arising 
from the use of H3Africa samples or data. This is to ensure that the consortium is being 
acknowledged in studies that use H3Africa data and also that the nine months publication 
embargo has been respected (H3Africa DARP). This is important as it may be considered a way of 
checking concerns of “helicopter research” whereby sample collected in Africa are exported to 
HICs and African researchers who collected the samples are not involved in the data analysis and 
publications, nor are the provided with information on how and what samples are being used.  
TheH3Africa consortium policies support the MCA principle, as there are indications of 
stakeholders being accountable to each other. However, there is the absence of accountability 
mechanisms to other stakeholders such as study communities and policy makers in Africa. That 
is would, study communities and policy makers be informed of how the consortium is achieving 
its equity oriented goals. H3Africa also seems to have adopted the use of an independent expert 
committee to advice the consortium on whether or not it is achieving its set goals, thereby 
bringing in accountability to an external body.This is permissible in MCA as long as the 
responsibilities of stakeholders are clearly defined.  
5.10 Points of divergence between the governance framework and H3Africa 
governance related documents 
Overall, the document analysis showed that most of H3Africa policies broadly align with all the 
principles promoted in our framework, except for certain specific cases. In some cases, the 
documents provided recommendations which were not included in our framework, but this was 
mainly in terms of practical implementation. A case in point is the shared responsibility principle, 
specifically the responsibilities assigned to the DBAC, scientific journals, and the independent 
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body for monitoring and evaluation (section 5.8). Also, the H3Africa best practice guidelines 
mentioned the need for respectful and harmonious relationships especially with study 
communities (section 5.1.3; Relevance). This was not captured in the framework and was 
therefore considered as a possible points of revision (reflective equilibrium). 
5.11 Chapter Summary 
I have presented an analysis of how H3Africa policy and governance related documents align or 
diverge form the key principles for promoting fairness and justice in genomics research and 
biobanking in Africa, as articulated in our proposed governance framework (Chapter 3). With a 
few exceptions on requirements for shared responsibility and MCA, the majority of the proposed 
Framework requirements already constitute part of governance of H3Africa. An indication that it 
is likely to meet the expectations of all stakeholders and that the Framework’s recommendations 
could be practically implemented. 
In the next chapter, I report on the analysis of the in-depth interviews. The interviews investigate 
if H3Africa stakeholders consider the frameworks principles as important in promoting justice 
and fairness in genomics research and biobanking.  
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Chapter 6: Stakeholders’ Perspectives on Governance 
Requirements for Genomics Research in 
Africa 
In Chapter 5, I presented an analysis of H3Africa governance documents. The aim was to explore 
how the principles advocated for in the proposed governance Framework are upheld by the 
governance practices of H3Africa and if there were any points of divergence. In this chapter, I will 
present the analysis of the in-depth interviews conducted with H3Africa stakeholders. The aim 
of the interviews was to test our framework’s principles against the expectations of the different 
stakeholders in genomics research in Africa. That is to explore if their expectations of governance 
are similar to that proposed in the Framework or if there were points of divergence that should 
be considered (reflective equilibrium).  
Fifteen (15) in-depth, one-on-one interviews were conducted with members of the H3Africa 
consortium who have been involved in developing governance policies for H3Africa. Interviewees 
belonged to one or more of the following stakeholder groups: researchers, funders, REC 
members, policy makers, IEC and the DBAC. The interview transcripts were thematically analysed 
according to the principles described in our proposed governance framework. In presenting the 
results, I will also simultaneously discuss the results and provide an interpretation where 
necessary and then state if the intuitions of the stakeholders align or diverge from our 
framework’s principles which include: shared sovereignty; solidarity, furthering the ideals of 
health justice ( FIHJ), reciprocity, transparency, shared resources, shared responsibility, mutual 
trust and mutual collective accountability (MCA). 
6.1 Shared Sovereignty 
In the interviews, I prompted researchers to reflect on some of the decision-making processes 
that they have been involved in, within H3Africa. This involved questions around who was 
involved in the process, what approaches where used, if they thought they voices of all 
stakeholders were taken into consideration. All interviewees were of the opinion that processes 
to develop H3Africa policies had to a large extent followed a consensus-driven deliberative 
process but that the process could be improved. This was because, they felt that in some cases, 
the policies may have been influenced by more influential stakeholders, most likely the funders. 
There was also agreement that deliberative and consensus driven dialogue should be the ideal 
process for developing ethics and governance policies. For some of the interviewees, deliberative 
processes are a show of respect and indicate that no one stakeholder group is dictating what 
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needs to be done to their African partners. Below, I present the different expectations for shared 
sovereignty as per the interviews. 
6.1.1 Consensus driven deliberations 
In the framework, we had recommended that decision-making processes should be deliberative 
and that decisions should be reached via consensus. Overall interviewees were of the opinion 
that in developing H3Africa governance policies, consultations were done with different 
stakeholder groups, either through face-to-face meetings and or/ electronically, and that this 
allowed for some degree of deliberations. There was also a parallel view that certain stakeholder 
groups (research participants and policymakers) were left out of the decision-making process. 
Overall, the processes were considered fair and transparent.  
I think it was not a rushed process. It was a process which was structured in a 
way that there were a series of discussions and consultations of the different 
drafts that were developed. I think it was a fair process, given the stakeholders 
who were already involved. We have already said that some stakeholders may 
have been left out. There was transparency, there was discussion, and there 
was openness. (Ntube) 
One of the downsides of deliberative decision-making is that it is time-consuming and requires a 
lot of resources. We asked interviewees if this is not sufficient to avoid deliberative processes, 
and if so, what other decision making processes could be ideal. There was agreement that 
deliberative processes take a lot of time but that it was a necessary when new policies and 
governance mechanisms are being developed.  
Well, it has to be resourced, it is time-consuming, but when you are doing 
something that is new, you are introducing new concepts, I think ultimately it 
is ethically the only sound way to do it….. So what feels like a slowing down of 
the process, initially, will actually create better research ultimately. …..I do not 
think you have to do that level of ethics deliberation for everything, some 
things are much simpler, but this was all new and complex and ethics 
committees had no training in most of this stuff. So it is unfair to expect them 
to make decisions on things that they know very little. (Nxumalo) 
Deliberative processes that are inclusive and consensus driven were therefore considered to be 
good way of reaching decisions, especially when new ideas and policies are being discussed. This 
aligns with our framework’s requirements for deliberative decision making. 
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6.1.2 Inclusivity 
Inclusivity requires that all stakeholders who may be affected by a decision should be included in 
the decision-making process. Requirements for inclusivity include: Breadth (mass and range) and 
qualitative equality (See section 2.2.2d Inclusiveness). 
6.1.2a Breadth 
The steering committee (SC) the data and biospecimen access committee (DBAC) and the 
working groups (WG) are the main decision making structures in H3Africa. The composition of 
these governance structures varied depending on their activities but stakeholder groups that 
mainly involved in decision making include: African researchers, HIC researchers, funders, RECs, 
and in the case of the DBAC, a community representative. We also noted in the analysis of 
H3Africa governance documents that decision-making within H3Africa is dominated by three 
stakeholder groups: IEC (mainly HIC researchers), funders, IEC and African researchers. We asked 
interviewees if there were any stakeholder groups that should have been included in decision 
making but were often left out were left out of decision-making processes. In response to this, 
interviewees mentioned study communities and argued that it was important to include them in 
decision making because there should be “nothing about them, without them” 
The group of stakeholders that I can say was missing from the process of 
developing the framework is the group of ordinary potential participants in 
genomic/genetic research. It is important to include this group of stakeholders 
under the fairness slogan that states: "Nothing about them without them” 
(Zoya) 
A major dilemma for most interviewees however was the appropriate method to be used for 
engaging this this stakeholder group and how the representatives will be selected considering 
that that research participants for population genomics studies are often recruited from several 
“communities”. 
But when we talk of a community member, what community are we going to 
pull that from? Is it a community member who is part of a life project, which 
could be just one project? So certainly we should have given a voice to a 
particular community and I don’t think it would have been a disservice to the 
process at all. If anything it would have enhanced the process. But I am just 
trying to figure out how would they be involved (Palesa) 
Some interviewees suggested it may be best to involve study communities in decision-making at 
the project level, especially where organised patient groups exist. Other proposals included: 
allowing RECs to represent the interest of study participants; and developing public engagement 
activities that seek the opinion of the public on certain genomics research policies. 
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Whilst including a wider range of stakeholders in decision making is important, it should be done 
in such a way that no one stakeholder group is disproportionately represented. This is to ensure 
that no one stakeholder group dominates decision-making by virtue of numbers. I asked 
interviewees if the decision-making processes in H3Africa were, in any way, disproportionately 
influenced by a certain stakeholder group. Some interviewees mentioned that stakeholders from 
HICs have had a major say in decision-making compared to the African stakeholders. 
The reality is that the power still resides out of Africa. If we are going to take 
this view that is very democratic and you have got two African researchers in 
a group of 7, the power struggle is there. ….. So it doesn’t matter how much 
voting you are going to take. So I think that the way that it has worked in some 
projects is for Africans to actually be the PIs. So immediately you shift power, 
you shift not only the power but you shift people's understanding of what is at 
stake (Kofi) 
Some of the interviewees said this shift in power dynamics has and has actually seen African 
researchers take more control of decision-making. Although occasionally the funders would want 
to have a major say in a particular decision  
The steering committee is composed of the PIs, and the steering committee is 
where the decisions are made on governance documents. So basically I think 
they handed the power to the PI’s, and they took that on…..So I think it is that 
policy that the PI had to be African. And the second bit of that is, making sure 
that the ones in charge of the governance are the PIs. That gives them the say 
and a shift in direction. I also think over time their voice became stronger, once 
the funding was in place, once they started feeling their way and finding their 
voice. I think the dynamic of power has shifted. I think the funders originally 
said a lot more and were more in control and they still occasionally wave the 
funder stick, but I actually think that the steering committee has found its 
voice and has worked. (Nxumalo)  
We also asked interviewees which stakeholder groups, in their opinion, was more powerful and 
therefore likely to influence certain policies in their favour compared to other stakeholder 
groups. It was suggested that this were mainly funders and researchers from HICs. 
I always did have slight concerns about the roles of funders in the decision on 
broad consent for example. The potential influence of funders is huge in 
developing a governance framework and it’s how you balance that. That will 
always be the problem. (Palesa) 
Such an imbalance could be addressed through research capacity building and the equitable 
sharing of research resources. 
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There are groups that probably have more power because they have more 
money or more resources, it is always like that, not just in Africa. But what 
could be leveraged on the other side where they do not have money or 
resources is to give them more education more information and build capacity 
(Sanyu) 
The interviews and document analysis suggest giving power to the less influential stakeholders, 
building their capacity, and where possible, assigning more resources to them. These different 
ways of minimising the a disproportionate influence over decision making by a particular 
stakeholder group powerful stakeholders on decision-making and in achieving a fair research 
collaboration is in line with the FIHJ principle.  
6.1.2b Qualitative Equality 
Qualitative equality is about ensuring that deliberations occur in a democratic environment, i.e. 
each stakeholder group is not just represented, but has a chance, through reasoned argument, 
to equally influence the final decision. The document analysis showed that the development of 
some policies, especially by WGs, met the qualitative equality requirement. In the interviews I 
asked our interviewees if the qualitative equality requirement was achieved during decision 
making processes in H3Africa. 
I think it was a collective process. I think that whatever views were expressed, 
it was done in a collective manner so again. I don’t feel after having read the 
document that I was strongly in disagreement with anything. So I think that 
my views will probably be reflected in the document but through a collective 
process and not through an individual process. (Diarra) 
The document analysis showed that the Ethics and Regulatory Issues WGs had consulted non-
H3Africa members when developing some H3Africa ethics and governance policies. The question 
therefore was whether consulting other stakeholders was appropriate and important. Some 
interviewees felt that consultation of a wide range of stakeholders improved the deliberative 
process. They were also of the opinion that consultation is part of decision-making in traditional 
African settings and should be adopted in decision making in global health research.  
I would say that it is a deliberative process in that there was back and forth 
movement in terms of discussions. You know, during the calls, people have the 
opportunity to ask questions and to ask for guidance from experts….. If you 
look at a lot of our African communities, we actually have our traditional 
leaders, but our traditional leaders do not make decisions alone. They actually 
consult. They've got a group of elders who work with them, they consult those 
elders, that is actually go down to the lower levels and then they consult the 
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lower levels when they meet they consult amongst themselves and then they 
advise the leader (Chishala) 
Consultation therefore forms an important part of decision-making in African settings. In the 
framework, we had suggested that the views of stakeholder groups who are not traditionally 
involved in decision-making within the consortium (e.g. study communities and policy makers), 
could be captured during community or public engagement activities. Consultation seems to be 
one of the methods of achieving this and could be incorporated as part of public engagement 
activities.  
6.1.3 Relevance 
Another requirement for shared sovereignty is that decisions should appeal to the values and 
norms of the different stakeholders that may be affected by the decision. In the interviews it 
emerged that in developing some governance policies for H3Africa, there were calls for 
governance should be cognisant of values and principles that are upheld in most African settings. 
There were also issues of the need for any such governance regime to be able to 
promote respect for communitarian values that are reflective of the nature that a 
number of African cultures and settings. (Eyadema) 
This lends support for our choice to adopt principles from Ubuntu that were not necessarily 
promoted by the two other accounts of global health justice and governance (SHG and GGH). 
Some interviewees also suggested that decision-making processes should not only align with the 
norms and principles considered important by all affected stakeholders, but that it should also 
take into account the historical reasons that underpine certain decisions in genomics research 
and biobanking in Africa.  
One [governance] that is built on mutual respect and trust. One that is 
beneficial to both parties, one that is cognisant of the needs and principles that 
underpin the historical need for this process. (Palesa).  
One of the underlying reasons for calls for justice and fairness in genomics research and 
biobanking consortia in Africa has been the historical experiences of exploitation of African 
researchers and study populations. The quote above suggests that in designing governance 
mechanisms, genomics research and biobanking consortia in Africa should actively seek to 
promote policies that will minimise the chances of exploitation of African researchers and 
research participants.  
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6.1.4 Conflict Management  
Conflict management is a key requirement for shared sovereignty. The document analysis 
showed that conflict management was mainly discussed in terms of the workings of the DBAC 
and that this may require use of an ad-hoc committee. From the interviews, it transpired that 
there hasn’t been any conflict at the level of the DBAC or in the development of policies that 
required conflict resolution by an independent body. It was therefore not possible to explore if 
the use of an ad-hoc or independent body worked better in conflict resolution. However, some 
of the interviewees felt that deliberating and reaching consensus is one of the best ways of 
resolving conflict.  
I think it (consensus driven dialogue) minimises conflict. In ethics, people have 
very strong views, and that is why I think it can take some time to come to a 
consensus on the best approach in terms of ethical governance for example. 
But I think it gives everyone a chance to express their views, and then the 
ultimate product in terms of guidelines, can say where there is flexibility to 
adjust to local conditions or local views. So I think that, that is the approach 
that best promotes both the science and minimises conflict. (Kinela) 
This seems to suggest that in the case where an entity such as the ad-hoc committee is used to 
resolve issues of conflict, the process should be deliberative and a solution reached via 
consensus. Like all decision-making structures, the composition of the ad-hoc committee should 
be such that each stakeholder has an equal chance to influence the decision making process.  
6.2 Solidarity 
Solidarity based actions would require that genomics research in Africa: further the ideals of 
health justice (FIHJ); that samples and data be shared broadly; and that benefit sharing 
mechanisms are available. Our analysis of H3Africa governance-related documents showed that 
there was a call for HICs to show solidarity with populations in Africa by supporting genomics 
research in Africa so as to prevent a genomics divide between Africa and HICs. There was also a 
call for solidarity from African populations to the global community in terms of allowing for broad 
sharing of samples and data, so as to facilitate genomics variation studies that would benefit 
populations worldwide. We will present the views and expectations of interviewees in relation 
to using genomics as a tool to addressing global health inequities in section 6.3 (Furthering the 
ideals of health justice (FIHJ).  
In terms of sharing of samples and data, H3Africa policies support the sharing of data and samples 
with other researchers and entities from around the world for the purposes of research and 
innovation. However, this will be done through controlled access, via the H3Africa DBAC. The 
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intention for controlled access is to minimise exploitation of African scientist whilst also allowing 
maximum use of samples and data by African scientists. When interviewees were asked about 
their views on broad sharing of samples and data, the responses were in support for maximum 
sharing of samples and data and solidarity-based reasons were often cited as the reason why 
they will support the broad sharing of samples and data.  
Solidarity is used a lot in terms of fighting a common threat. So you have this 
image of people standing shoulder to shoulder supporting each other. So 
reciprocity goes with all of that; so if I support you, you will support me and so 
forth. So I think in the context of genomics research, what reciprocity could 
mean, is that if research participants are willing to not only participate in 
research but share data, then there should be a reciprocal sharing of data 
back. (Kinela)  
The quote above, which is similar to views expressed by other interviews highlights reciprocity-
based-solidarity, which is a common feature of African communitarianism. Furthermore, it shows 
a link between the principles of solidarity and reciprocity. It was therefore common for 
interviewees to suggest that the requirement for broad sharing of data should also be 
accompanied by requirements to prioritise research on health conditions prevalent in the study 
communities and that is done in collaboration with African researchers.  
Access can be made open to all researchers regardless of institutional base, so 
long as they are working on health conditions affecting African populations 
and/or working in collaboration with scientists based in African institutions. 
(Eyadema) 
Although concerns of exploitation in global health research may have over the years led to a 
nervousness by African researchers to share samples and data, the interviews suggest that there 
is growing willingness to share data, in as much as African populations and researchers benefit 
from the process. The major concern therefore is not about open sharing of samples and data, 
rather it is more of an expectation of reciprocity, one which ensures that all stakeholders  harness 
some degree of benefits.  
There was also the view, based on Ubuntu values, that the sharing of samples and data between 
African researchers is likely to be easily accepted by group of persons who share a common value 
or who trust each other. This would mean that the sharing of samples and data would be easier 
between trusted collaborators and between African researchers compared to sharing between 
researchers with no established and trusted relationship. As one interviewee explained, Ubuntu 
is stronger within people who share a common value.  
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Ubuntu is probably strongest within an ethnic group and then gets weaker 
and weaker as one moves out from the ethnic group. So as you well know, 
someone is more likely to be impartial to do something within an ethnic group, 
and less inclined to do something across ethnic groups, and then obviously less 
inclined to do something across international borders (Sankara).  
This solidarity with other African researchers or with a trusted collaborator may have been 
enhanced by previous experiences of parachute research. More so, it highlights the importance 
of the principle of mutual trust and how it relates to the principle of solidarity. 
Whether you are from Africa, Asia or Europe, you are a human being. And 
therefore we are trying to advance the science of humanity and the 
understanding of health and humanity. But at the same time, you do not want 
to be the person that is practicing Ubuntu, where you are giving away your 
samples to someone who has no understanding or idea of what Ubuntu 
means, and is going to take advantage of you…..I think Ubuntu could work 
provided everybody is on the same page. Similarly, if you want to decide on a 
hierarchy of access, then you would possibly say that an African requestor 
would be viewed more favourably than a non-African requestor, so that 
priorities are given to regional collaboration rather than international 
collaboration, with a view to build regional capacity. (Sankara) 
This suggests that priority for access to samples and data should be given to H3Africa researchers 
and then to African researchers or to collaborations that involve African researchers. H3Africa’s 
data access policies promote priority access to samples and data by African researchers, 
especially for the primary researchers. Therefore, controlled access to samples and data as 
suggested in our framework, seems to be an approach that is supported by stakeholders involved 
in research as the ethical thing to do at this time. 
6.3 Furthering the ideals of health justice (FIHJ) 
The third principle in our framework is furthering the ideals of health justice (FIHJ). The rationale 
for including African populations in genomics research and biobanking has already been 
described in previous chapters. This includes, broadly, a scientific imperative and an ethical 
imperative. The scientific imperative is based on the importance of capturing the diversity of the 
African genome so as to inform current global understanding of: differential susceptibility to 
complex diseases; response to pharmacological agents; and the interplay between genetics and 
the environment. The ethical imperative is based on fears that failure to include African 
populations in genomics research could lead to a possible genomics divide and further 
exacerbate global health inequities. Whilst there is a widely held view that genomics holds 
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promise in improving healthcare, it must be performed in a particular way to address global 
health inequities.  
As stated in the Framework, for genomics research have a responsibility to prioritise health 
conditions that are a major contributor to the disease burden in worst-off populations; build 
research capacity for genomics research; and have a plan for the translation of genomics research 
findings to clinical interventions or policies which would then be made accessible to study 
populations.  
6.3.1 Research priorities for genomics research in Africa. 
The Framework recommends that genomics research in Africa should focus on diseases that are 
a major contributor to the disease burden in the study population, and for which genomics is 
likely to provide significant public health benefits. This also applies to secondary uses of samples 
and data. In the interviews, I asked different stakeholders how they expect genomics research in 
Africa to address global health inequities. Overall, they were of the opinion that genomics 
research in Africa would not only address health issues of benefit to African populations but 
would also be of benefit to non-African populations. However, in selecting research priorities, 
emphasis should be on addressing the health needs of African populations especially those that 
are a major contributor to the disease burden.  
I think it is important that research that is done on African populations has, at 
least, a good probability of improving health in Africa, for example by 
establishing the genomic basis of particular disease conditions which 
hopefully will lead to better therapies in the future. Now, my understanding is 
that research in H3Africa, which is what I am familiar with, has already 
identified new genetic variants that were not known before. Those of course 
are not only helpful for African health, but are important for the global 
community as well. But it certainly has been the case that there are severe 
global health inequities and imbalances that need to be redressed in terms of 
poorer life expectancy, for example, in certain parts of Africa. It is important 
that the research that is done, has the possibility of leading to outcomes which 
will improve that situation, which will advance the overall goal of greater 
health equity across the globe. (Kinela) 
The emphasis seems to be that population genomics studies in Africa should be tied to particular 
disease conditions. Interviewees did not refer to specific diseases, but opined that it should be 
diseases that disproportionately affect African populations. 
We know that there are some diseases that clearly affect African or poor 
countries in a disproportionate manner. So I believe our energies should also 
be more focused in those areas. So by addressing those diseases of poverty 
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affecting African countries, we are trying to improve the health conditions of 
the people. (Chishala)  
Despite the proposal to focus on diseases that are a major contributor to the disease burden, it 
was also echoed that setting priorities for genomics research in Africa is not very straightforward. 
It would require that not only prioritising health conditions that are a major causes of morbidity 
and mortality, but those ones for which for which genomics studies are likely to yield more 
knowledge or lead to new health interventions. 
 I would want to prioritise what is important for Africa. But in order to 
determine what is best for Africa, it’s not that simple. It is not simply the 
common disorders that we have on the continent but those disorders which 
would give the best investment in terms of the knowledge they generate, 
which could result in the development of preventives, diagnostics or 
therapeutics that would benefit people on the continent. I would not 
necessarily just go for the common disorders. (Diarra) 
Despite the dominant suggestion to focus on diseases that are a major contributor to the disease 
burden in African populations, an exception was made for rare genetic diseases. The reason being 
that leaving out this these category of health conditions will be a missed opportunity to develop 
interventions for rare genetic diseases, especially as these diseases could also serve as models 
for understanding certain pathologies and developing interventions for them. 
But one would say a very interesting category of diseases, which is certain rare 
disorders, and if you were just going for the common disorders, you would 
then not allow research to happen in these rare disorder. These rare disorders 
very often would require critical information on for example signalling and 
other pathways which can allow for rational drug design and for the 
development of very specific agents, which would not have been developed 
had one not focussed on these rare disorders. (Diarra) 
The interview data demonstrates that selecting a research target may be very complex for 
genomics and will require that consideration be given not only to the disease burden, but to other 
factors such as evidence of genetic aetiology and the cost benefit ratio compared to other 
interventions. Also, it may be difficult to determine at an early stage what diseases are likely to 
benefit more from genomics interventions, except for single gene disorders. A view that is shared 
by some genomics researchers in Africa (Munung et al., 2018). This supports the proposed 
Framework’s requirement for research priority setting.. However, the proposed framework did 
not cover the inclusion of rare genetic diseases. Rare diseases are health conditions with a low 
prevalence of less than 5/10,000 (Montserrat Moliner and Waligóra, 2013). They are often 
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chronic, lifelong and present in diverse ways including a range of physical and neuro-
developmental manifestations, and mental health disorders such as depression, psychosis and 
anxiety disorders (de Vries, 2017, Montserrat Moliner and Waligóra, 2013). It is estimated that 
8% of the global population present with rare genetic diseases, a majority of which are single-
gene diseases. Given the Mendelian pattern of inheritance of most rare genetic conditions, rare 
diseases provide a good model for understanding genetic mechanisms for diseases. However, 
given the fewer number of persons with rare genetic diseases, biobanks and registries that could 
support genetic studies on rare diseases and hopefully lead to improved clinical management for 
persons with rare genetic conditions. I will therefore revise the framework recommendations to 
include rare diseases as a priority area for genomics research and biobanking in Africa.  
6.3.2 Capacity Building  
The second requirement for FIHJ is to build the capacity of genomics research in Africa, so as 
toenable LMICs to generate their own research evidence. This requires that capacity building 
should be evidenced based, takes place at different levels (project, institution and national level), 
and over a longer period of time, until such that African researchers have the capability to 
conduct independent research. Research capacity building should involve: technical and financial 
assistance for genomics research in Africa; coordinating the activities of the different actors (to 
minimise redundancies); and empowering individuals and groups that are engaged in genomics 
research and biobanking in Africa. The analysis of H3Africa governance-related documents 
document shows that capacity building is at the core H3Africa projects and the focus has been 
on infrastructural capacity building, training of African researchers at different levels (Masters, 
PhD and skills building) and African leadership of genomics projects. 
Interviewees also mentioned that research capacity building is an integral part of H3Africa 
projects. It is hoped that the capacity building efforts of H3Africa will eventually lead to a skill set 
of African researchers who are able to independently conduct high quality genomics research. 
This was considered critical in ensuring that African researchers answer questions that is of 
relevance to their study populations. 
In H3Africa, one critical element was building the capacity of the African 
research community so that the researchers would eventually have the 
required capacity, not only for the P.Is but also for the next generation of 
researchers. So you would have a cadre of researchers who would themselves 
be able to do the analysis and research to a high standard. So I think part of 
that inequities, recognising that it exist and starting to address it will be the 
right thing. So starting with the researchers and enabling them to collaborate 
in synergy with researchers was a good place to start because initially there 
wasn’t enough expertise on the African continent. So I think this kind of 
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twinning model which came out from the H3Africa was very important. So I 
think it is also important to focus on quality of capacity building. (Nxumalo) 
 Capacity building was also considered important in minimise exploitation as it would, in the 
future, enable African researchers to carry out their own independent research.  
Capacity building is a big thing for us. And so for me, any policy that we build 
in Africa or that is an afro-centric policy just have to include that component. 
We have got the genetic material which the world is looking for. And it is not 
just a matter of just handing it out. We want to build resources so that we can 
in fact grow our local genomics expertise. (Kofi) 
The different forms of capacity building listed in our conceptual framework came up in the 
interviews and they were similar to what we had also reported in a study on the benefits of 
genomics research in Africa (Munung et al., 2017). 
The principle of FIHJ also requires that genomics research and biobanking consortia in Africa build 
capacity for the translation and uptake of genomics research findings. One way of doing this is 
through building capacity for genomics medicine and public literacy in genomics. In the document 
analysis, I showed that public engagement is listed as a component of H3Africa’s capacity building 
plan. In the interviews this also emerged as a key area that will benefit from capacity building. 
Interviewees thought that was important for a couple of reasons, including: enabling study 
populations to comprehend research procedures and processes; empowering communities to 
take part in decision-making in genomics research and biobanking; a well as facilitating uptake of 
genomics medicine in Africa.  
When we first formulated this in 2011, we realised that genomics in general, 
is not well known in the country… And our little experience at that time 
showed that investing in educating people before you started the study, was 
probably the right thing to do. We endeavoured to fill the gap so that it does 
not create a lot of problems for us as we carried out our research. So we had 
a multi-prong approach. We targeted the community in general, not just the 
community with Disease AA but the Country X community in general. We 
developed communication tools that you probably know about. And they were 
widely distributed, not just in Country X but across the continent as well. That 
opened up a dialogue, so you started to hear of all of these issues being 
discussed on radio…it opened up a social dialogue around genomics. (Ola) 
In terms of capacity building in genomics medicine, we have, in a recent publication, reported 
the expectations of African researchers on capacity building in genomics medicine in Africa and 
the impact it could have on global health inequities (Munung et al., 2018). In this study, similar 
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views were also echoed and these are all in line with our framework’s requirement for building 
capacity for genomics medicine in Africa.  
6.3.3 Translation 
The last of the three requirements of FIHJ is that global health research consortia should have a 
plan for the translation of research findings and to ensure that study populations have access to 
proven interventions.  
The review of H3Africa documents suggests that caution should be applied when discussing 
translation as genomics research is still at the early stages in Africa. This was also echoed by some 
interviewees, but others stated that despite the need for caution in discussing translation, 
government funding agencies tend to prioritise research of which the outcomes are more likely 
to be translated to improved healthcare for local populations. 
Sometimes improving health actually takes longer…. The translation is really 
interesting, so I think it depends on the scheme which you are funding in, but 
I think in its narrower sense there has been a focus, and there is more of a 
focus, especially from government funders, on translation outcomes or 
outcome-focussed research. (Nxumalo) 
Given the current context of genomics research, whereby the translation of research findings to 
clinical interventions or policy may be long term, a closer alternative to provision of post-trial 
benefits is the feedback of research results (generic and individual findings). Generally, 
interviewees felt that the feedback of individual genetic findings as well as general research 
outcomes should be mandatory. The suggestion to incorporate the feedback of genetic findings 
was always followed by an acknowledgement of the challenges and required capacity needed to 
return results of genomics research to study participants or populations in Africa. Firstly, in the 
context of research, it is not clear who has the obligation to take up the responsibility, given that 
researchers are not necessarily physicians and may not have the capacity to make clinical 
decisions based on a genetic test that was done as part of research. Secondly, there are a limited 
number of genetic counsellors to deliver test results and provide the required services. Thirdly, 
it is unclear what is expected of researchers in cases where the results are not “actionable”. 
However, interviewees were of the opinion that sharing generalised research findings with study 
populations or individual test results with participants is important. Arguments for this were 
based on the principle of reciprocity.  
 It [feedback of study findings] is a very difficult issue and the problem is that 
often the data that the researchers have is not clear enough; it may just be 
raw research. But if you do find something that could be lifesaving, for 
example, then I think that the idea that there is an obligation to feedback 
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information gets more force. And I think many people take that view. For 
example, the recent guidelines that were issued by the International Council 
of Medical Sciences, said there is an ongoing consensus that at least some 
information should be sent back. Then we have got the question of whose 
obligation is it, because researchers are not necessarily people's doctors… 
There is a shortage of genetic counsellors in Africa as in many other parts of 
the world. But I think there is a growing feeling that as an important part of 
reciprocity, that somebody has the obligation to feedback information that 
could be of benefit to research participants. (Kinela) 
I did not engage researchers on the details of implementing the feedback of genetics findings in 
practice, as that would have been above the scope of this study. However, in a previous study, 
we had reported that limited capacity for the feedback of individual genetic test results, could be 
addressed through incorporating the training of medical geneticist and genetic counsellors as 
part of ongoing capacity building activities for genomics research in Africa (Munung et al., 2017, 
Munung et al., 2018). H3Africa has also developed a decision tree for the feedback of individual 
genetic test findings in H3Africa projects22. The policy is to feedback results only in cases where 
all of the following apply: the finding is actionable; there is consent for feedback of findings or 
these is the possibility to re-contact the participant; the test results have been verified by a 
certified laboratory or alternative genotyping test; and there are genetic counselling services or 
other healthcare providers within the project who can provide genetic counselling.  
From the interviews and document analysis, it is obvious that a translational pathway for 
genomics research will require a multidimensional approach that goes beyond the availability of 
proven interventions such as diagnostics and therapies, to include: genetic counselling, health 
behaviour, and health economics. These different dimensions would have to be taken into 
consideration when developing a translational plan and building capacity for genomics medicine 
in Africa. This supports our governance framework requirements for FIHJ. 
6.4 Reciprocity 
The principles of solidarity and reciprocity are tightly linked and it was common for interviewees 
to use the terms interchangeably, as seen in some of the quotes above (Section 6.2 Solidarity). 
Solidarity-based reciprocity is about achieving a symmetrical relationship between the giver and 
the receiver and therefore generates an expectation by the giver to receive something in return 
(Tosam et al., 2017). For interviewees who were familiar with Ubuntu, this reciprocal relationship 
is necessary for equitable research collaborations in Africa. For instance, when one interviewee 
                                                     
22https://h3africa.org/wp-content/uploads/2018/05/H3%20decision%20tree%20final_print_3%20(1).pdf Accessed 
27 January 2019 
 138 
 
was asked what they considered a key guiding principle for governance of genomics research and 
biobanking in Africa, they responded that it will be reciprocity. 
…reciprocity-This is seen in various cultures, where people are accustomed to 
returning favours done to them in equal measure” (Eyadema) 
To further highlight the need for symmetrical and reciprocal relationships, another interviewee 
mentioned that African researchers and other stakeholders should not lose sight of the purposes 
of genomics studies in Africa and the reasons why study populations provided samples and data, 
which is because they hope that the research will either be of benefit to them, to their 
communities or to the world at large. Ubuntu puts an obligation on stakeholders to ensure that 
the outcomes of genomics studies are made available and accessible to study populations in 
Africa and that they benefit from their participation in these studies. This justifies the need for 
benefit sharing arrangements in genomics research and biobanking in Africa. 
Personalised medicine is one of the outcomes of very advanced genomics 
studies. But how many people, even if it becomes the future of medicine, how 
many of us Africans would actually afford that? Or even will our public health 
systems be available to afford that? So, while I really like the Ubuntu 
philosophy, but there is also that other aspect of the fact that we are living in 
a very capitalistic free market economy and we also need to negotiate 
appropriately for benefits and I think that is where the fair benefits 
arrangements come in. (Wanyika) 
In our governance framework, the principle of reciprocity could be operationalised in terms of 
having benefit sharing arrangements at the project level or at the level of the consortium. This 
may include: health development projects; capacity building; feedback of research results; public 
education in genomics and biobanking; access to genomic medicine interventions; and 
recognising the contribution of African researchers who were involved in the generation of the 
primary data. Just as in the analysis of H3Africa documents, reciprocity was discussed in the 
interviews in two major ways, namely benefits to study communities and benefits to H3Africa 
researchers. In terms of benefits to study communities, some interviewees suggested that it was 
important for genomics research consortia to articulate benefit sharing arrangements, as it is one 
way of recognising the contributions of research participants and study populations. 
Do we have some sort of a reward system that recognises the communities for 
making available those bio-specimens? How will we see it in practice? Will it 
be in terms of monetary gains, is it in sharing of intellectual property 
downstream? I think there must be a way to recognise where the bio-
specimens came from and by extension where the data came from. (Kofi) 
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Some of the interviewees felt that having benefit sharing arrangements not only recognises the 
contributions of the community but are also an indication that study communities are not only 
used as an ends to a means. It is also shows respect for study communities and participants.  
Once you have collected data from an area it does not mean that you forget 
about them, but you also even have to think about those people when it comes 
to sharing the benefits from the particular studies. So if you look at that in 
itself, it also resonates well with Ubuntu, where we are saying we do not want 
to exploit people, but we want to respect people and view them as complete 
beings, view them as part of us, and in that way we are then saying we need 
to share those benefits with them. (Chishala) 
A key question therefore is: what are the benefits of genomics research and biobanking that 
could be shared with study communities? I had suggested in the Framework that benefits could 
take the form of health development projects, capacity building, feedback of research results, 
public education in genomics; and access to genomic medicine interventions. Suggestions from 
interviews included the return of study findings, sharing of profits and the availability of proven 
interventions. 
Well there can be a direct benefit of the research: return of results, therapeutic 
products, vaccines, kits all sold back at discount or made available for free. 
Then whatever proportion of your profits can be shared with the community, 
but there is no guarantee what kind of profit you are going to make (Sankara) 
Some of these benefits can only be made available if there is a translation plan by the consortium. 
This could be at the project or consortium level. Given that genomics is a basic science and that 
it make take time for the research findings to be translated to policy of clinical interventions, 
some of the interviewees felt that the return of study results (individual and generic) was 
therefore a direct benefit to study communities and participants.  
I definitely think that there need to be a clause in there where we as 
researchers describe to the participants that information would be relayed 
back to them. And I think sometimes we find that people use the argument 
that do the public want to know the details? But I think it is not right. And we 
should share to the level that people can comprehend…. I think that also 
shows respect and it might be much easier for people in the future to relate to 
what you want them to do and then by extension you might have more 
participants in future etc. (Kofi) 
For some interviewees, knowledge is important and there should be a commitment by 
researchers to provide study communities with information emanating from their studies.  
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The benefits of research may not be tangible, and it may not even be a cure 
down the line although that may be hoped for, but knowledge itself is an 
important good which can be shared and also the benefit of building capacity 
in the places where research is done. (Kinela) 
Capacity building is another form of benefits that was suggested in the conceptual framework 
and this was echoed by our interviewees. In Section 6.3.2 (Capacity Building), I presented the 
benefits of research capacity building and stated that the limited capacity for genomics research 
and genomics medicine in Africa could widen global health inequities.  
Overall, the interview data shows support for the principle of reciprocity. It also shows that a key 
way of actualising the principle of reciprocity was in the form of identifying appropriate benefits 
and having benefit sharing arrangements. Possible benefits that emerged from the interviews 
include: the feedback of results (both generic and individual genetic test results), research 
capacity building and access to proven interventions that may arise from these studies. Previous 
work in our group has detailed possible benefits and benefit sharing arrangements for genomics 
research and biobanking in Africa (Munung, 2016) and all these are in line with the proposed 
Framework. 
6.5 Transparency 
The Framework’s principle on transparency demands that genomics research and biobanking 
consortia should ensure that institutional and decision-making processes are open, accessible 
and comprehensible to all stakeholders. It also requires the free flow of information amongst 
stakeholders. In the interviewees, transparency was seen as a core principle for the governance 
of genomics research and biobanking in Africa. Interviewees suggested different ways by which 
transparency could be promoted including: informing communities on the activities of the 
consortium; and making available information on the use of samples and data. They also 
described that transparency has the advantage of promoting trust between stakeholders.  
I think one of the best ways of ensuring accountability and transparency is to 
make your guidelines and principles open on how you do things… I think one 
of the most important in accountability, which also contributes to 
transparency, is adequate documentation. So adequate documentation, 
traceability and those kind of things, those small practices, will make people, 
have trust in the system. (Wanyika) 
Some interviewees also suggested that transparency on the use of resources, particularly 
samples and data. There should be some documentation showing how resources have been used 
and/or equitably shared. This could for example be through: having reports on persons who have 
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accessed datasets from H3Africa projects; and the use of a biobank catalogue to document 
sample sharing.  
I like this notion of a biobank catalogue. We have seen it in the H3Africa 
project. I saw it last year with another project where a summary information 
for each of the biobanks is captured somewhere, say on a website, and linked 
to that information, is information about what happened to the samples. And 
so that will be a place you can go to, to have a look and it could also be easy 
may be technically just to send out an alert also saying the samples are being 
used by this people out there. (Kofi) 
It was also suggested that stakeholder engagement could be one way of promoting transparency. 
The purpose of such an engagement is to inform the different stakeholders about the activities 
of the consortium and how it is achieving its goals. Again, the advantage of this approach is that 
it could build trust between the different stakeholders.  
It is important to make effort and to provide information that is accessible to 
the people that are donating to ensure that transparency is respected and so 
the people know what is going to be done with their material and far as one 
is able to get the message across (Diarra) 
There was particular emphasis on ensuring that study communities and research participants are 
provided with adequate information on project. The reason for this emphasis could be that, 
compared to the other stakeholder groups, this group has been left out of many activities. It 
could also be seen as a way of respect for study communities as has earlier been described (See 
6.1 Shared Sovereignty and 6.4 Reciprocity). The idea of the “right to know” was used to argue 
for this position.  
Because I think they have a right to know. They have a right to know what the 
researchers are carrying out. What they are looking for. They may not be 
directly involved but it will be good that they should be aware of what the 
program involves. (Makena) 
Lastly, there is need for transparency in decision-making. This was usually discussed in light of 
the activities of the DBAC and there was the suggestion that genomics research and biobanking 
consortia should design protocols for documenting decision-making processes, including how 
decisions would be made and who would be involved in the process. This may involve the use of 
standard operating procedures. 
Like in other scientific committees they need standard operating procedures 
which is developed in a very careful manner, in a thoughtful manner. I would 
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suggest standard operating procedures on how to make decisions, how to 
approve studies, who to involve, will there be any monitoring. They need to 
discuss their responsibilities and at the same time also come out with standard 
procedures on how to execute those functions. (Lumusi) 
It was suggested that good communication practices on decision-making and use of resources as 
well as and inclusive processes were important in promoting transparency. 
A bad collaboration is where parties are not communicating, are not disclosing 
intentions and activities at the right time, at the right manner. Where there 
are more than two groups, some groups may feel left out and they are not 
privy of what is going on. And then of course, abuse of resources or dishonest 
disclosure. (Sanyu) 
These different propositions support the Framework’s recommendation for transparency in 
decision-making and the use of resources. In the framework, I had proposed that a consortium 
should make publicly available, the processes by which decisions are made. The idea of a 
standard operating procedure maybe one practical way of implementing the principle.  
6.6 Shared Resources 
One of the key requirements for equity oriented global health research is that resources should 
be shared such that resources received by each partner are in proportion to their needs. Also and 
that LMIC partner should ideally receive a majority of the resources. The Frameworks principle 
on shared resources requires that a majority of the research resources should be controlled by 
African researchers and research institutions, unless doing so would mean that the research does 
not get done (e.g. because of funding criteria) This is because inequalities in resources between 
LMICs and HICs involved in global health research consortia tend to confer more benefit to HIC 
partners and have a tremendous impact on overall decision-making. In Table 8 (chapter 5, Shared 
resources), I listed the different resources in genomics research and biobanking in Africa 
including: data, samples, human resources, infrastructure, IP and financial resources.  
A requirement of H3Africa funding is that at least 51% of project funds should be spent in 
institutions in Africa. Equally, all H3Africa projects must be led by African researchers. The reason 
being that these allows for African partners to have more control of research resources. It also 
minimises power imbalances, in terms of resources, between researchers in Africa and HICs. A 
situation which has often put African researchers at risk of exploitation. In addition, the primary 
funding awards were made to African institutions who could then distribute funds to project 
partners, including collaborators based in HICs. Interviewees felt that this worked well in 
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minimising fears of exploitation and that other global health research consortia in Africa should 
emulate the H3Africa model. 
My understanding of why that worked is specifically because the call was very 
clear that there has to be an African leader. And the way it was structured, 
the African PI was in charge of everything. Essentially everything had to be 
passed through the PI. So that is where I think it avoided a lot of problems that 
would have been caused by people feeling they are being undermined because 
they are not trained in genomics or people feel they are not up to scratch and 
all of that.(Ola) 
Interviewees also mentioned resources that were similar to those reported in the review of 
H3Africa document, including: samples, data, financial resources, human resources, research 
infrastructure, publication, IPs and patents. The Framework required that samples and data be 
made widely available, for solidarity based reasons, but that this should be done in such a way 
that recognises global inequities in health and research. In Section 6.3.1, I presented 
interviewees’ preference for data and samples to be used for research that has a good probability 
of improving the health of populations in Africa and in reducing global health inequities. 
Interviewees also stated that samples and data are a key resource and should be shared such a 
way that allows African researchers to make maximum use of their datasets. This was mainly 
because of limited research capacity in Africa and past experiences of exploitation. In terms of 
addressing concerns of research inequities, one way this has worked out in H3Africa is to have 
an embargo period which allows African researchers to analyse and publish their data before it 
is shared. 
I certainly do agree with the principle [publication embargo period] because 
Africa has been exploited over many years and I think that it is fair to allow 
people who have generated this data, but may not count as the most 
prominent researchers yet on the planet, to give them an opportunity to 
analyse that data and to draw whatever benefits they can in order to be able 
to advance their own research activities. If Africa had not been exploited for 
all these decades and they had not been such a discrimination which has 
resulted in this huge difference in capacity between our continents and for 
example Europe or North America, then I would say that embargo is not 
justified. (Diarra) 
Another point that emerged from the interviews, in relation to research resources was ownership 
of samples and data. In the framework, the shared resources principle requires that the primary 
research institutions in Africa serves as custodians of samples and data. In the interviews, there 
was a perception that ownership of samples and data is quite controversial, with some 
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interviewees suggesting that ownership claims on samples should be avoided in preference for 
custodianship, while data ownership should rest with the researchers who generated the data. 
So my view of ownership of [bio]material is that normally the entity that is 
keeping the [bio]material, there is nothing like absolute ownership but the 
entity that is keeping the material should hold this in in trust on behalf of the 
material providers. So that is with respect to material. But ownership of the 
data that is generated out of the material should be vested on those who have 
made an intellectual contribution to that data (Wanyika) 
Issues of ownership rights have downstream implications for intellectual property and patents of 
innovations that may arise from the use of data. It was suggested in the interviews that IP rights 
for innovations should be retained by research institutions rather than individual researchers. 
The expectation was that institutions would ensure that royalties are provided to the innovators. 
I am comfortable with the idea that the institution should own the IP. That 
doesn’t mean that it can’t be utilised by people even within the university 
through licensing for example, of a patent. Because those benefits then flow 
back to the university and also to inventors. (Diara) 
Given that data are generated from samples, it is confusing if someone was to have custodianship 
of samples while data ownership is assigned to a different entity or individual. I had suggested in 
the framework that data ownership should be assigned to the institutions. I will keep this 
recommendation. This is because if interviewees expect IPs to be owned by research institutions, 
then by default, they would need to have some “ownership” claims over the data. However, 
issues of patents, ownership of data and IPs will benefit from future studies.  
6.7 Shared Responsibility 
Shared responsibility is a core principle in our governance framework. Questions to interviewees 
on shared responsibility mainly explored the responsibility of stakeholder groups in terms of the 
equity-oriented activities, such as: FIHJ (selecting research target, capacity building and 
translation); shared sovereignty; and reciprocity. The responses were similar to the requirements 
of our framework, which is that stakeholders be assigned responsibilities based on the function 
that they typically assume. In the interviews, the responsibility for capacity building was assigned 
to funders and national governments; the return of results to African researchers and healthcare 
workers; and community engagement to African researchers. The interview data also suggested 
that funders have the responsibility of ensuring that genomics research in Africa aligns with local 
health needs. This was because they believed funders had the required financial resources and 
can therefore promote equity oriented research by directing research funding to the health 
 145 
 
needs of the study population. This was not to say that funders should dictate the research 
agenda. Rather, it was suggested that research priority setting should be guided by 
epidemiological parameters. 
There is usually the problem that the funding countries or the funders might 
actually dictate what issues to focus on. But what we are saying is, researchers 
need to focus on diseases that are affecting the majority of populations across 
Africa. (Chishala) 
This also suggests that African researchers have a critical role to play vis-à-vis the funders in 
identifying and selecting research priorities for genomics research and biobanking in Africa. 
African Researchers were assigned this responsibility because they assume leadership roles (P.Is) 
in projects and are therefore expected to conduct research that is of relevance to their 
communities.  
They [African researchers] have a responsibility of leadership. The need to be 
those who plan the research with regards to the priorities of their countries. 
They have to convince the funders that the money should be used for research 
that is important for their countries and not the priority of the funder. The 
problem with African researchers is that as soon as someone is ready to pay 
the say yes....They have to try to convince the funders, the policy makers and 
the western partners that this is what we want to do and do not let us waste 
our time on something else because this is the priority of our country. 
(Makena) 
From the quote above, it can be said that funders and African researchers have the responsibility 
of ensuring that genomics studies aligned to local research and health priorities. These views are 
similar to our frameworks requirements for shared responsibility.  
The responsibility for building research capacity lies with the nation state. But justice requires 
that when nation states are unable to do build their research capacity, global health actors should 
support them to do so. This has been the case for genomics research and biobanking in Africa. 
The interview data however revealed that a heavy reliance on funders is not sustainable and that 
African governments have to take up their primary responsibility of building capacity for health 
research in their respective countries. To show the importance of government involvement in 
research capacity building, one interviewee said that in countries where there has been 
government commitment, genomics research projects have thrived. 
I do not think the funders have the responsibility to completely redress all the 
inequities. I think local governments have the responsibility to up their 
research spending and build some of the infrastructure that needs to sit 
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underneath some of these initiatives. The ones that flourish in H3Africa, I still 
think, are the ones for which local government was involved and there was 
pre-existing infrastructure. So I think it is a mixed model; I think for funders, if 
you are going to fund this type of initiative then capacity development is part 
of it, and you have to acknowledge it. But that cannot solely rest with the 
funders, some responsibility has to be taken by local government, and that is 
a tough thing to ask, but some African governments do see the value in doing 
it. (Nxumalo) 
In terms of benefit sharing, whilst there are challenges associated with the return of research 
results, the H3Africa policy for the feedback of genetic test results assigns the responsibility of 
return of incidental findings to principal investigators. Interviewees who mentioned the return 
of study results as a primary benefit equally saw it a sign of respect for study communities and a 
way of building trust between researchers and study communities. An additional suggestion was 
made for an independent body to be responsible for benefit sharing arrangements. This is similar 
to what we had previously reported in a study that interviewed African genomics researchers 
(Munung, 2016). The current study however suggested that this responsibility should be 
extended to African researchers, funders, and secondary users of data/samples from H3Africa 
projects 
I think in as much as the decisions around what benefit sharing should look 
like need to be taken by the three groups that are mentioned….there should 
be an oversight group or an oversight body which, again, is constituted of the 
three groups that we have mentioned and who would then do the knots and 
bolts. I think it will ultimately have to come from either the state or it would 
have to come from the private sector like a private company that has been 
employed specifically for this purpose (Diara) 
Responsibilities should be allocated based on the functional requirement principle, that is, 
responsibilities should be assigned based on the function that a stakeholder group will typically 
assume. The interviews suggest that the responsibilities assigned to funders and to primary 
researchers are in line with our framework recommendations. However, the introduction of an 
independent body for benefit sharing arrangements will need to be considered when revising the 
framework. 
6.8 Mutual Trust 
In developing the framework, I mentioned that trust is a necessary precondition of solidarity and 
that it is difficult to imagine solidarity based relationships that are void of trust. I then proposed 
that the principle of trust could be promoted in genomics research and biobanking consortia 
through recognising the interdependence of all stakeholders (solidarity) and also acknowledging 
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the contributions that the different stakeholder groups are making towards the overall success 
of the success of the project. This could take the form of public engagement activities and 
recognition of the contributions of African researchers (e.g. acknowledgement in publications 
and conference papers). Interviewees identified different relationship in genomics research and 
biobanking where the principle of trust is key. This includes: relationships between HIC and 
African researchers/institutions and relationships between researchers and research participants 
or study communities. Trust between African and HIC researchers could be built through 
respecting collaborators and ensuring that the voices of all partners are given equal regard. 
Respect also emerged in the interviews as a key value that is important in fostering trust between 
the different stakeholder groups. 
So if we are looking at trust between the researchers, that is, between the 
researchers from Africa and those from the north, it is very important for them 
to maintain that trust. Trust can actually come out through respect for each 
other, if the researchers from the north respect the researchers from Africa 
and then those from Africa respect those from the north, then they actually 
know that they will be deciding on issues together.(Chisala) 
It was also suggested that a broader approach to building trust is through research integrity 
mechanisms. According to one interviewee, current research malpractices in global health 
research have led to the breakdown of trust between collaborators. This includes failing to give 
credit to collaborators in research outputs such as publications. To remedy this situation, it was 
suggested that research institutions should develop policies on research integrity that cover 
some of these salient issues.  
 But there are also issues within a research project; people taking credit for 
work that has been done by other people, and this is all a huge international 
problem now, in terms of what is called research integrity. For example people 
publishing fake publications or stealing someone else's intellectual property; I 
think research integrity is the key here….. So I think it would be good to have 
some consultation with every consortium about the kinds of mechanisms that 
promote research integrity in Africa. (Kinela) 
Generally, it was felt that trust between researchers in Africa and researchers in HICs was not 
straightforward and would take time to build mainly because of historical experiences of 
exploitation of African researchers. Based on the observation that African researchers are more 
likely to share data with researchers with whom they have an established and trusted research 
collaboration (Carr and Littler, 2015, Bull et al., 2015), I had proposed in the framework that 
efforts should be made to support collaborations for which there is a long term plan for 
collaboration. As discussed in Section 6.2 (solidarity), building trust can take time and tends to 
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be stronger between persons who share the same values. This supports the need for long term 
collaborations. Interviewees also described that tools such as memorandums of understanding 
or mutually agreed terms could play an important role in promoting or maintaining trust.  
Trust between primary PI’s and the international collaborators is a totally 
different story, I do not think it is easy, because historically it is not there, there 
is no historical precedent for that. And trust is something that you build up 
over time……I believe you need a contract to support trust between PI’s and 
their collaborators, you cannot base it on good faith (Sankara) 
On the other hand, trust between researchers and research communities could be built or 
sustained through respect for study communities, open communication with study participants 
or communities and engaging study communities as partners in research rather than sample 
donors only. As reported above, and in previous sections, having respect for study communities 
requires informing them of research procedures and outcomes as they have the right to know 
how their samples and data are being used to improve the health of populations in their 
communities and globally. It will also requires involving them, like other stakeholder groups, in 
decision-making. 
Trust also has to do with dissemination of information; trust also has to do 
with looking or viewing communities not as means to an end but also as ends 
in themselves. Here, what we are saying is viewing our communities not 
simply as a source of raw materials for research, but as a partner in the 
research process. That kind of respect actually brings about trust between the 
research communities and the researchers. But there is also need for open 
communication lines between those two groups… I have seen some groups 
who have been coming up with stakeholder engagement plans which clearly 
detail the various bits that are put in place, to improve the relations between 
the research communities and the researchers. (Chishala) 
From the interview data, respect, accountability, shared decision-making and transparency are 
necessary factors for building trust between stakeholders in genomics research and biobanking 
in Africa and interviewees often discussed these principles together. The suggestions conform to 
our framework requirements for the principle of trust which include: recognising the 
contributions of all stakeholders; stakeholder engagement; and transparency on samples and 
data use, as well as inclusive decision-making processes.  
6.9 Mutual Collective Accountability (MCA) 
Mutual collective accountability (MCA) is about ensuring that stakeholders are accountable to 
one another. Our framework requires that genomics research and biobanking consortia in Africa 
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establish ways for ensuring: that shared sovereignty is achieved; that resources are being used 
towards promoting health justice; and that all actors are performing their assigned roles and 
responsibilities. The MCA principle requires that this be done through setting standards for 
decision-making processes and identifying indicators and benchmarks for success. Interviewees 
generally considered accountability to be a key principle for the governance of genomics and 
biobanking in Africa. However, many interviewees felt that the implementation of MCA will be 
relatively difficult because of challenges with identifying which stakeholder group should be 
accountable to the other and at what phase of the research project. This is because MCA is about 
stakeholders voluntarily agreeing to be accountable to each other, therefore penalties are 
unlikely. Nonetheless, some interviewees suggested that accountability mechanisms within the 
consortium need to be developed and that this is the responsibility of the funders.  
The problem with accountability is who should be held accountable, who are 
they accountable to? I think you need to figure out who the person is going to 
be accountable to and at what level. Because if we are saying that it is the 
ERCs [RECs] that are accountable, they have no enforcement procedures. Yes, 
they can decide that they’re not going to issue a renewal in the year the 
progress report is sent in. But that never actually happens. So who potentially 
can have the most oversight? It is probably the funders. (Palesa) 
For other interviewees, the challenge of implementing MCA could be overcome through 
assigning the responsibility of accountability to an independent agency.  
There should be an agency who would take responsibilities when something 
needs to be accounted for. So such an agency needs to be identified. Like the 
researchers would need to be accountable, ethics committees needs to be 
accountable and experts like the international collaborators need to be 
accountable to different stakeholders…. I think it is a shared responsibility 
between the parties in the collaboration. (Lumusi) 
However, the consortium will have to first define the responsibilities of each stakeholder group, 
without which it will be almost impossible to hold any stakeholder accountable. This is in line 
with the shared responsibility requirement. In the document analysis, I demonstrated that 
besides annual reports submitted to funders by principal investigators, there was an emphasis 
for accountability mechanisms for sample and data sharing. The document analysis also showed 
that secondary users of data are accountable to the DBAC, whilst the DBAC is accountable to the 
primary ethics committees and to the steering committee; and researchers are accountable to 
RECs and to study communities. These different forms of accountability also emerged from the 
interviews. 
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one has to take responsibility for the material that one is analysing and for the 
data that is generated and it needs to be protected and the researchers that 
are obtaining this material have a duty to ensure that the data that comes 
from this is fed back in a meaningful way. So this covers a broad spectrum all 
the way from interacting with the community after the study to directly 
working with the communities to providing them with information which 
again requires a tremendous amount of skills because it is difficult to give this 
information back without making people anxious and fearful. (Diarra)  
Different layers of MCA came up in the interviews ranging from: accountability by primary data 
collectors to the ethics committees that approved the primary studies; accountability by primary 
researchers to study communities; accountability to funders by primary researchers; the DBAC 
to the entire consortium. Interviewees also suggested a number of ways by which accountability 
might be actualised was through monitoring of samples and data use and this responsibility was 
assigned to the DBAC and biobanks. 
I don’t know if it is the DBAC who should make a report stating these are the 
request we received, this is what we approved to share this year and for this 
reason or there needs to be a body that that checks what the DBAC is doing. 
There should be an activity report from the biobank. There is a need to know 
what has been done with the samples and data and also as a proof of concept. 
Because also this is something quite new, to show that so far it has been useful 
to store the samples in a regional biobank in an African biobank and that so 
far it has been useful and has increased the number of publications from the 
funding, that there are African scientist who are ready to speed up research 
activities (Makena) 
Another area where MCA is expected is in decision-making. Our governance framework requires 
that genomics research and biobanking consortia in Africa should monitor and ensure that 
decision-making processes are inclusive. This form of accountability was not found in the 
document analysis. In the interviews, it was suggested that it could be done through developing 
mechanisms for stakeholder engagement. 
I think there are several ways of promoting accountability and transparency, 
Part of it [accountability] would also be to encourage all the groups to come 
up with clear stakeholder engagement plans that clearly describe how 
information is going to be disseminated to the various stakeholders, that 
clearly show the various stakeholders that are H3Africa partners working 
with, so as to improve the relations and also transparency (Chishala) 
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Responses for MCA are in line with our framework’s principle of MCA, but for the suggestion that 
an independent committee should monitor and evaluate if a consortium is achieving its equity 
oriented goals. The document analysis revealed that the IEC has the role of doing a peer review 
of the consortium’s activities. This will be considered as an addition to our framework. 
6.10 Chapter Summary 
In this chapter, I have presented the analysis of the interview data and compared the data with 
the principles in our governance framework for genomics research and biobanking in Africa. I 
also described points of divergence between the proposed Framework and the empirical data. 
Overall, the empirical data largely supports the normative theories and recommendations made 
in our principles-based governance framework, but for minor differences in framework 
requirements, and an emphasis on the importance of the principle of respect. In the next chapter, 
I will discuss these differences and indicate possible areas of revision. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 152 
 
Chapter 7: Framework Revision and Application to Justice-
related ELSIs in Genomics Research and Biobanking 
in Africa 
In the last two chapters, I reported on the results of the empirical work that was conducted as 
part of the overall study. This involved thematic analysis of H3Africa governance-related and one-
one-in-depth interviews with different stakeholders in the H3Africa consortium. The data was 
analysed against the principles in the proposed Framework ( Chapter 3), and the results showed 
a broad support for the Framework’s principles and recommendations. In this chapter, I report 
on the points of divergence between the empirical data and the principles promoted in our 
framework. I also presented the revisions that will be made to the framework.  
7.1 Conceptual Governance Framework versus Empirical Data 
The aim of the empirical arm of this study was to test the principles in the proposed framework 
against existing governance policies of a genomics research consortia in Africa; and the 
expectations and experiences of different stakeholder groups. To do this, I used the reflective 
equilibrium approach. Reflective equilibrium requires using methods of scientific inquiry to test 
a normative conclusion or statement (Davies et al., 2015, De Vries and Van Leeuwen, 2010). 
 I probed two types of empirical data: H3Africa governance documents and in-depth interviews 
with H3Africa stakeholders. Where there were differences between the framework requirements 
and the empirical data, I checked if these differences were related to the practical 
implementation of the recommendations made in the principle itself was not considered an 
important driver for promoting justice and fairness in genomics research in Africa. Where the 
differences were more of concerns related to practical implementation, I checked the empirical 
data with existing literature to see if there was support for that particular view from other 
studies. If the literature showed support for the empirical data, the Framework was revised 
accordingly. The same applied where a new principle emerged from the empirical data. In which 
case, I equally checked if the new principle was related to any of the principles in the Framework. 
If that was not the case, and existing literature showed that the principle was important for 
promoting justice in global health research, it was then added it to the framework as a new 
principle.  
Overall, the principles were broadly supported by the empirical data but for minor points of 
divergence, related to the recommendations on how the principles could be actualised. A new 
principle, mutual respect emerged from the scientific enquiry (mainly interviews).  
 153 
 
7.1.1 Points of Divergence and proposed revisions 
Points of divergence between the empirical data and our conceptual framework were identified 
for the following principles: shared sovereignty; furthering the ideals of health justice (FIHJ); 
shared responsibility and mutual collective accountability (MCA). A principle that emerged from 
the empirical data which was not part of our conceptual framework is mutual respect. I present 
these different points of divergence and the possible points for revision. In presenting the 
principle of mutual respect, I will provide supporting quotes from the data. This is because 
compared to the other principles, I had not previously presented the data on mutual respect. 
Following a discussion of each point of divergence, I will include text for a proposed revision of 
the framework. 
7.1.1a Mutual Respect 
Interviewees frequently mentioned that mutual respect between stakeholders was a necessary 
requirement for genomics research consortia. In the documents analysis (Section 5.1.3; 
Relevance), the best practice guidelines emphasises the need for respectful and harmonious 
relationships between stakeholders. In the interviews, reference was also made to the 
importance mutual respect as a principle that should guide interactions between stakeholders. 
Interviews also linked the principle of mutual respect, to other principles in our conceptual-based 
governance framework such as reciprocity, shared sovereignty and trust. For example, some 
interviewees where of the opinion that reciprocity-based activities such as benefit sharing are a 
sign of respect for study communities and an indication that study communities were not used 
as a means to an end. Other scholars have also demonstrated the interconnectedness of the 
principles of mutual respect, reciprocity and trust (Merson et al., 2015, Umoren et al., 2012). 
Mutual respect is the feeling shared between two or more people, on the value or importance of 
something or someone. Ubuntu as about communitarianism and humanness, and at the centre 
of that humanness is reciprocity, which also demands that individuals respect one another 
because they need one another, irrespective of one’s social class (Dolamo, 2014). A number of 
authors have argued that the principle of mutual respect is important in global health research 
collaborations (Hunt and Ridde, 2016, Tindana and de Vries, 2016, Moodley, 2017) and genomics 
research and biobanking. In the interviews, mutual respect between stakeholders was also 
considered a key principle that should be promoted in genomics research and biobanking in 
Africa. This suggestion was made mainly in reference to study communities and mutual respect 
between researchers in HICs and African researchers. 
I think one fundamental principle is respect. Respecting the communities that 
actually provide the genomic data. Like the sources, the sample sources for 
instance. Those communities should be respected. (Wanyika) 
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In societies that live by Ubuntu, mutual respect is seen as inherent in promoting human dignity, 
regardless of a person’s social standing (Arthur et al., 2015, Mcunu, 2004). Similar views were 
echoed in the interviews.  
So the issue of dignity, respect of the participants and the researchers and the 
issue of ensuring that exploitation is not repeated and that there is a fairness 
in the way in which the process is undertaken, that if there were any benefit 
to be derived from this, it is shared in a way which is equitable (Diarra)  
Overall, some interviewees were of the opinion that in a research collaboration where mutual 
respect exist, and where stakeholders and collaborators treat each other as moral equals, the 
chances of one group exploiting the other are likely to be minimised.  
Ubuntu is that which separates human beings from animals, so understanding 
Ubuntu actually means you are understanding issues to do with personhood. 
Understanding Ubuntu is about understanding how to respect someone…So if 
you look at that in itself it also resonates well with Ubuntu, where we are 
saying we do not want to exploit people, but we want to respect people and 
view them as complete beings, view them as part of us, and in that way we 
are then saying we need to share those benefits with them. (Chishala) 
When interviewees talked about the principle of mutual respect, they mainly referred to mutual 
respect between researchers and study populations and between HIC researchers and African 
researchers. It was alluded that showing respect for study communities requires researchers to 
engage with study communities about research procedures and outcomes. It was also suggested 
that showing respect for study communities has the potential to build trust and to establish a 
good relationship that would facilitate future research. Some interviewees therefore thought 
that informing study populations on research progress and outcomes should be included in 
governance-related policies and that this responsibility should be assigned to African 
researchers.  
I definitely think that there needs to be a clause in there where we as 
researchers describe to the participants that information would be relayed 
back to them. And I think sometimes we find that people use the argument 
that does the public want to know the details? But I think it is not right…….So 
I would be pushing for information. Once we get the data, it is to go through 
the channels through which the informed consent was obtained and then 
make available either a summary information via the nurse or staff member 
or the persons who were in contact with the community, to then get back to 
them and give them feedback. I think that also shows respect and it might be 
 155 
 
much easier for people in the future to relate to what you want them to do, 
and then by extension you might have more participants in future. (Kofi) 
In terms of mutual respect between African researchers and HIC researchers, it was suggested 
that this would require that the voices of African researchers are taken into consideration during 
decision making processes, especially in decisions on how samples and data would be used. The 
emphasis on samples and data could be an indication that fears of exploitation of African 
scientists consolidate around these resources. Some interviewees argued that is disrespectful to 
be in a collaboration where the concerns of African researchers are not considered. 
 When I was talking about respect, at that moment I was actually talking 
about respect between the researchers from the richer countries and 
researchers from African countries. So here I mean as part of the collaboration 
the voices of African researchers should be heard, so it is not about 
researchers from the richer countries dictating what is supposed to be done 
as part of that collaboration. But we are saying that the researchers from 
Africa should also have their voices being heard and should also be able to 
suggest what can be done using the data. (Chishala) 
It can be inferred from the quotes above that there is a link between mutual respect, reciprocity 
and shared sovereignty. Also, mutual respect was often talked of in terms of African 
communitarian values and its importance in upholding human dignity. I acknowledge the added 
value mutual respect brings to equitable global health research collaborations, as argued by the 
interviewees, and also how it links to reciprocity and trust. Given the emphasis on this principle 
and that it serves as a foundation for some of the other principles promoted by Ubuntu, I will 
revise the framework to include mutual respect as a key principle. It also shows that there is 
added value if genomics research and biobanking consortia in Africa are governed based on local 
values and norms. This is in line with the relevance requirement of shared sovereignty. 
7.1.1b Framework revision  
Mutual respect 
Mutual respect is the feeling shared between two or more people, on the value or importance of 
something or someone. It is an integral part of an African communitarian worldview and involves 
respecting one another because we need one another, irrespective of differences in resources 
and social standing (Dolamo, 2014). Respect is also a value integral to promoting human dignity 
(Arthur et al., 2015, Mcunu, 2004).  
 Genomics research and biobanking consortia in Africa should ensure that their policies, 
processes and procedures are in line with local values and norms. 
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 The voices of African stakeholders (researchers, policy makers and study communities) 
should be solicited and taken into consideration when designing polices for genomics 
research in Africa.  
 
 Genomics researchers in Africa should inform study communities of the progress and 
outcome of studies in which they participated. This includes information on how samples 
and data have been used. 
 
7.1.2 Shared Sovereignty 
A second point of divergence between our framework and the empirical data, was for the 
principle of shared sovereignty, specifically the involvement of study populations in decision 
making. Shared sovereignty requires that all stakeholder groups who may be affected by a 
decision should be involved in decision-making (inclusiveness) and that decisions should be 
reached via consensus. Whilst the interview data showed broad support for including study 
populations in decision making, there was also the perception that it will be practically difficult 
to do so. This was primarily based on concerns of identifying representatives of study 
populations.  
Despite expressed concerns on practicalities of including study populations in decision making, I 
will keep the principle in the framework. This is because the inclusion of research participants in 
the governance of global health research avoids an expert driven governance model that has in 
some instances led to great criticism and loss of trust in biobanking projects (Palsson, 2008). Also 
interviewees considered it important that participants should be given a voice in decision making, 
a view that has also been recently echoed by some bioethics researchers (Juengst and Meslin, 
2019). H3Africa governance policies also suggest that public engagement is important for 
transparency and building trust. Considering the apparent consensus on the importance of the 
principle, the only problem appears to be with its practical implementation. In the literature, 
there are suggestions on how research participants or communities could be involved in the 
governance of genomics research and biobanking (Avard et al., 2009, Dry et al., 2017, McCarty et 
al., 2011, O'Doherty et al., 2012). These include: the use of surveys; public discourse; community 
engagement; focus group discussions; consultations and public meetings, all of which can be 
broadly categorised as public engagement activities. Some of these suggestions are consistent 
with the interview data on possible ways of including study populations. Future work on 
appropriate mechanisms for including study populations in decision making in of genomics 
research and biobanking consortia in Africa will be important. No changes will be made to the 
shared sovereignty section of the proposed framework.  
 157 
 
7.1.3 Furthering the ideals of health justice (FIHJ) 
The third point off divergence between our conceptual framework and the empirical data is the 
principle of furthering the ideals of health justice (FIHJ), specifically with regard to research 
priority setting. In the framework, I proposed that genomics research projects in Africa should 
focus on health conditions that are a major contributor to disease burden in Africa and for which 
genomics research is likely to yield maximum public health benefit. Our empirical data (both 
document analysis and interviews) are coherent with this recommendation. However, the 
empirical data suggests that priorities for genomics research and biobanking in Africa should be 
broadened to also include rare diseases (section 6.3.1). The reason being that the monogenetic 
nature of most rare diseases makes them good models for genomics studies in generally, but also 
because the rarity of these conditions often means that persons affected by them often struggle 
with the management of their conditions, from diagnosis to treatment because of limited 
investment in research on these diseases. Genomics could serve as a way of finding the 
underlying genetic causes of these diseases, assist in developing new diagnostics as well as lead 
to changes in medical care for patients with rare diseases. The framework will be modified to 
capture this suggestion. 
7.1.3a Framework revision 
Genomics research and biobanking consortia in Africa should, in addition to health conditions 
that are major contributor to the disease burden in Africa, also prioritise genomics studies on 
rare genetic conditions. This would allow for the development of diagnostics, rational drug design 
and for the development of very specific agents that would improve the health of worst-off 
populations with rare diseases, without which health inequities within the same population 
group will be worsened.  
7.1.4 Shared Responsibility 
The fourth principle where there was divergence between the framework’s principles and the 
empirical data is the shared responsibility requirement for benefit sharing. I had assigned the 
responsibility for benefit sharing to researchers, research institutions and funders. The interview 
data suggests that in addition to funders and researchers, an independent body may be used to 
enforce the implementation of benefit sharing. This view has also been expressed by other 
genomics researchers in Munung et al (2016). Given the complexity of implementing benefit 
sharing mechanisms (Schroeder et al., 2005, Schulz-Baldes et al., 2007), an independent 
organisation familiar with the process may be best suited to carry out this role. This is line with 
the functional requirement principle (which forms the bases of the shared responsibility) that 
were stakeholders are unable to carry out their role, they may be supported to carry out their 
responsibility. This does not shift the responsibility of benefit sharing from researchers and 
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funders, rather it is to support implementation. I will add this recommendation to the revised 
framework.  
7.1.4a Framework revision 
Genomics research and biobanking consortia may use an independent organisation or entity as 
one approach to implementing benefit sharing arrangements. The role of this organisation should 
be defined by African researchers, funders, study populations and policy makers including how 
their responsibilities differ from those of other stakeholders who have benefit sharing 
responsibilities  
7.1.5 Mutual collective accountability 
The fifth and final point of divergence between our framework and the empirical data is with the 
principle of mutual collective accountability (MCA). MCA is a system of peer review whereby 
stakeholders are answerable to one another, and in some instances to an external body (Ruger, 
2012b). The latter is only permissible when the roles and responsibilities of the different 
stakeholders are clearly defined (Ruger, 2013). The empirical data suggest that an external body 
may be required to implement MCA. The H3Africa document review for example, showed that 
this task is currently assigned to an independent expert committee, whilst the interview data 
suggests that it should be delegated to an independent organisation with no affiliation to the 
H3Africa consortium. I will include this suggestion in the framework. This is because in cases 
where accountability to an external body is required, the roles and responsibilities for 
stakeholders should be clearly defined. Our framework principle on shared responsibility requires 
that genomics research and biobanking consortia clearly identify the roles and responsibilities of 
all stakeholders who are involved in the project. Just like with the revision for shared 
responsibility, above, this is more about a change in implementation, rather than in principle.  
7.1.5a Framework revision 
Genomics research and biobanking consortia in Africa may use independent organisations to 
evaluate if the consortium is achieving its equity oriented goals. In which case the roles and 
responsibilities of all stakeholders as well as indicators for success should have been clearly 
defined by all stakeholders specifically, study populations and African researchers/institutions, 
as these stakeholder groups are most affected by inequities in genomics research in Africa.  
7.2 Application of the Principles-based Governance framework to Justice-Related 
ELSIs in Genomics Research and Biobanking in Africa  
In chapter 1, I presented the justice-related ELSIs in genomics research and biobanking in Africa 
(See section 1.1). I also mentioned that most of the justice-related ELSIs are shaped by data and 
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sample sharing practices that characterise population genomics research in Africa. Some of these 
ELSIs can be linked to the history of scientific imperialism or “extractive “biomedical research 
collaborations in Africa (Okwaro and Geissler, 2015, Tangwa, 2017, Parker and Kwiatkowski, 
2016). The justice-related ELSIs in genomics research and biobanking in Africa which I described 
in chapter 1 include: exploitation of African populations; ownership of samples and data, access 
to samples and data, benefit sharing, intellectual property/patents. In Table 10 below, I present 
the different principles in our framework that may be used when addressing these different ELSIs. 
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Table 10: Link between principles and recommendations proposed in the governance framework and the justice-related ELSIs in genomics 
research and biobanking in Africa 
Justice-related ELSI Framework principles 
that address the ELSI 
Examples of framework recommendations that help address the ELSI  
Exploitation of African researchers 
and study populations 
FIHJ 
Shared sovereignty 
Shared resources 
Mutual respect 
Solidarity 
Reciprocity 
Mutual trust 
MCA 
Voices of all stakeholders should be included in decision making. 
 
Genomics research in Africa should prioritise the health needs of African 
populations.   
 
A greater proportion of the resources should be allocated to support capacity 
building of African researchers and research institutions.  
 
Where genomics research leads to new interventions, these interventions 
should be made available to study populations. 
 
The contributions of primary data producers should be acknowledged in 
publications and other outputs emanating from the use of samples and data. 
 
 Access to samples and data Solidarity 
Shared resources 
MCA 
Shared sovereignty 
FIHJ 
Shared responsibility 
Samples and data should be shared for use in research. However, sharing of 
samples and data should take into consideration the health needs of African 
populations who provided samples and by extension, data.  
 
Samples and data should be used to address health issues that are a major 
contributor to the disease burden in Africa. 
 
Research consortia should provide study populations, research ethics 
committees that reviewed the primary studies and African researchers with 
information on how samples and data have been used. 
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Decision making on access to samples and data should involve all affected 
stakeholders  
 
Priority for access to samples and data should be given to research projects that 
either have a plan for collaborating with African researchers, addresses the 
health needs of populations in Africa or that that allocate resources towards 
capacity building in LMICs  
 
Ownership of samples and data Shared resources 
Solidarity 
Mutual trust 
Research institutions involved in primary studies should serve as custodians for 
samples and data stored in biobanks and databases respectively 
 
Benefit sharing Solidarity 
Reciprocity 
FIHJ 
Mutual Trust 
Mutual respect 
Shared resources 
In cases where an intervention is developed from the study, there should be 
mechanisms in place to ensure sustained access to the intervention  
 
Genomics research and biobanking consortia should carry out public 
engagement activities that aim at communicating project-related information, 
such as use of samples, research outcomes and study progress, to study 
populations 
 
Genomics research consortia should state what kind of benefits are likely to 
accrue to study communities because of their participation in studies  
 
Intellectual Property and patents FIHJ 
Shared resources 
 
Researchers and research institutions that file patents or IP rights for 
innovations arising from the use of genomic datasets should disclose how they 
would ensure access to resulting products by populations in Africa 
 
Contributions of African researchers and research institutions should be 
recognised when filing patents or IP rights 
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7.3 Chapter Summary 
 I used the reflective equilibrium approach to test our framework’s principles against current 
governance practices of genomics research as well as the governance expectations of different 
stakeholders in genomics research and biobanking in Africa. Our goal was to have a framework 
the principles and recommendations of which can be considered binding for all rational agents 
and are also not too abstract or far removed from reality so that they can usefully inform practice 
(Davies et al., 2015). In this chapter, I presented the points of divergence between our 
governance framework and the empirical data and proposed the introduction of a new principle 
(mutual respect) and revisions to the governance framework. I ended the chapter with a 
presentation of the different principles in our governance framework that could be appealed to 
when addressing the different justice-related ELSIs in genomics research and biobanking in 
Africa. 
In the final chapter of this thesis, I will briefly discuss the outcome of our study and make 
recommendations for future research.   
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Chapter 8: Discussion, Future Research and Conclusion 
Recent years have seen an increase in population genomics studies in Africa, largely fuelled by 
fears of a possible genomics divide that would in turn widen global health inequities. (Gurdasani 
et al., 2015, H3Africa Consortium, 2014, Singer and Daar, 2001a). The success of these population 
genomics studies depends on: a well-coordinated network of collaborative studies; the 
establishment of biobanks; and the sharing of samples and data with other researchers. 
However, data and sample sharing raise a number of ethical, legal and social issues (ELSIs) that 
will need to be addressed by genomics research consortia in Africa. Some of these ELSIs focus on 
individual-level issues (micro-level justice), others are more concerned with broader societal 
issues (macro-level justice). This thesis sought to propose a governance mechanism that could 
be used to address these macro-level justice concerns in genomics research in Africa. This is 
important as there is a near absence of regulatory support that could be used as a backbone to 
address justice-related ELSI raised by genomics research and biobanking in Africa (de Vries et al., 
2017). Also, the absence of harmonised regulations for the export of samples and data in Africa 
means that there are differences in country-level regulation on how specific ELSIs could be 
addressed. The development of governance mechanisms that are broad enough to address these 
ELSIs could be an approach to filling this gap in regulation (Chen and Pang, 2015, de Vries et al., 
2017, Parker and Kwiatkowski, 2016). Such governance mechanisms will have to be based on 
principles that could foster sound ethical research in Africa (de Vries et al., 2017) and which are 
reflective of African cultural values (Staunton and Moodley, 2013). In this thesis, I used the 
normative bioethics oriented approach (NPOB) to develop a principles-based governance 
framework for genomics research and biobanking in Africa. The Framework is informed by: two 
different theories of global health justice and governance and the African moral theory of 
Ubuntu. Its principles were identified using a convergence approach. Its recommendations were 
further tested using the reflective equilibrium approach, an empirical bioethics method.  
8.1  Summary of Study and Discussion 
In this thesis, I set out to develop a governance mechanism that could address the justice-related 
ELSIs in genomics research and biobanking in Africa. The specific objectives were to:  
1. Identify principles, values and norms that can promote justice and fairness in genomics 
research and biobanking in Africa; 
2. Propose a principles-based governance framework for genomics research and biobanking 
in Africa that links its policies to the promotion of justice; 
3. Investigate how the governance of current day genomics research and biobanking 
projects in Africa have considered concerns of justice and fairness; 
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4. Explore the views of key stakeholders on fair and just governance mechanisms for 
genomics research and biobanking in Africa. 
 
I started with a description of the justice-related ELSIs in genomic research and biobanking in 
Africa. These were mainly issues related to: access to samples and data; benefit sharing; 
ownership of samples and data; intellectual property; and the exploitation of African researchers 
and study populations. I argued that these justice-related ELSIs could be best addressed through 
governance. Governance is about principles, values, norms, rules and decision making processes 
that guide the activities and expectations of actors involved in a specific activity (Hufty, 2011, 
UNDP, 1997). Whilst governance may be principles-based or rules-based (Arjoon, 2006), I opted 
to develop a principles-based governance framework.. The reason being that principles-based 
governance is broader in scope and has more latitude and flexibility compared to rules-based 
governance. Therefore the framework will likely appeal to the broad range of stakeholders 
involved in genomics research and biobanking in Africa.  
In order to identify principles that may guide the governance of genomics research and 
biobanking in Africa, I turned to two theories of global health justice and governance as well as 
the African moral theory of Ubuntu. The two theories of global health justice were: shared health 
governance (SHG) and global governance of health (GGH). I selected these theories because they 
link global health research to the promotion of justice. Also, they provide guidance for the 
governance of global health programs and argue that health research should aim to addressing 
global health inequities. Ubuntu, on the other hand, has informed governance in many African 
settings. It is also considered the way of life of African people. Using the convergence approach, 
I did a conceptual and normative analysis of SHG, GGH and Ubuntu to identify principles that 
could inform the governance of genomics research and biobanking in Africa. This required 
identifying principles and/or values that were common in SHG, GGH and Ubuntu. I then used 
these principles to develop a framework for the governance of genomics research and biobanking 
in Africa. The following principles were identified from the conceptual and normative analysis 
using the convergence approach: shared sovereignty, transparency, shared resources, shared 
responsibility, mutual trust and mutual collective accountability (MCA) (Table 2). Principles which 
were not promoted by all three governance theories, but which were included in the framework 
include: Furthering the ideals of health justice (FIHJ), solidarity and reciprocity. FIHJ is promoted 
by SHG and GGH and not directly by Ubuntu. This is because Ubuntu does not primarily speak to 
global health, compared to SHG and GGH which were specifically designed to address global 
health inequities. However, Ubuntu requires that individuals within a community or defined 
group, work together to achieve a common good or a shared goal. Therefore, if Ubuntu was to 
be applied to global health, it would likely support a governance approach that seeks to address 
 165 
 
health inequities and promote the common good. It is based on this that the FIHJ principle was 
adopted into the framework. Solidarity and reciprocity are also not promoted in all three 
governance theories. Reciprocity is promoted in Ubuntu only, while solidarity is promoted in 
Ubuntu and complemented by SHG (reflective solidarity). I kept these two principles because my 
overall goal was to develop a governance framework that is informed by norms and values shared 
by African populations. Also, the empirical data shows that, different stakeholders referred to 
Ubuntu, solidarity and reciprocity to justify their preference for certain governance processes.  
As described in Chapter 7, a new principle that emerged from the empirical data (not originally 
part of our principles-based framework) is mutual respect. The initial framework was revised to 
include mutual respect as a core guiding principle. Mutual respect is the feeling shared between 
two or more people on the value or importance of something or someone. The principles of 
mutual respect, mutual trust, solidarity and reciprocity were often discussed together in the 
interviews, suggesting a link between them. Similar observations on the inter-relatedness of 
these principles have been put forth in the literature on global health research (Umoren et al., 
2012, Hunt and Ridde, 2016, Tindana and de Vries, 2016, Merson et al., 2015).  
The empirical data largely supported the frameworks principles and recommendations, but for a 
few points of divergence. For example, the document analysis showed that there was little 
involvement of study populations in decision making. Also, whilst the stakeholders that were 
interviewed acknowledged the importance of including this stakeholder group in policy 
development, they also expressed concerns about the practicability of such an approach. This 
may suggest that the Framework’s recommendation to involve study populations in decision 
making may be challenging, from a practical point of view. Because the challenge was mainly a 
practical one but the overall recommendation received wide support, this particular 
recommendation was maintained in the revised Framework. Genomics research and biobanking 
consortia in Africa would have to actively identify appropriate ways of involving study 
populations in decision making and overall governance.  
Public engagement is one approach that researchers can use to build public confidence and trust 
in health research (Daudelin et al., 2011, Samuel and Farsides, 2017). A key characteristic of 
public engagement is dialogue between “experts” (researchers) and the general public. It allows 
researchers to: listen to the public; gain an understanding of public views about certain 
biotechnologies, and incorporate these views in the implementation of their projects (Samuel 
and Farsides, 2017). There is a noticeable increase in community engagement in genomics 
research and biobanking projects in Africa (Campbell et al., 2015, Staunton et al., 2018, Mboowa 
et al., 2018, Jenkins et al., 2016, Rotimi et al., 2007). However, it appears that community 
engagement activities for genomics research in Africa have mainly focussed on: outreach 
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activities for specific diseases; ensuring that study procedures are sensitive to local beliefs and 
practices; and explaining concepts in genomics and biobanking with the goal of improving 
informed consent comprehension. However, little attention has been given to soliciting 
community views on policies for genomics research and biobanking. Whilst community 
engagement may, arguably, empower study populations to take part in decision making through 
improving public knowledge of genomics and biobanking, there is a critical need to go beyond 
that and to capture the voices of study communities when developing governance policies for 
research in which they are actively involved. This is because the long-term sustainability of 
genomics research and biobanking in Africa, as in other parts of the world, will no doubt depend 
on the acceptability of governance policies by all stakeholders, including study populations. This 
is key given the historical exploitation of these two stakeholder groups in global health research 
and structural inequities in health and health research between Africa and HICs. Whilst the voices 
of African researchers are increasingly being captured in the development of policies for 
genomics research and biobanking in Africa, the same cannot be said for study populations. Going 
forward, genomics research and biobanking consortia in Africa should seek to ensure that the 
voices of study communities are represented in decision making, a view that has been echoed by 
some researchers (Juengst and Meslin, 2019). 
Mutual collective accountability (MCA) is another principle in the proposed framework where 
there was little mention of its practical implementation in H3Africa documents. There was 
equally some uncertainty from stakeholders on how it could be implemented. The interview data 
suggests that an independent organisation should be used for evaluating if the consortium is 
achieving its goals. However, MCA is about internal accountability and if some degree of 
accountability to an external body is expected, then the responsibilities of stakeholders to 
entities within and outside the consortium will have to be clearly defined. This is critical for 
transparency and also in building trust between African researchers and study communities. 
African researchers have an obligation to ensure that information on use of samples and data are 
fedback to study communities in ways that are comprehensible to the lay public. Another area 
where MCA is required but for which there was little information on its implementation is shared 
sovereignty. This requires monitoring if decision making processes are inclusive and meet the 
other requirements of shared sovereignty.  
A final principle that requires some elaboration in its implementation is the principle of mutual 
trust. Trust is a person’s reliance on someone or something to carry out their responsibilities or 
keep their promises (Beauchamp and Childress, 2001). Mutual trust requires that trust be shared 
by all parties involved in a shared activity. Trust is essential in addressing concerns of exploitation 
of African researchers and study populations (Jao et al., 2015, Pang, 2003, Sankoh and 
Ijsselmuiden, 2011, Moodley, 2017, Moodley and Singh, 2016, Parker et al., 2009).The empirical 
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data suggested that the level of trust decreases as one moves away from closed circles. This is to 
say that researchers are more likely to share data with researchers with whom they have already 
established a trusted research collaboration and also between African researchers. Whilst there 
is growing literature on the importance of mutual trust in global health research collaborations 
between HICs and African researchers, little is known about the role or importance of trust in 
research collaborations between African researchers and if they would automatically trust each 
other by virtue of being African researchers. This will benefit from future studies that broadly 
look at data sharing or equitable research collaborations between African researchers and 
whether trust and other principles in our framework should be given prominence.  
8.2 Overall Study Limitations23 
My insider status as a student in the H3Africa consortium may have constituted a significant 
source of bias in my analysis of the empirical data. As described in chapter 1 (Section 1.6; 
Researcher’s Positionality), I received a PhD stipend from an H3Africa funded project and at some 
point also worked as a part-time research assistant for the H3Afica Ethics and Regulatory Issues 
Working Group. As a research assistant, I participated in the development of an H3Africa 
governance document. This document formed part of the empirical data. Also, one of my thesis 
supervisors is: the previous chair of the H3Africa ethics and regulatory issues working group; an 
H3Africa principal investigator; and a member of the H3Africa steering committee. Our position 
in H3Africa afforded us an opportunity to both to articulate the topic of this PhD and to give 
provide insight into why it mattered and how it could be done. It also allowed us to identify and 
access key interviewees. This probably motivated for the high response rate that I received for 
the in-depth interviews. However, it also meant that we were to some extent analysing the merits 
of our own work and could therefore have been biased. We sought to address this potential bias 
by 1) identifying the risk early on and committing to honesty and transparency in discussing it 
throughout the project and 2) appointing an external supervisor who had no prior involvement 
in H3Africa. We asked her to critically detect any possible bias as we carried out the research and 
interpreted the data. One that came up early on in the study, was that much reference was made 
to H3Africa when discussing genomics research projects in Africa. This was resolved by ensuring 
that we highlighted as much as possible, the activities of other human genomics research 
consortia in Africa (Section 1.2).  
I used a case study approach to explore if the proposed governance framework is in line, or at 
par, with the everyday governance practices of genomics research and biobanking in Africa and 
                                                     
23 Limitations specific to the empirical work (study population, access to documents and interviews) were described 
in Chapter 4, Section 4.4 
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if it met the expectations of the different stakeholders. This involved thematic analysis of 
H3Africa governance-related policies and one-on-one in-depth interviews with different H3Africa 
stakeholders. One of the major shortfalls from the interviews is that I did not include 
representatives from study populations, and therefore did not solicit their views in testing the 
governance framework. This was mainly for two reasons: Firstly, this stakeholder group had not 
been involved in the development of H3Africa governance policies. Secondly, whilst the H3Africa 
DBAC policy states that the DBAC has a representative of research participants, the first DBAC 
meeting took place towards the end of the data collection phase for this study. It would have 
been challenging to reach out to this representative at this time. Also, representatives of study 
communities had not previously been involved in developing H3Africa governance and may 
therefore have little insight into the governance practices of the consortium. Whilst it is 
important to test our principles against the views of this stakeholder group, they were relatively 
new to the consortium and had not been involved in any decision making or development of 
policies. However future studies should actively seek to explore the views and governance 
expectations of this stakeholder group. 
8.3 Directions for Future Research  
 I had set out to understand how the ideals of justice could be advanced in genomics research 
and biobanking consortia in Africa. To do this, I had opted to articulate a governance framework 
whose principles speak to the justice-related ELSIs in genomics research and biobanking. Using a 
normative bioethics oriented approach, I developed a principles-based governance framework 
for genomics research and biobanking in Africa. The principles promoted in this conceptual 
framework were tested empirically using the reflective equilibrium approach. 
This research unveiled further questions which could be investigated to enrich the discourse on 
justice and fairness in genomics research and biobanking in Africa. Firstly, one of the 
requirements of the shared sovereignty principle is that genomics research and biobanking 
consortia in Africa should involve study populations in decision making. This was supported by 
the different stakeholders that were interviewed. However, there are operational challenges to 
the implementation of this requirement. With the growing need to see research communities as 
partners in research, it will be important for future studies to identify practical and meaningful 
approaches for involving study populations in the governance of genomics research and 
biobanking in Africa. Further research should focus on developing models for science 
communication programs for genomics as well as models for meaningful involvement of study 
communities in decision making processes and governance as a whole.  
Secondly, most of the principles promoted in the framework have separate requirements that 
would need to be fulfilled. For example, shared sovereignty has detailed requirements for 
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inclusivity, publicity, qualitative equality, deliberativeness, breadth, range and so forth. It was 
difficult to unpack, in detail, all these different requirements in a single study. Therefore, future 
studies that explore individual principles (alongside the different requirements of the principle), 
will throw more light on how the different requirements maybe achieved in the governance of 
genomics research and biobanking in Africa. 
Thirdly, the interview data highlighted the importance of including study populations in decision 
making. However, the views of this stakeholder group were not captured in this study. It will be 
important for future studies to explore the involvement of study populations in decision making 
across different genomics research consortia to check if their views align with the principles 
promoted in the governance framework and to propose areas of revision where necessary. 
Fourthly, there is a need to further explore the shared responsibility requirement especially in 
cases where the responsibilities are not clear at this time and where the primary responsibilities 
of African stakeholders has been shifted to HIC partners. A case in point is the responsibility of 
African governments in setting research priorities for genomics and in providing funding for such 
studies. This should include possible public engagement approaches for policy makers in Africa. 
Also, the empirical data suggest that African leadership of genomics studies could minimise the 
exploitation of Africa researchers and study populations. Whilst H3Africa has adopted seems to 
have adopted this position, there is little evidence to support this claim. With a growing number 
of African-led global health programs in Africa, it will be important for future studies to check the 
for potential of African leadership of global health research collaborations to minimise 
exploitation, and the impact this may have on the governance of global health.  
Lastly, the empirical aspect of this thesis focussed on the H3Africa consortium. H3Africa is a 
relatively well resourced genomics research and biobanking consortium and lots of efforts have 
gone into engaging different stakeholders and developing ethics policies. It is likely that the 
majority of the interviewees’ opinions may have been influenced by the consortium’s policies. 
Also, our interviewees constituted a small portion of the pool of stakeholders in genomics 
research and biobanking in Africa. In-depth interviews or surveys with non-H3Africa researchers 
in genomics or biobanking may shed light on the acceptability of our framework’s principles for 
the broader pool of persons involved in genomics research and biobanking in Africa. This should 
also be extended to private and commercial initiatives involved in genomics research. 
8.4 Conclusion 
The overall aim of this study was to propose a governance framework for genomics research and 
biobanking in Africa that will address macro-level justice-related ELSIs in genomics research 
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collaborations in Africa. I wanted to develop a governance mechanism that is informed by 
principles and values that are likely to be shared by all stakeholders in genomics research in Africa 
and that allows for flexibility in its implementation.  
Using the convergence approach and relying on two theories of global health justice (Shared 
health governance and global governance of health) as well as an African indigenous governance 
model, Ubuntu, I developed a principles-based governance framework for genomics research and 
biobanking in Africa. I suggest that the governance of genomics research and biobanking in Africa 
should be informed by the following principles: Solidarity; reciprocity; shared sovereignty; 
mutual respect; shared resources; furthering the ideals of health justice; shared responsibility; 
mutual collective accountability; transparency and mutual trust. I advocate for a governance 
mechanism whereby decision making is inclusive of all stakeholders especially research 
participants and study populations. 
 I also set out to develop a governance framework that is based on principles, yet not too abstract 
such that its implementation becomes challenging. For each principle therefore, I made 
recommendations on how they may be practically applied within genomics research and 
biobanking consortia. The framework’s principles and requirements were broadly supported by 
stakeholders that were interviewed and also represented in the ethics governance documents of 
the H3Africa consortium. This would suggest that the principles and recommendations are largely 
in line with stakeholders’ perceptions of how justice and fairness may be promoted in genomics 
research and biobanking.  
Although the framework was developed to support the governance of genomics research and 
biobanking in Africa, its principles may be more broadly applicable to other global health research 
programs in Africa such as clinical trials and research on environmental and public health.    The 
justice-related ethical issues in genomics research and biobanking arise as a result of the practice 
of sample and data sharing as well as storage of samples (and associated data) for future un-
specified research. Whilst this is a common practice in genomics research and biobanking, it is 
fast becoming a characteristic of different kinds of health research. As such, I hope that the 
research reported in this thesis will support efforts aimed at promoting justice in global health 
research in general. Equally, whilst the framework developed in this thesis was meant to cater 
for the governance of genomics research in Africa, the normative analysis, particularly the 
convergence approach, showed that all the principles should apply to global health research in 
general. Therefore, the Framework will make a contribution to the governance of collaborative 
research globally. 
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